Polymer Ultrasound Contrast Agents for Targeted Drug and Gene Delivery by Cochran, Michael
Polymer Ultrasound Contrast Agents for Targeted Drug and Gene Delivery 
 
 
A Thesis 
Submitted to the Faculty 
of 
Drexel University 
by 
Michael Cochran 
in partial fulfillment of the 
requirements for the degree 
of 
Doctor of Philosophy in Biomedical Engineering 
December 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ii 
 
Acknowledgements 
 
 First, I would like to thank my advisor Dr. Margaret Wheatley for her guidance and 
support. By whatever gift of luck, I had the opportunity to work with an incredibly caring and 
enthusiastic advisor. This thesis would not have been possible without all of her help over the last 
five years.  
 I would also like to thank all of my committee members: Dr. Kenneth Barbee, Dr. Adrian 
Shieh, Dr. Flemming Forsberg and Dr. Michael Soulen for their collaboration, guidance and 
feedback. 
 My past and present lab mates also deserve thanks for helping me survive life in the 
basement for so long, especially John Eisenbrey, Nicola Francis, Carl Solis, Boriphat Methachan, 
Nutte Tarn Teraphongphom, Reva Street and Lauren Jablonowski. 
 I would like to acknowledge all of the undergrads who have helped me over the years 
with this research: Natalia Portonoy, Richard Ouma, Theresa Bustamante, Arpit Shah, Geena 
Rajan, Jen Rajan Daniel, Michael Fraher, Mi Thant Mon Soe and Amber Green.  
 I would also like to thank Laura Shih for letting me work with her as an undergraduate 
and for everything she taught me. I appreciate her patience and trust now more than ever. 
 For all of their help with the animal studies at the University of Pennsylvania I would like 
to thank Susan Schultz, Marion Knaus, Karla Carlisle, Lee Shuman, Tim Jenkins, Sarah White 
and Stephen Hunt.  
 I would like to thank all of my friends and family, especially Ben, the best brother I could 
ask for. And most importantly I would like to thank and dedicate this thesis to my parents, James 
and Svetlana Cochran, for their love, support and encouragement that has guided me throughout 
my life. I am so grateful for everything that you have done for me. 
 
iii 
 
Table of Contents 
 
 
LIST OF TABLES .......................................................................................................................... vi 
LIST OF FIGURES  ...................................................................................................................... vii 
LIST OF ABBREVIATIONS AND SYMBOLS ......................................................................... xiv 
ABSTRACT ................................................................................................................................. xvii 
1. INTRODUCTION ..................................................................................................................... 1 
1.1 Statement of the Problem ................................................................................................. 1 
1.2 Thesis Objective ................................................................................................................ 2 
2. BACKGROUND ....................................................................................................................... 6 
2.1 Cancer and Cancer Treatments ...................................................................................... 6 
2.1.1 Breast and Liver Cancer ........................................................................................ 6 
2.1.2 Solid Tumor Biology  ............................................................................................ 7 
2.1.3 Current Treatments for Breast and Liver Cancer ................................................... 9 
2.1.4 Doxorubicin, Paclitaxel and Docetaxel ................................................................ 12 
2.1.5 Cancer Targeted Drug Delivery ........................................................................... 15 
2.1.6 Mononuclear Phagocyte System .......................................................................... 18 
2.2 Ultrasound ....................................................................................................................... 21 
2.3 Ultrasound Contrast Agents .......................................................................................... 23 
2.3.1 Existing Ultrasound Contrast Agents................................................................... 25 
2.3.2 Polymer Ultrasound Contrast Agents .................................................................. 26 
2.3.3 Ultrasound Induced Microbubble Behavior ......................................................... 26 
2.3.4 Blood Vessel Permeability ................................................................................... 31 
2.3.5 Radiation Force .................................................................................................... 32 
2.3.6 Ultrasound Triggered Drug Delivery ................................................................... 34 
2.4 Gene Delivery .................................................................................................................. 38 
2.4.1 Viral Vectors ........................................................................................................ 38 
2.4.2 Non Viral Vectors ................................................................................................ 39 
2.4.3 Ultrasound and Ultrasound/UCA Assisted Gene Delivery .................................. 42 
3. MATERIALS AND METHODS ............................................................................................ 46 
3.1 Materials .......................................................................................................................... 46 
3.1.1 UCA Fabrication Materials .................................................................................. 46 
3.1.2 Cell Culture Materials .......................................................................................... 46 
3.1.3 Plasmid Preparation Materials ............................................................................. 47 
3.1.4 Other Materials .................................................................................................... 47 
3.2 Methods............................................................................................................................ 47 
3.2.1 Contrast Agent Fabrication .................................................................................. 47 
3.2.2 Drug Loaded Contrast Agent Fabrication ............................................................ 48 
3.2.3 Nanoparticle Fabrication ...................................................................................... 49 
3.2.4 In Vitro UCA Characterization ............................................................................ 49 
3.2.4.1 Size and Zeta Potential Measurements .......................................................... 49 
3.2.4.2 Drug Encapsulation Measurements ............................................................... 50 
3.2.4.3 Acoustic Testing In Vitro .............................................................................. 50 
3.2.4.4 In Vitro Drug Release .................................................................................... 52 
3.2.5 Characterization of Nano Shard Behavior ........................................................... 53 
3.2.5.1 Potential for Nanoparticle Extravasation ...................................................... 53 
3.2.5.2 In Vitro Tumoricidal Activity........................................................................ 54 
3.2.6 In Vivo Doxorubicin Delivery to a Rat Hepatocellular Carcinoma ..................... 55 
3.2.6.1 Establishment of Rat Liver Cancer Model .................................................... 55 
iv 
 
3.2.6.2 In Vivo Comparison between Ultrasound Contrast Agents Nanoparticles and 
Free Doxorubicin ........................................................................................... 56 
3.2.6.3 Biodistribution ............................................................................................... 57 
3.2.6.4 Tumor Growth ............................................................................................... 59 
3.2.6.5 Autoradiography ............................................................................................ 59 
3.2.7 Escherichia Coli (E. Coli) and Plasmid Preparation ............................................ 59 
3.2.7.1 E. Coli Transformation .................................................................................. 59 
3.2.7.2 Plasmid DNA Preparation ............................................................................. 60 
3.2.7.3 Quantifying Plasmid DNA Concentration .................................................... 61 
3.2.8 Nucleic Acid Loading .......................................................................................... 62 
3.2.8.1 Incorporation ................................................................................................. 62 
3.2.8.2 Surface Loading ............................................................................................ 63 
3.2.9 DNA Integrity ...................................................................................................... 64 
3.2.10 Microbubble Triggered Gene Delivery In Vitro .................................................. 65 
3.2.11 Imaging and Quantification ................................................................................. 66 
3.2.12 Ultrasound Exposure Conditions ......................................................................... 68 
3.2.13 Cell Cycle Synchronization ................................................................................. 73 
3.2.14 Statistical Analysis ............................................................................................... 74 
4. RESULTS AND DISCUSSION ............................................................................................. 75 
4.1 In Vivo Delivery of Dox Loaded UCA to Morris 3924a Tumor Model ...................... 75 
4.1.1 Ultrasound Image Enhancement .......................................................................... 75 
4.1.2 Plasma Doxorubicin Levels ................................................................................. 76 
4.1.3 Organ and Tumor Doxorubicin Levels ................................................................ 78 
4.1.4 Tumor Growth ..................................................................................................... 84 
4.1.5 Autoradiography .................................................................................................. 85 
4.1.6 In Vivo Delivery of Dox Loaded UCA Conclusions ........................................... 86 
4.2 Characterization of Paclitaxel and Docetaxel Loaded UCA ....................................... 86 
4.2.1 Effect of Ptx Loading on Acoustic Enhancement and Stability........................... 87 
4.2.2 Effect of Ptx Loading on Microbubble Size ........................................................ 89 
4.2.3 Paclitaxel Payload and Encapsulation Efficiency ................................................ 90 
4.2.4 In Vitro Paclitaxel Release ................................................................................... 92 
4.2.5 Nanoparticle Extravasation Potential of Ptx Loaded Microbubbles .................... 93 
4.2.6 In Vitro Tumoricidal Activity of Ptx Loaded Microbubbles ............................... 94 
4.2.7 Effects of Docetaxel Loading on Acoustic Enhancement and Stability .............. 97 
4.2.8 Effect of Dtx Loading on Microbubble Size ........................................................ 98 
4.2.9 Docetaxel Payload and Encapsulation Efficiency ............................................... 99 
4.2.10 In Vitro Docetaxel Release ................................................................................ 100 
4.2.11 Nanoparticle Extravasation Potential of Dtx Loaded Microbubbles ................. 102 
4.2.12 In Vitro Tumoricidal Activity of Docetaxel Loaded Microbubbles .................. 103 
4.2.13 Paclitaxel and Docetaxel Loading Conclusions ................................................. 104 
4.3 Development of Nucleic Acid Loaded UCA for Gene Delivery ................................ 105 
4.3.1 DNA Loading by Incorporation ......................................................................... 106 
4.3.2 DNA Loading by Surface Adsorption ............................................................... 111 
4.3.2.1 Effect of DNA Molecular Weight on DNA Loading .................................. 116 
4.3.2.2 Effect of PEI Concentration on DNA Loading ........................................... 117 
4.3.2.3 Effect of Ionic Strength on DNA Loading .................................................. 119 
4.3.2.4 Effect of DNA Concentration on DNA Loading ......................................... 120 
4.3.2.5 Plasmid DNA Loading ................................................................................ 121 
4.3.2.6 Effect of Surface Adsorption on Microbubbles .......................................... 122 
4.3.2.7 Effect of DNA Loading on Plasmid Integrity ............................................. 124 
v 
 
4.3.3 DNA Loaded UCA Conclusions ........................................................................ 129 
4.4 Ultrasound Triggered Gene Delivery In Vitro ............................................................ 130 
4.4.1 Pressure Amplitude ............................................................................................ 130 
4.4.2 Duty Cycle ......................................................................................................... 133 
4.4.3 Pulse Repetition Frequency and Pulse Length ................................................... 136 
4.4.4 Pressure and Pulse Length ................................................................................. 140 
4.4.5 Microbubble Concentration ............................................................................... 143 
4.4.6 Exposure Time ................................................................................................... 145 
4.4.7 Radiation Force .................................................................................................. 148 
4.4.8 Calcium and Magnesium Ion Concentrations .................................................... 149 
4.4.9 Multiple Staggered Exposures ........................................................................... 155 
4.4.10 Cell Cycle Manipulation .................................................................................... 158 
4.4.11 Poloxamer .......................................................................................................... 161 
4.4.12 Influence of Cell Line on Transfection Efficiency ............................................ 162 
4.4.13 DNA Loaded Microbubbles ............................................................................... 164 
4.4.14 Ultrasound Triggered Gene Delivery Conclusions ............................................ 166 
5. CONCLUSIONS AND FUTURE RECOMMENDATIONS ............................................... 168 
5.1 Conclusions .................................................................................................................... 168 
5.2 Future Recommendations ............................................................................................ 169 
List of References ........................................................................................................................ 172 
Appendix A: Sonoporation with Short Pulse Lengths ................................................................. 197 
Appendix B: Dose Escalation and Multiple Doses of Dox UCA in Rat HCC Model ................. 207 
VITA ............................................................................................................................................ 216 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
List of Tables 
 
 
Table 3.1: Number of Animals Receiving Each Treatment  ......................................................................... 57 
 
Table 4.1: Effect of Drug Loading on UCA Properties .............................................................................. 105 
 
Table AB.1: Number of Rats in Each Treatment Group ............................................................................ 208 
 
Table AB2: Dox Concentration in Organs and Tumor at 6 Weeks (ng Dox/mg Tissue) ........................... 211 
 
Table AB2: Diameter of Tumors Measured by Ultrasound (cm) ............................................................... 213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
List of Figures 
 
 
Figure 2.1: Chemical structure of A) 
14
C labeled doxorubicin and B) doxorubicinol the major metabolite of 
Dox that conserves the radio labeled carbon group (adapted from Yoo et al.) ............................................. 13 
 
Figure 2.2: Chemical structure of Ptx and Dtx from Andersen et al. Colored portions of the molecule 
indicate the differences in chemical structure ............................................................................................... 14 
 
Figure 2.3: A theoretical acoustic pulse measured at the focus of a transducer ........................................... 23 
 
Figure 2.4: Schematic of targeted drug delivery with polymer microbubbles. The drug loaded 
microbubbles can be injected intravenously and flow freely through the vasculature until exposed to 
ultrasound where they will experience 1) primary radiation forces that will push the bubbles to the vessel 
wall. The ultrasound pressure wave will cause 2) microbubble cavitation as the gas in the bubble rapidly 
expands and contracts in response to the changes in pressure. When exposed to ultrasound with sufficient 
intensity the microbubble will undergo 3) inertial cavitation, destroying the polymer shell resulting in drug 
loaded polymer fragments less than 400 nm in diameter. The energy released by the inertial cavitation is 
capable of breaking apart cell junctions, creating pores and 4) enhancing the permeability of the blood 
vessel. The polymer fragments can then 5) escape the leaky vasculature of the tumor and accumulate within 
the tumor interstitium. The polymer fragments will then degrade over the course of weeks providing 6) a 
sustained release of drug at the tumor. This diagram is not drawn to scale................................................... 37 
 
Figure 3.1: Cell cycle of MCF 7 cells. ......................................................................................................... 74 
 
Figure 4.1:Doppler ultrasound images of Morris 3924a tumors (shown within the green boxed region) in 
the livers of ACI rats after the injection of A) 12 mg ultrasound contrast agent, B) a combination of 6 mg 
nanoparticles and 6 mg ultrasound contrast agent, C) 12 mg nanoparticles and D) free doxorubicin. All 
images were taken with identical machine settings ....................................................................................... 76 
 
Figure 4.2: Effect of delivery vehicle on the concentration of doxorubicin in plasma. Vehicles include: 12 
mg ultrasound contrast agent , 12 mg nanoparticles , a combination of 6 mg nanoparticles and 6 
mg ultrasound contrast agent  or free doxorubicin . After 5 minutes plasma drug concentrations 
were significantly greater in rats treated with free doxorubicin compared to all other treatments (p<0.0470) 
and concentrations were significantly greater in rats treated with nanoparticles compared to ultrasound 
contrast agents (p=0.0052) n=5. .................................................................................................................... 77 
 
Figure 4.3: The effect of vehicle type on the percentage of doxorubicin taken up by the spleen. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment. ............................................................................................ 78 
 
Figure 4.4: The effect of vehicle type on the percentage of doxorubicin taken up by the left liver (a) and 
right liver (b). Vehicle consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a 
combination of 6mg UCA and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were 
quantified at 4 hours , 7 days  and 14 days  after treatment. ................................................. 79 
 
Figure 4.5: The effect of vehicle type on the percentage of doxorubicin taken up by the lungs. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment. ............................................................................................ 80 
 
Figure 4.6: The effect of vehicle type on the percentage of doxorubicin taken up by the heart. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
viii 
 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment. ............................................................................................ 81 
 
Figure 4.7: The effect of vehicle type on the percentage of doxorubicin delivered to the tumor. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment (n=3 for all except free dox at 4 hours 7 and 14 days due to 
lack of tumor growth in some animals). ........................................................................................................ 82 
 
Figure 4.8: The biodistribution of doxorubicin loaded ultrasound contrast agents. Samples were quantified 
at 4 hours , 7 days  and 14 days  after treatment. Drug levels in the spleen, liver, lungs and 
heart all peaked at 4 hours and dropped significantly after 14 days (p<0.0212) while drug levels in the 
tumor showed no significant drop in drug levels from day 0 to day 14 (p=0.7447). ..................................... 83 
 
Figure 4.9: Effect of vehicle on tumor growth in rats.  Vehicles include; 12 mg ultrasound contrast agent 
, 12 mg nanoparticles , a combination of 6 mg nanoparticles and 6 mg ultrasound contrast agent 
 or free doxorubicin . All rats were insonated for 20 minutes after injection.  Tumors treated with 
ultrasound contrast agent did not show a significant increase in size over 14 days (p=0.3214) and had 
significantly less growth than rats treated with free doxorubicin after 14 days (p=0.0390). n = 3 for all 
except free dox at 4 hour 7 and 14 days due to lack of tumor growth in some animals. ............................... 84 
 
Figure 4.10: Autoradiography images of tumors treated with 12 mg ultrasound contrast agent (UCA), 12 
mg nanoparticles (NP), a combination of 6 mg nanoparticles and 6 mg ultrasound contrast agent (COM) or 
free doxorubicin (Free Dox) and sacrificed after 4 hours, 7 days or 14 days. ............................................... 86 
 
Figure 4.11: Effects of Ptx loading concentration on the acoustic behavior, (a) enhancement and (b) 
acoustic stability in vitro of UCA loaded with (0% , 3% , 6% , 12% , 18%  and 24% 
Ptx). No significant difference in maximum enhancement was observed at any loading concentration 
(p>0.076), however samples loaded with 12% Ptx or greater showed significantly more shadowing at a 
dose of 15 µg/ml  (*p<0.0058). All samples loaded with 3% Ptx or greater showed significantly less 
stability than unloaded UCA after 15 minutes (**p<0.034). ......................................................................... 88 
 
Figure 4.12: Effect of Ptx loading concentration on UCA size. Unloaded contrast agent had a diamter of 
1.38 ± 0.06 µm, UCA loaded with 12, 18 and 24% were significantly larger (p<0.0197) with diamters of 
1.86 ± 0.13 µm, 2.02 ± 0.39 µm and 2.83 ± 0.67 µm respectively. ............................................................... 90 
 
Figure 4.13: Final Paclitaxel payload as a function of initial loading concentration (a) and encapsulation 
efficiency (b). Paclitaxel loaded UCA approached their maximum payload of 129.46 µg/mg (encapsulation 
efficiency of 64.73%) at an initial loading concentration of 18% Ptx with no significant increase in payload 
when the initial loading concentration was increased to 24% Ptx (p=0.8807). Numbers above bars represent 
payload in µg Ptx/mg UCA. .......................................................................................................................... 91 
 
Figure 4.14: In vitro drug release profile of Ptx from drug loaded UCA exposed to ultrasound   and 
uninsonated UCA  . The release profile of insonated UCA closely matched the release of uninsonated 
UCA over the first week of release (p>0.56). After 21 days significantly more Ptx had released from 
insonated UCA compared to UCA not exposed to ultrasound (*p<0.05). .................................................... 93 
 
Figure 4.15: Transport through membranes with 400 nm pores of Ptx loaded UCA exposed to ultrasound 
 and uninsonated UCA . After twenty minutes of insonation, 75% more Ptx was forced through the 
400 nm pores than uninsonated controls (p<0.001). ..................................................................................... 94 
 
Figure 4.16: Effect of treatment regime on tumoricidal activity of UCA. Samples were either not insonated 
(patterned) or insonated at 5 MHz for 20 minutes (solid) and assayed 72 hours post treatment.  Unloaded 
ix 
 
UCA not exposed to ultrasound , unloaded UCA exposed to ultrasound , 18% Ptx loaded UCA 
not exposed to ultrasound  and 18% Ptx loaded UCA exposed to ultrasound . Unloaded UCA 
exposed to ultrasound and uninsonated loaded UCA showed no significant decrease in cell viability at any 
concentrations tested (p>0.4827).  Ultrasound contrast agents loaded with 18% Ptx and exposed to 
ultrasound showed significantly greater anti tumor activity at concentrations of 0.1, 1.0 and 10 µg/ml  
compared to uninsonated controls (p<0.01). ................................................................................................. 96 
 
Figure 4.17: Effect of docetaxel loading on the acoustic enhancement (a) and acoustic stability (b) in vitro 
of polymer ultrasound contrast agents loaded with 0% , 3% , 6% , 12% , 18%   and 
24% docetaxel. A significant decrease in maximum acoustic enhancement was observed in samples 
loaded with 24% docetaxel (*p<0.05) while samples loaded with 18% or less showed no significant 
change. A significant decrease in acoustic stability was observed in all samples loaded with 12% docetaxel 
or greater (*p<0.05). ...................................................................................................................................... 98 
 
Figure 4.18: Effect of docetaxel loading on ultrasound contrast agent size. Unloaded contrast agent had an 
average diameter of 1.38 ± 0.06 µm with no significant change in size observed with docetaxel loading. .. 99 
 
Figure 4.19: Docetaxel payload (a) and encapsulation efficiency (b) as a function of initial loading 
concentration. A maximum docetaxel payload of 106.9 ± 22.0 µg docetaxel/mg contrast agent was 
observed with an initial loading of 24% resulting in an encapsulation efficiency of 40 ± 8%. ................... 100 
 
Figure 4.20: In vitro drug release profile from polymer ultrasound contrast agents loaded with 18% 
docetaxel that were either insonated   or uninsonated  . After 24 hours, significantly more docetaxel 
had been released from the insonated samples compared to uninsonated microbubbles (p<0.05). Inset: 
docetaxel release over first 6 days. .............................................................................................................. 102 
 
Figure 4.21: Transport through membranes with 400 nm pores of ultrasound contrast agent loaded with 
18% docetaxel that were insonated    or uninsonated  . After 20 minutes of exposure to ultrasound, 
significantly more docetaxel had been forced through the pores compared to the uninsonated samples 
(p<0.05). ...................................................................................................................................................... 103 
 
Figure 4.22: Tumoricidal activity of docetaxel loaded microbubbles. MCF 7 breast cancer cells were 
treated with unloaded microbubbles that were not exposed to ultrasound , unloaded microbubbles 
exposed to ultrasound , microbubbles loaded with 18% docetaxel and not exposed to 
ultrasound  and microbubbles loaded with 18% docetaxel and exposed to ultrasound . Cell 
viability 72 hours post treatment showed that unloaded microbubbles had no effect on cell viability while 
docetaxel loaded microbubbles exposed to ultrasound had significantly greater antitumor activity compared 
to unloaded bubbles and drug loaded bubbles that had not been exposed to ultrasound at concentrations 
greater than 0.1 µg contrast agent/ml. ......................................................................................................... 104 
 
Figure 4.23: Effect of N:P ratio on size (a) and zeta potential (b) of PEI-DNA complexes made in 150 mM 
NaCl at a pH of 7.0 and a maturation time of 15 minutes (n=3). ................................................................ 107 
 
Figure 4.24: Effect of N:P ratio on the total DNA payload of UCA loaded by incorporation. DNA loading 
increased significantly with increasing N:P ratios up to 2.5:1, remained unchanged at 5:1 and 10:1 ratios 
and then dropped significantly when the N:P ratio increased from 10:1 to 20:1 (*p<0.05, n=3). ............... 109 
 
Figure 4.25: Effect of N:P ratio of DNA-PEI complexes loaded into UCA on the size (a) and zeta potential 
(b) of UCA (n=3)......................................................................................................................................... 111 
 
Figure 4.26: Effect of PEI concentration in the second emulsion on the acoustic enhancement (a) and 
stability (b) of polymer microbubbles (n=3) ............................................................................................... 112 
 
x 
 
Figure 4.27: Effect of PEI concentration in the second emulsion on microbubble diameter (a) and 
percentage of microbubbles larger than 6.5 µm (b) (n=3). .......................................................................... 114 
 
Figure 4.28: Effect of PEI concentration in the second emulsion on zeta potential of PLA microbubbles 
(n=3). ........................................................................................................................................................... 115 
 
Figure 4.29: Agarose gel electrophoresis (0.7% agarose gel run at 100 V for 100 minutes) comparing 
uninsonated salmon DNA (B) with salmon DNA insonated for 3 minutes (C). A 1kBp ladder is shown in 
lane (A).  ...................................................................................................................................................... 116 
 
Figure 4.30: Effect of DNA molecular weight on DNA payload of 1% PEI coated PLA UCA after 
incubating UCA with DNA for 0.25, 1 and 2 hours (n=3). ......................................................................... 117 
 
Figure 4.31: Effect of PEI concentration used in the second emulsion on DNA payload of UCA incubated 
in 100 µg/ml sDNA dissolved in diH2O (n=3).  .......................................................................................... 119 
 
Figure 4.32: Effect of ionic strength on DNA payload of PLA PEI-UCA made with 1% PEI (n=6). ....... 120 
 
Figure 4.33: Effect of initial loading concentration of sDNA on DNA payload of UCA made with 1%PEI 
(n=3). ........................................................................................................................................................... 121 
 
Figure 4.34: Plasmid DNA before (A) and after (B) incubating 2 mg of 1% PEI UCA with 100 (1), 50 (2), 
25 (3), 12.5 (4), 6.25 (5), 3.13 (6) and 1.56 µg plasmid DNA (7).  ............................................................. 122 
 
Figure 4.35: Effect of DNA loading by surface adsorption on the size (a) and zeta potential (b) of UCA 
made with 1% PEI (n=3). ............................................................................................................................ 123 
 
Figure 4.36: Effect of DNA loading by adsorption on the acoustic enhancement (a) and stability (b) of 
polymer microbubbles made with 1% PEI (n=3). ....................................................................................... 124 
 
Figure 4.37: Effects of plasmid DNA integrity on agarose gel electrophoresis migration. ........................ 125 
 
Figure 4.38: Effect of loading and ultrasound on integrity of plasmid DNA. Control plasmid DNA (A) was 
compared with the supernatant after DNA was incubated with 1% PEI UCA (B) or with control UCA 
without PEI (C). Plasmid DNA incubated with control UCA that were then insonated were also examined 
(D).  ............................................................................................................................................................. 126 
 
Figure 4.39: Effect of loading and ultrasound on integrity of plasmid DNA. Control plasmid DNA  
incubated with 5M NaCl (A) was compared DNA released from 1% PEI UCA (B) or with DNA exposed to 
ultrasound while loaded onto PEI UCA then released with 5 M NaCl. The high NaCl concentration used to 
load these samples resulted in the „U‟ shaped bands (“smiling”). ............................................................... 127 
 
Figure 4.40: Effect of loading and ultrasound on integrity of plasmid DNA (n=3). Lower levels of 
supercoiled DNA may have lower transfection efficiencies. ...................................................................... 128 
 
Figure 4.41: Agarose gel electrophoresis examining the effect of growth media and serum on plasmid 
DNA loaded 1% PEI UCA. The gel was loaded with a 1kb ladder (A), control plasmid DNA (B), the 
supernatant after incubating plasmid with PEI UCA (C), the supernatant after incubating DNA loaded UCA 
with water (D) RPMI (E) RPMI + 1% FBS (F) RPMI + 10% FBS. Lanes (H), (I) and (J) contain RPMI 
with 0%, 1% and 10% FBS.  ....................................................................................................................... 129 
 
Figure 4.42: The effect of pressure amplitude and center frequency on (a) transfection efficiency, (b) total 
fluorescence intensity and (c) cell viability. MCF 7 cells were insonated for 15 seconds with 0.25 mg/ml 
PLA UCA and 10 µg/ml of free plasmid DNA with a PL of 20 µs and PRF of 3000 Hz (n=5). ................ 133 
 
xi 
 
Figure 4.43: The effect of pulse repetition frequency on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) viability of cells insonated with a constant pulse length of 20 µs and the effect of pulse 
length on (d) transfection efficiency, (e) total fluorescence intensity and (f) viability of cells insonated with 
a constant pulse repetition frequency of 3000 Hz. All cells were insonated for 15 seconds at 1 MHz with a 
pressure amplitude of 500 kPa and a PLA microbubble concentration of 0.25 mg/ml (n=4). .................... 136 
 
Figure 4.44: The effect of pulse repetition frequency and pulse length on (a) transfection efficiency, (b) 
total fluorescence intensity and (c) cell viability. Cells were insonated for 15 seconds with 0.25 mg/ml PLA 
UCA and 10 µg/ml free plasmid DNA with a pressure amplitude of 1 MPa and a constant duty cycle of 
0.06 (n=5). ................................................................................................................................................... 138 
 
Figure 4.45: Fluorescent images of MCF 7 breast cancer cells expressing GFP 24 hours after exposure to 
ultrasound with a constant acoustic pressure amplitude of 1 MPa while the PRF and PL were 
simultaneously adjusted to maintain a constant DC of 0.06 and an ISPTA of 2.0 W/cm
2
 (Size bar = 100 µm). 
Pulse length (µs) along y axis and center frequency along x axis. .............................................................. 139 
 
Figure 4.46: Effect of PL and pressure amplitude on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) viability of cells insonated with a constant PRF of 3000 Hz and a pressure and PL that 
were simultaneously changed to maintain a constant ISPTA of 2.0 W/cm
2
 (n=5).  A constant UCA 
concentration of 0.25 mg/ml and free plasmid DNA concentration of 10 µg/ml were used. ...................... 141 
 
Figure 4.47: Effect of PL and pressure amplitude on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) viability of cells insonated for 15 seconds with a constant PRF of 1 Hz and a pressure and 
PL that were simultaneously changed to maintain a constant ISPTA of 0.33 W/cm
2
 (n=5). A constant UCA 
concentration of 0.25 mg/ml and free plasmid DNA concentration of 10 µg/ml were used. ...................... 142 
 
Figure 4.48:The effect of PLA microbubble concentration on (a) transfection efficiency, (b) total 
fluorescence intensity and (c) viability of cells insonated for 15 seconds with a constant pressure amplitude 
of 1 MPa, PL of 12 ms and PRF of 5 Hz with 10 µg/ml free plasmid DNA (n=5). .................................... 145 
 
Figure 4.49: The effect of insonation time on the (a) transfection efficiency, (b) total fluorescence intensity 
and (c) cell viability of cells insonated with 0.05 mg/ml UCA, 10 µg/ml free plasmid DNA and a center 
frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz (n=6).......................... 146 
 
Figure 4.50: Effect of ultrasound on acoustic enhancement of PLA UCA. Native UCA were compared 
with uninsonated UCA incubated in a water bath for 2 minutes but not exposed to ultrasound (uninsonated) 
or microbubbles exposed to ultrasound with a center frequency of 1 MHz, a pressure amplitude of 1 MPa, 
PL of 12 ms and PRF of 5 Hz for 2 minutes (insonated). ........................................................................... 147 
 
Figure 4.51: The effect of radiation forces on (a) transfection efficiency, (b) total fluorescence intensity 
and (c) cell viability of cells insonated for 15 seconds with a center frequency of 1 MHz, a pressure 
amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml along with 10 µg/ml 
free plasmid DNA. The direction of ultrasound exposure was changed from pushing UCA towards cells to 
away from cells (n=6). ................................................................................................................................ 149 
 
Figure 4.52: The effect of cell culture medium on transfection efficiency (a) fluorescence intensity (b) and 
cell viability (c) of cells insonated for 15 seconds with a center frequency of 1 MHz, a pressure amplitude 
of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml along with 10 µg/ml free 
plasmid DNA. Cells were insonated in either RPMI or DMEM, both containing 10% FBS (n=6). ........... 150 
 
Figure 4.53: The effect of cell EDTA concentration on transfection efficiency (a) fluorescence intensity (b) 
and cell viability (c) of cells insonated for 15 seconds with a center frequency of 1 MHz, a pressure 
amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml. Cells were 
insonated in DMEM with 10% FBS and 0-2 mM EDTA (n=6). ................................................................. 152 
 
xii 
 
Figure 4.54: The effect of calcium ion concentration on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) cell viability of cells insonated for 15 seconds with a center frequency of 1 MHz, a 
pressure amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml. 
Microbubbles and plasmid were suspended in PBS containing 0.49 mM magnesium chloride and 0-2 mM 
calcium chloride (n=6). ............................................................................................................................... 154 
 
Figure 4.55: The effect of magnesium ion concentration on (a) transfection efficiency, (b) total 
fluorescence intensity and (c) cell viability of cells insonated for 15 seconds with a center frequency of 
1 MHz, a pressure amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml. 
Microbubbles and plasmid were suspended in PBS containing 1.0 mM calcium chloride and 0-1 mM 
magnesium chloride (n=6)........................................................................................................................... 155 
 
Figure 4.56: The effect of multiple exposures on (a) transfection efficiency, (b) total fluorescence intensity 
and (c) cell viability of cells insonated for 15 seconds with 0.05 mg/ml UCA at a center frequency of 1 
MHz, a pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz. Cells were treated either once (1x) or 
twice, with the second exposure 4 hours after the first (0 h 4 h) or 12 hours after the first (0 h 12 h) (n=5).157 
 
Figure 4.57: Merged image of phase contrast, EGFP (green) and propidium iodide (red) in cells treated 
with 0.05 mg/ml microbubbles, 10 µg/ml plasmid DNA in RPMI with 10% FBS. (A) no ultrasound, (B) 
(1x treatment) 15 seconds of ultrasound at 1 MHz, 1 MPa, with a PL of 12 ms and PRF of 5 Hz, (C), 2x 
treatment (0 h 4 h) with the same ultrasound exposure 4 hours after the first and (D) 2x treatment (0 h 12 h) 
with the same exposure 12 hours after the first (size bar = 50 µm). ............................................................ 158 
 
Figure 4.58: Distribution of DNA content per cell in untreated cells and cells synchronized with a double 
hydroxyurea block and assayed 0, 4, 8, 12 and 16 hours after hydroxyurea was removed.  ....................... 160 
 
Figure 4.59: The effect of cell cycle on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) of cells synchronized by a double hydroxyurea block then insonated for 15 seconds with 0.05 
mg/ml UCA and a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz. 
Cells were insonated at 0, 4, 8 or 12 hours after the end of the second hydroxyurea block (n=6).  ............ 161 
 
Figure 4.60: The effect of poloxamer 188 on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) of cells insonated for 15 seconds in RPMI with 10% FBS, 0.05 mg/ml UCA, 10 µg/ml plasmid 
DNA and 0 or 100 µM poloxamer 188 and a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL 
of 12 ms and PRF of 5 Hz (n=6). ................................................................................................................ 162 
 
Figure 4.61: The effect of cell type on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) of cells insonated for 15 seconds in media with 10% FBS, 0.05 mg/ml UCA, 10 µg/ml plasmid 
DNA. ........................................................................................................................................................... 164 
 
Figure 4.62: Effect of DNA loaded UCA on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) (all measured 24 hours after transfection) of cells insonated for 15 seconds in RPMI with 10% 
FBS, 0.25 mg/ml UCA, 5.5 µg/ml plasmid DNA and a center frequency of 1 MHz, pressure amplitude of 1 
MPa, PL of 12 ms and PRF of 5 Hz (n=3). ................................................................................................. 167 
 
Figure AA.1: Acoustic pulse of a focused 5 MHz transducer triggered by a pulser/receiver measured using 
a 0.5 mm PVDF needle hydrophone by Piyush Arora in Dr. Lewin‟s lab in the department of Biomedical 
Engineering at Drexel. ................................................................................................................................. 197 
 
Figure AA.2: Florescent image of cells insonated with a PRF of 5 kHz and a PPP of 1.68 MPa. Only cells 
within the focus of the transducer had enhanced uptake. The diameter of the area with enhanced uptake was 
measured and shown in red. ........................................................................................................................ 198 
 
Figure AA.3: Effect of pulse repetition frequency (PRF) on cell viability (a), sonoporation efficiency (b) 
and sonoporation area (c) (*p<0.05, **p<0.01, ***p<0.001). .................................................................... 199 
xiii 
 
 
Figure AA.4: Effect of peak positive pressure amplitude on area of FITC-dextran uptake (a) and 
sonoporation efficiency (b) (*p<0.01). ........................................................................................................ 200 
 
Figure AA.5: Effect of insonation time on sonoporation efficiency (*p>0.01).......................................... 202 
 
Figure AA.6: Effect of PRF on diameter of the region of cells with enhanced uptake of FITC-dextran. .. 202 
 
Figure AA.7: Beam plot of focused 5 MHz transducer used in sonoporation experiments measured using a 
0.5 mm PVDF needle hydrophone by Piyush Arora in Dr. Lewin‟s lab in the department of Biomedical 
Engineering at Drexel. ................................................................................................................................. 203 
 
Figure AA.8: Pressure profile along the x axis of the focused 5 MHz transducer used in these sonoporation 
experiments. Measured using a 0.5 mm PVDF needle hydrophone by Piyush Arora in Dr. Lewin‟s lab in 
the department of Biomedical Engineering at Drexel. ................................................................................ 204 
 
Figure AA.9: Effect of radiation force on sonoporation efficiency. Diagram of direction of applied 
ultrasound (a), effect of direction on sonoporation efficiency (b) and effect of direction on sonoporation 
area (c). ........................................................................................................................................................ 205 
 
Figure AB1: Effect of microbubble dose on the size of the rat spleen measured after death. .................... 210 
 
Figure AB2: Dox levels in the tumor and organs 6 weeks after the first treatment or after animal 
sacrifice due to distress. Animal death occurred at different times after treatment making comparison 
difficult. ....................................................................................................................................................... 212 
 
Figure AB3: Effect of treatment and dose on animal survival ................................................................... 213 
 
Figure AB4: Scanning electron microscope image of Dox loaded microbubbles made damaged 
homogenizer probe. ..................................................................................................................................... 214 
 
 
 
 
 
 
 
  
xiv 
 
List of Abbreviations and Symbols 
 
BAEC: Bovine aortic endothelial cells 
COM: Combination of ultrasound contrast agents and nanoparticles 
DC: Duty cycle 
DI: Deionized 
DOPE: Dioleoylphosphatidylethanolamine 
Dox: Doxorubicin 
DNA: Deoxyribose nucleic acid 
Dtx: Docetaxel 
E. coli: Eschericia coli 
EDTA: Ethylenediaminetetracetic acid 
EEO: Electroendoosmosis 
EGFP: Enhanced green fluorescent protein 
EPR: Enhanced permeability and retention 
FBS: Fetal bovine serum 
FDA: Food and drug administration 
FITC: Fluorescein isothiocyanate 
I: Intensity 
IPA: Isopropyl alcohol 
ISPPA: Spatial peak pulse average intensity 
ISPTA: Spatial peak temporal average intensity 
HCC: Hepatocellular carcinoma 
HPLC: High performance liquid chromatography 
LB: Luria Bertani 
xv 
 
LSC: Liquid scintillation counting 
MPS: Mononuclear phagocyte system 
MW: Molecular weight 
NP: Nanoparticles 
OCT: Optimal cutting temperature 
P188: Poloxamer 188 
PBS: Phosphate buffered saline 
PEG: Polyethylene glycol 
PEI: Polyethyleneimine 
PI: Propidium iodide 
PL: Pulse length 
PLA: Poly(lactic acid) 
PLGA: Poly(lactic co glycolic acid) 
PNP: Peak negative pressure 
PRF: Pulse repetition frequency 
Ptx: Paclitaxel 
PVA: Poly(vinyl alcohol) 
RFU: Relative fluorescence units 
sDNA: Deoxyribose nucleic acid from salmon testes 
Tris: Tris(hydroxymethyl)aminomethane 
TRITC: Tetramethylrhodamineisothiocyanate 
UCA: Ultrasound contrast agents 
VEGF: Vascular endothelial growth factor 
5FU: 5 fluorouracil 
%ID: Percentage of initial dose 
xvi 
 
P: Pressure (Pa) 
α: Attenuation coefficient (cm-1) 
L: Distance (cm) 
f: Frequency (MHz) 
Z: Acoustic impedance (N s/m
3
) 
ρ: Density (kg/m3) 
c: Speed of sound (m/s) 
I: Intensity (W/cm
2
) 
R: Reflection coefficient (no units) 
dP: Pressure drop (Pa) 
σ: Surface tension (N/m) 
r: radius (m) 
F: force (N) 
R0: Initial Radius (m) 
fr: Resonance frequency (Hz) 
δ: damping coefficient (N s/m) 
V: Velocity (m/s) 
ƞ: Shear viscosity (m2/s) 
κ: Compressibility (m2/N) 
d: distance (m) 
 
 
 
 
  
xvii 
 
Abstract 
Polymer Ultrasound Contrast Agents for Targeted Drug and Gene Delivery 
Michael Cochran 
Margaret A. Wheatley, PhD 
 
 
 
 
 Ultrasound contrast agents (UCA) are encapsulated gas microbubbles that can respond to 
ultrasound by rapidly expanding and contracting (exhibiting cavitation) while also reflecting the 
acoustic signal. This ultrasound induced cavitation can be utilized to increase the permeability of 
blood vessels or to create transient pores in cell membranes. It may be possible to take advantage 
of these biological effects for ultrasound targeted drug and gene delivery.  
 Microbubbles made with a poly(lactic acid) shell and loaded with Doxorubicin (Dox) 
were previously developed in this lab and shown to rupture into 200-400nm drug loaded polymer 
fragments when exposed to ultrasound. The ability of this platform to provide ultrasound-targeted 
drug delivery in vivo was examined with a rat hepatocellular carcinoma model and compared with 
free Dox. Microbubbles were able to deliver significantly more drug to the tumor compared to 
free Dox (2.491 ± 0.501%/g tissue, vs. 0.373 ± 0.087%/g tissue, p= 0.047). However, 
significantly higher drug levels were also found in the spleen and liver of animals treated with 
microbubbles compared to free Dox.  
 Microbubbles were also loaded with more hydrophobic drugs including paclitaxel and 
docetaxel. Total payloads of 129.5 ± 1.8 and 80.8 ± 3.0µg drug/mg UCA were achieved for 
paclitaxel and docetaxel loaded microbubbles while maintaining the agents‟ acoustic activities. 
Both agents were able to provide a sustained in vitro release of drug from the shell over three 
weeks and the drug released from these agents was able to prevent the growth of MCF7 cancer 
cells in vitro. 
 Polyethyleneimine coated polymer microbubbles were also developed for ultrasound 
targeted gene therapy and were capable of carrying a DNA payload of 22.8 ± 0.13µg DNA/mg 
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UCA. Additionally, polymer microbubbles triggered with ultrasound enhanced the delivery of 
free plasmid DNA into the cytoplasm of MCF7 cells in vitro. Successful transfection required an 
acoustic pressure amplitude of 250kPa or greater and showed a strong dependence on frequency 
and pulse length, however these settings also resulted in significantly lower cell viability. 
Transfection efficiency was also affected by the calcium ion concentrations in the culture medium 
and stage of the cell cycle that cells were treated in.  
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1. INTRODUCTION 
 
1.1 Statement of the Problem 
 In 2012, over 1,600,000 people are expected to be diagnosed with cancer and over 
570,000 people are expected to die of cancer in the United States [1]. Significant progress in 
cancer treatment has been made; however, systemic delivery of toxic chemotherapy is still an 
important component of many treatment options. Most chemotherapeutics used (including 
anthracyclines and taxanes) are highly toxic to both cancer cells and non cancerous tissue and can 
cause dangerous systemic side effects, reducing the efficacy of the drug.  
 Ultrasound contrast agents (UCA) are small (<6 µm) gas bubbles encapsulated within a 
lipid, polymer or protein shell. When exposed to ultrasound, the gas core of microbubbles can 
rapidly expand and contract in response to applied pressure rarefaction and compression. The 
wall of a vibrating microbubble can expand and contract with velocities of up to 700 m/s and can 
generate enough force to create transient pores in cell membranes and enhance the permeability 
of blood vessels [2]. Research over the past ten years has focused on taking advantage of these 
unique ultrasound/microbubble interactions by developing microbubbles for targeted drug 
delivery and gene delivery. Many of the drug loaded microbubble platforms are based on lipid 
microbubbles that provide a rapid release of drug when triggered by ultrasound. One 
disadvantage of this approach is that drug released into the blood can be quickly transported away 
from the desired target. In addition the capacity to carry a co-encapsulated drug payload is limited 
by the thin phospholipid shell. 
 As an alternative to this approach, a doxorubicin (Dox) loaded polymer microbubble 
ultrasound contrast agent has previously been developed in our laboratory [3]. These 
microbubbles have been shown to reduce in size to less than 400 nm when exposed to ultrasound 
in vitro, presumably due to fragmentation of the polymer shell induced by inertial cavitation [4]. 
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These polymer fragments are small enough to escape the leaky vasculature of a tumor and 
accumulate within the tumor‟s interstitium, where they can provide a sustained release of drug 
into the tumor. 
 In addition to targeted drug delivery, these polymer microbubbles may also be useful for 
ultrasound-targeted delivery of nucleic acids to treat diseases including cancer, cardiovascular 
disease and diseases of the salivary gland including xerostomia (chronic dry mouth) and 
Sjorgen‟s Syndrome (an autoimmune disease that can destroy exocrine glands).While lipid and 
albumin microbubbles are frequently studied for gene delivery by ultrasound triggered 
microbubble destruction, the poly(lactic acid) microbubbles developed in this lab have some 
useful properties, such as their enhanced stability, that may make them a useful tool for 
ultrasound triggered gene delivery.  
 
1.2 Thesis Objective: 
 The overall goals of this research are to characterize the efficacy of this poly(lactic acid) 
microbubble drug delivery platform and develop methods for delivering other therapeutic 
bioactive compounds. A strategy comprised of the following four specific aims was used to reach 
these goals. 
 
Specific Aim 1: To characterize the ability of Doxorubicin (Dox) loaded ultrasound contrast 
agents to provide targeted drug delivery in vivo using a rat liver cancer model. In order to 
evaluate the platform‟s performance in vivo, it is necessary to conduct biodistribution studies.  
This was achieved by quantify drug levels in the blood, healthy organs and the targeted tumor. In 
addition, ultrasound targeted drug loaded UCA were compared with alternative treatments 
including free Dox, Dox loaded nanoparticles (NP) and a combination of UCA and NP. Our 
hypothesis is that doxorubicin loaded UCA will pass freely through the blood stream until 
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reaching the tumor where a focused ultrasound beam will interact with the UCA and generate 
primary radiation forces, pushing the UCA towards the vessel wall. The UCA will also cavitate in 
response to the applied ultrasound, increasing the permeability of the already leaky vasculature of 
the tumor. The ultrasound triggered microbubble destruction will also generate drug loaded 
polymer fragments less than 400 nm in size capable of escaping through the leaky vasculature of 
the tumor and accumulating within the tumor interstitium where the fragments will slowly 
degrade, providing a sustained, localized release of Dox. We also hypothesize that a micron sized 
UCA will have far greater interaction with the ultrasound beam than do NP, resulting in higher 
intra tumoral Dox concentrations. The benefits achieved by combining UCA with ultrasound 
(cavitation to enhanced blood vessel permeability, radiation forces to push UCA to the vessel 
walls, microstreaming to improve the flow of drug into cancer cells and the acoustic backscatter 
from UCA allowing them to be simultaneously visualized as they are triggered) may also be 
combined with NP which have their own unique advantages (including their enhanced 
circulation) by simultaneously delivering drug loaded NP with UCA triggered by ultrasound in 
order to improve drug delivery.  
 
Specific Aim 2: To encapsulate the taxanes paclitaxel (Ptx) and docetaxel (Dtx) within the 
polymer contrast agent platform and to evaluate the effect of the hydrophobic nature of the 
drug on the loading efficiency and acoustic properties in vitro. The maximum Dox loading 
obtained by incorporation was approximately 6.2 µg Dox / mg PLA corresponding to an 
encapsulation efficiency of 20.5%. Loading of Dox may have been limited by the amphipathic 
nature of the drug resulting in a partition coefficient that did not favor the drug‟s entrapment 
within the hydrophobic polymer shell of the UCA. Our objective is to load UCA with the more 
hydrophobic drugs Ptx or Dtx and characterize the agent‟s drug loading capabilities, acoustic 
properties and antitumor activity. It is hypothesized that Ptx can be loaded into polymer UCA 
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with a greater maximum payload and loading efficiency compared to Dox without compromising 
the agents acoustic properties. We expect that the synthetic taxane Dtx which is more hydrophilic 
than Ptx but still more hydrophobic than Dox will have a maximum payload and loading 
efficiency greater than Dox but less than Ptx.  
 
Specific Aim 3: To develop and characterize new methods for the loading of nucleic acids 
onto polymer contrast agents. Microbubble assisted gene deliver can be performed by co-
administering plasmid and microbubbles or by loading the plasmid directly onto the microbubble. 
Naked plasmid DNA can be rapidly degraded by nucleases found in serum. Encapsulating nucleic 
acids or condensing them with polycations can limit the exposure of plasmids to nucleases and 
protect them from rapid degradation. We hypothesize polymer UCA can be modified so that 
plasmid DNA can be loaded onto the surface and within the core of the microbubble, creating an 
agent that can transport and protect the desired plasmid until triggered by ultrasound to transfect 
the desired target. 
 
Specific Aim 4: To determine the effects of the acoustic exposure parameters and exposure 
conditions on the ability of polymer UCA to transfect cells in vitro. Microbubbles triggered 
with ultrasound can be utilized for spatially targeted gene delivery as the gas core of the 
microbubble will oscillate in response to ultrasound. This can generate enough shear force to 
create transient pores in cell membranes allowing the uptake of the desired plasmid. The response 
of the microbubble is dependent on its size and shell properties as well as the frequency, pressure, 
and duty cycle of the ultrasound used. A cell‟s response to sonoporation is also dependent on the 
content of the surrounding medium and the cell itself. It is hypothesized that the acoustic 
exposure parameters will have a significant effect on the transfection efficiency achieved with 
PLA UCA and the acoustic parameters necessary to transfect cells with PLA UCA will be 
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different than those used for lipid and albumin UCA. It is also hypothesized that transfection 
efficiency will be affected by the type of cell. 
 
 
2. BACKGROUND 
 
2.1 Cancer and Cancer Treatments 
Cancer describes a group of diseases with uncontrolled cell division that can invade other 
tissues. A cell can become cancerous when it accumulates mutations in the genes involved in 
regulating cell division. These mutations can be the result of DNA damage caused by radiation, 
toxins, microbes and viruses, inherited mutations, immune conditions or chronic inflammation. 
Cancerous cells can spread through the blood or lymphatic system, leading to metastasis, if the 
spread is not controlled, it can lead to death. In 2012, over 1,600,000 people in the United States 
are expected to be diagnosed with cancer and over 570,000 people are expected to die of 
cancer [1].  
 
2.1.1 Breast and Liver Cancer 
In 2012, breast cancer is expected to be the most common type of cancer in women in the 
United States, accounting for 29% of new cases. The survival rates 5, 10 and 15 years after 
diagnosis are 90, 82 and 77% respectively. The five year survival rate for women diagnosed with 
localized breast cancer that has not spread to the lymph nodes can be as high as 99%, when the 
cancer spreads to nearby lymph nodes the survival rate drops to 84% and if the cancer spreads to 
distal lymph nodes or organs, the survival rate drops to 23%. Despite the relatively high survival 
rates, breast cancer is the second leading cause of cancer death in women in the United States 
after lung, with over 39,000 deaths expected in 2012 [1]. Anthracyclines such as Dox are 
frequently included in the treatment of breast cancers [5-6] and can be combined with other drugs 
including paclitaxel [7]. These drugs are excellent subjects for ultrasound triggered drug delivery 
with microbubbles and this also makes breast cancer cells a useful tool for in vitro examination of 
the efficacy of these agents.  
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In the United States, over 28,000 new cases of liver cancer are expected to be diagnosed 
in 2012 and over 80% of these are expected to originate from hepatocytes leading to 
hepatocellular carcinoma (HCC) [8]. Additionally, 143,000 Americans are expected to develop 
colorectal cancer and over half will develop metastases, with many developing colorectal liver 
metastases [9].  The five year survival rate for patients diagnosed with liver cancer is 14%. 
Survival in patients that were diagnosed in an early stage is 27% but this quickly drops as the 
cancer spreads to regional and distant stages to 9 and 4% [1] making it the second most deadly 
form of cancer [10] and the third leading cause of cancer death worldwide [11]. The leading 
causes of liver cancer in the United States are alcohol related cirrhosis of the liver, fatty liver 
disease from obesity, hepatitis B and hepatitis C viruses [8, 10]. Systemic therapies for HCC have 
had very little success. Clinical trials with the hormonal therapy tamoxifen have shown negative 
results and systemic chemotherapy with Dox and cisplatin (the most active agents against HCC in 
vitro and in vivo) have only shown a partial response in 10% of patients with no improvement in 
survival [12]. Chemoemoblization with drug eluting beads is capable of delivering 150 mg of 
Dox to the liver over the course of a week with low systemic toxicity because of the controlled 
and localized release of the drug [12]. Transarterial chemoembolization can achieve a partial 
response in 15-55% of HCC and significantly delays tumor progression [13]. These results also 
suggest that ultrasound triggered delivery of Dox using drug loaded microbubbles may be a 
useful way to increase drug delivered to the tumor while reducing systemic exposure.  
 
2.1.2 Solid Tumor Biology 
 Tumorigenesis begins with mutational activation of oncogenes combined with mutational 
inactivation of tumor suppressor genes within a cell allowing it to divide aberrantly [14]. These 
mutated cells can divide as an avascular nodule less than 1-2 mm until reaching a steady-state of 
cell division and apoptosis [15]. Cancerous cells, like normal cells, need a supply of oxygen and 
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nutrients to support their metabolism which makes it necessary for the tumor cells to gain access 
to the hosts vascular system by inducing the formation of a new blood supply [16]. This tumor 
induced angiogenesis can be triggered by hypoxia or through the activation of oncogenes [17]. 
Angiogenesis in healthy tissue is a highly regulated process, however in tumors there is a 
disproportionate production of angiogenic growth factors (such as vascular endothelial growth 
factor, fibroblast growth factor or angiopoietin 2) and inhibitors (such as thrombospondin-1 [18] 
or transforming growth factor β1 [19]) that lead to an abnormal vascular system in tumors that 
can vary greatly from tumor to tumor [16]. The tumor-induced blood vessels can be made of both 
endothelial cells that are abnormal in shape and tumor cells [20]. They usually have no functional 
pericytes, causing them to be dilated, with uneven diameters and convoluted, with excessive 
branching and shuts. The vessels also lack a basement membrane and have fenestrae and 
transcellular holes which make the blood vessels especially permeable [16, 20]. The sizes of the 
endothelial gaps in some tumor vessels measured by microscopy can range from 100 to 1000 nm 
with most measuring approximately 700 nm. Tumors have also been observed to have a 
characteristic pore cutoff size ranging from 380 to 1200 nm with the majority between 380 and 
780 nm [21-22]. Others have observed intercellular openings in tumor vessels from 300 to 4700 
nm with an average of 1700 nm and transcellular holes from 200 to 900 nm with an average of 
600 nm [23]. These gaps are much larger than the 2 – 8 nm pores found in most normal tissue, or 
even the 40-60 nm pores found in the endothelium of the kidney glomerulus and the 150 nm 
pores in the sinusoidal endothelium of the liver and spleen [24-25].  
 The increased vascular permeability leads to the outflow of proteins and other molecules 
from the capillaries into the interstitium which causes an increase in the osmotic pressure of the 
interstitium [26]. In normal tissue a network of lymphatic vessels collects the extravasated fluid 
and proteins and transports them back to the venous circulation through lymphatic networks [27].  
However, in many tumors, no lymphatic vessels are detectable within the tumor [27], in other 
9 
 
tumors, functional lymphatic vessels can be observed at the periphery of the tumor while 
lymphatic vessels in the tumor are nonfunctional and compressed, possibly caused by mechanical 
stress generated by the proliferating cancer cells [26-28]. The combination of leaky tumor blood 
vessels and a nonfunctioning tumor lymphatic system along with the contraction of stromal 
fibroblasts generate a high interstitial fluid pressure in solid tumors [26]. In the interstitium of 
normal tissue, the net balance of osmotic pressure and hydrostatic pressure is 1 – 3 mm Hg less 
than the pressure in the capillaries resulting in a flow of fluid out of the vessels into the 
interstitium which is useful for transport of large molecules to cells [26]. However, the interstitial 
fluid pressure in tumors can be much higher than normal tissue, resulting in a net pressure that 
can be up to18 mm Hg greater than the pressure in the capillaries which reduces transport of large 
molecules and drugs from the blood into the tumor [26, 29]. The high interstitial fluid pressure in 
the center of the tumor also causes fluid, macromolecules and drugs in the center of the tumor to 
ooze out to the surface of the tumor where it can be recovered by the lymphatic system [30]. 
Watson et al. have shown that by using ultrasound to increase the temperature of tumors to 42 °C 
it is possible to reduce the interstitial fluid pressure and increase the accumulation of 
nanoparticles [31]. 
  
2.1.3 Current Treatments for Breast and Liver Cancer 
Breast cancer treatments 
 Treatment of breast cancers will usually involve surgical removal of the tumor and 
surrounding tissue (lumpectomy) or of the entire breast (mastectomy). Surgery is often combined 
with radiation therapy, hormone therapy or monoclonal antibodies. Studies have shown a 
significant decrease in recurrence when lumpectomy was combined with irradiation, however 
there was no significant difference in survival after 20 years of patients receiving lumpectomy 
combined with irradiation compared with mastectomy [32].  
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With radiation therapy, ionizing radiation in the form of X-rays or gamma rays is 
delivered to the area of the tumor, usually through an external beam. The ionizing radiation 
creates free radicals which can cause damage to DNA and sufficient damage to the cell‟s DNA 
can inhibit proliferation and lead to cell death through necrosis or apoptosis. The information 
from computed tomography images can be used to create 3-D maps of tumors for 3-D conformal 
radiation therapy in order to accurately distribute the radiation dose in the tumor volume [33]. 
Even with a highly controlled dose, radiation therapy still causes damage to the DNA in healthy 
cells in the area, especially skin cells and is associated with other side effects including muscle 
stiffness and lymphedema. And while the use of radiation therapy as an adjuvant to lumpectomy 
can provide a drop in recurrence, there has been no improvement in survival [32]. 
 Surgical removal of tumors is now often combined with chemotherapy either before or 
after the surgery to help kill any cancer cells that have spread beyond the visible tumor. Some of 
the most common drugs used to treat breast cancer are Dox, epirubicin, Dtx, Ptx, 
cyclophosphamide and 5 fluorouracil (5FU). These drugs are often given in combinations such as 
5 FU, Dox and cyclophosphamide (FAC), or Dtx, Dox and cyclophosphamide (TAC) and can 
improve survival rates by as much as 38% [5-6]. Side effects of chemotherapy can include lower 
resistance to infection, increased bleeding, nausea, hair loss and fatigue [6].  
 
Liver cancer treatments 
 Surgical removal of a section of the liver containing small tumors is the primary 
treatment option for patients with non-cirrhotic livers, which is only 5-10% of patients in the 
West [34]. In patients with cirrhotic livers, resection is not an option when the patient suffers 
from portal vein hypertension or shows other signs of liver dysfunction. There is also a 70% 
chance of tumor recurrence within 5 years [34-35]. Liver transplantation is an option that could 
cure both the cancer and the cirrhosis. When patients are selected with tumors less than 5 cm they 
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can achieve a 5 year survival rate as high as 70% [36]. However, there are over 18,000 people 
waiting for liver transplants and only 5000 donors per year leading to waiting times longer than 
12 months in the United States [34, 37]. 
 For patients with unresectable HCC there are numerous percutaneous strategies for tumor 
ablation. Repeated percutaneous injections of ethanol can achieve response rates as high as 50% 
in patients with tumors smaller than 5 cm [38]. Tumor ablation can also be achieved through 
microwave, laser, radiofrequency or cryoablation. Radiofrequency ablation uses high frequency 
electromagnetic waves to generate enough heat to kill cells in a controlled pattern around an 
antenna guided into the tumor and has been shown to be more effective than ethanol injection 
[12]. In some poorly differentiated tumors, the needles used for these percutaneous treatments can 
cause needle track seeding, causing the tumor to spread outside the liver along the needle track 
[39]. 
 Arterial embolization, the most commonly used treatment for unresectable HCC, involves 
the obstruction of the hepatic artery using gelatin or microspheres and can cause extensive 
necrosis in highly vascular HCC [12]. The embolizing microspheres can be mixed with drugs 
such as Dox or cisplatin to provide a localized release of drug in the liver, or combined with 
radioactive beads for a localized dose of internal radiation therapy [12]. Chemoemoblization with 
drug eluting beads is capable of delivering 150 mg of Dox to the liver over the course of a week 
with low systemic toxicity because of the controlled and localized release of the drug [12]. 
Transarterial chemoembolization can achieve a partial response in 15-55% of HCC and 
significantly delays tumor progression [13]. 
 Systemic therapies for HCC have had very little success. Clinical trials with the hormonal 
therapy tamoxifen have shown negative results and systemic chemotherapy with Dox and 
cisplatin (the most active agents against HCC in vitro and in vivo) have only shown a partial 
response in 10% of patients with no improvement in survival [12].  
12 
 
2.1.4 Doxorubicin, Paclitaxel and Docetaxel 
 Doxorubicin belongs to a group of drugs called anthracyclines which are widely used for 
systemic chemotherapy in cancer patients [40]. Doxorubicin, shown in figure 2.1 consists of an 
aglycone ring covalently bound to an amino sugar. The primary mechanisms of action of Dox 
involve the ability of the aglycone ring to intercalate between DNA base pairs and to inhibit 
topoisomerase II. The role of topoisomerase II in normal cell division is to create transient double 
strand breaks in the DNA, then allow the DNA double helix to untwist, then reseal the breaks in 
the DNA without any changes to the DNA sequence. In cells treated with Dox, the amino sugar in 
Dox helps the intercalated drug form a stable DNA-Dox-topisomerase II complex. This complex 
stabilizes an intermediate step of the topoisomerase II pathway and prevents DNA resealing [41]. 
Additional modes of action of Dox involve the generation of hydroxyl free radicals, inhibition of 
topoisomerase I, inhibition of DNA polymerases, inhibition of DNA repair and inhibition of 
mitochondrial oxidative phosphorylation [40, 42]. 
 Doxorubicin has been used to treat various types of solid tumors including those arising 
in the breast, bile ducts, esophagus, endometrial tissue, lung and liver [43]. However the systemic 
delivery of Dox results in side effects including myelosuppression, neutropenia, alopecia and 
nausea. While these side effects are usually temporary, the most serious risks associated with Dox 
are from its cardiotoxicity. The use of Dox can cause dilative cardiomyopathy and irreversible 
congestive heart failure, possibly caused by the generation of free radicals [41, 44].  The risk of 
congestive heart failure is dependent on the cumulative dose. When the cumulative dose reaches 
500 mg per square meter, over 4% of patients develop congestive heart failure, this percentage 
increases to 36% when over 600 mg of drug is used [44].  
 The major metabolite of doxorubicin is doxorubicinol (figure 2.1B) which is formed by 
cytoplasmic NADPH dependent aldo-keto reductase. This alcohol metabolite, doxorubicinol, is 
thought to be the major cause of the cardiotoxicity associated with Dox use [45]. Figure 2.1 
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shows the position of the radio labeled 
14
C used in our experiments, which is preserved in 
doxorubicinol. 
 
 
 
Figure 2.1: Chemical structure of A) 
14
C labeled doxorubicin and B) doxorubicinol the major metabolite of 
Dox that conserves the radio labeled carbon group (adapted from Yoo et al.[46]. 
 
 
 
 Both Ptx and Dtx (figure 2.2) are members of the taxane class of anticancer drugs which 
work as microtubule stabilizing agents. In normal cell division, α and β subunits of tubulin bind 
together with GTP to form the profilaments that build microtubules. These microtubules extend 
from the centrosomes at each end of the cell and attach to the kinetochore of sister chromatids 
during metaphase. The microtubule lengths can then adjust to create the required tension to allow 
the sister chromatids to separate and allow mitosis to continue [47]. Ptx and Dtx can bind to a 
hydrophobic pocket at the inner surface of β tubulin and stabilizes the microtubule preventing 
disassembly [48]. By interfering with microtubule dynamics, Ptx can alter the microtubule 
tension across the kinetochore during anaphase, preventing separation of sister chromatids and 
Dtx can disrupt centrosome organization [47].  At nanomolar concentrations, Ptx and Dtx can 
prevent mitosis and cause cell death through apoptosis or necrosis [47, 49-50]. In vitro, Dtx is a 
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more potent inhibitor of microtubule disassembly compared to Ptx [51] and has shown greater 
anti tumor activity against breast, colon and ovarian cancer cell lines [51-53]. 
 
 
 
Figure 2.2: Chemical structure of Ptx and Dtx from Andersen et al. [54] Colored portions of the molecule 
indicate the differences in chemical structure.  
 
 
Ptx and Dtx have shown significant activity against solid tumors including breast cancer 
and ovarian carcinomas [55-57]. The clinical effectiveness of Ptx has been limited by its poor 
solubility [58] making it necessary to deliver Ptx in a formulation (Taxol®) of 1:1 Cremophor® 
EL and ethanol. Dtx is more hydrophilic than Ptx and is delivered in a solution of Tween 80 and 
ethanol. Systemic delivery of Taxol can cause severe side effects including hypersensitivity 
reactions [59] neurotoxicity, cardiotoxicity and neutropenia [60]. Systemic delivery of Dtx in a 
formulation of Tween 80 and ethanol results in fewer hypersensitivity reactions than Ptx, but also 
unusual side effects including skin toxicity and fluid retention [51, 53] as well as hematological 
and neuromotor toxicity [52].   
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2.1.5 Cancer Targeted Drug Delivery 
 The effectiveness of systemic delivery of chemotherapeutic agents has been limited by 
the lack of selectivity of most anticancer drugs resulting in significant toxicity to normal tissues. 
Targeted drug delivery for cancer therapy involves delivering therapeutic concentrations of drug 
to target cells while reducing systemic exposure and improving the therapeutic index. One group 
of these targeted drug delivery vehicles relies on controlled release delivery depot systems for 
implantation into or adjacent to a cancerous tumor. Examples of these delivery vehicles include 
drug eluting wafers, films, rods, gels and particles [61]. These implantable delivery vehicles can 
be used as an adjuvant to surgery and help kill cancer cells in the resection margins to prevent a 
localized recurrence. They can provide a prolonged release of drug over weeks or months directly 
to the disease site but their use is limited to resectable tumors.  
The other group of targeted drug delivery systems involves the systemic delivery of 
particles (liposomes, dendrimers, nanoparticles, microspheres or polymer-drug conjugates) that 
can passively target tumors through the enhanced permeability and retention (EPR) effect, or can 
be actively targeted to tumor cells through cell markers (integrins, monoclonal antibodies, 
peptides, folic acid receptors). Environment responsive carriers can be triggered to release drugs 
at the desired target through changes in temperature or pH while other carriers can be triggered 
through external stimuli, including light, heat, magnetic fields, and ultrasound waves [62].  
 The EPR effect is a tumor specific characteristic that is often taken advantage of for drug 
delivery [63]. The high permeability of the angiogenic blood vessels found in tumors can allow 
macromolecules and particles to escape through pores that can range from 380 – 780 nm [21]. 
Most tumors also lack functioning lymphatic vessels that would clear away the extravasated fluid 
and particles in healthy tissue [28]. The combination of enhanced permeability and limited 
lymphatic drainage is unique to tumors and can allow the accumulation of macromolecules 
greater than 40 kDa and drug delivery vehicles in the tumor [63-64]. 
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The EPR effect has been utilized in many drug delivery vehicles including Doxil, which 
are polyethylene glycol (PEG) coated liposomes, less than 100 nm in diameter, containing 
Dox [65]. Doxil has been approved for treatment of Kaposi sarcoma, metastatic ovarian cancer 
and metastatic breast cancer [65-66]. Doxil has a circulation half life of over 70 hours compared 
to less than 10 minutes for free Dox, this allows the liposomes to accumulate within the tumor 
and can lead to intracellular drug levels 10 times higher in the tumor compared to adjacent tumor-
free tissue [66-68]. Doxil also reduces the amount of free drug in plasma which is an important 
factor in reducing cardiotoxicity [44, 67]. When Doxil was given to nude rats, approximately 2% 
of the initial dose per gram of tissue was found in the tumor 4 hours after treatment, after 120 
hours this dropped to 0.36 % of the initial dose per gram. The majority of the drug was found in 
the spleen and kidney with over 5% of the initial dose per gram in the spleen and 8% of the initial 
dose per gram in the kidney [65]. While Doxil has shown lower cardiotoxicity compared to Dox, 
Doxil still causes side effects including nausea, lowered blood count and hand-foot syndrome. It 
has also been obsereved that the infusion of Doxil can cause an immediate hypersensitivity 
reaction that may be caused by activation of the complement system [69]. 
 Others have tried to improve on these passively targeted liposomes by developing Dox 
loaded liposomes that are targeted to markers on the endothelial cells in tumors [70]. Pasorino 
et al. used Dox containing liposomes with a peptide containing asparagine-glycine-arginine 
(NGR) to target CD13, a protein expressed on endothelial cells of most solid tumors. When they 
used these vascular targeting liposomes to treat neuroblastoma, lung and ovarian cancer in mice 
they observed an enhanced survival compared to free Dox and un-targeted Doxil [70]. They 
attributed this enhanced efficacy to the ability to directly destroy the tumor vasculature by using 
the vessel targeting agents [70]. Tuscano and others have developed Dox loaded liposomes 
conjugated to a monoclonal antibody targeting CD22 to treat Non-Hodgkin‟s lymphoma. In 
xenograft bearing mice, they observed 80% higher drug levels in the tumors treated with targeted 
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liposomes compared to untargeted liposomes but also a 60% increase in drug levels in the spleen 
when the antibody was used [71]. 
 Ptx has also been incorporated into many nanoparticle drug delivery vehicles and one of 
them, Abraxane, has been approved for use in metastatic breast cancer by the FDA [72]. 
Abraxane consists of 130 nm particles of human serum albumin reversibly bound to Ptx, this 
formulation allows Ptx to retain its therapeutic benefits while eliminating the toxicities and other 
disadvantages caused by the Cremaphor used in Taxol [73]. This results in an improved safety 
profile for Ptx in the absence of Cremaphor [74]. The use of Abraxane in metastatic breast cancer 
patients resulted in significantly greater response rates and fewer cases of grade 4 neutropenia 
compared to Taxol [75]. Pharmacokinetic studies have shown that Abraxane has a 50% larger 
volume of distribution compared to Taxol, indicating the micelles created by the Cremaphor used 
in Taxol are limiting the availability of Ptx and preventing the distribution of Ptx into the tissue 
[75]. The use of albumin can also improve transport across endothelial cells by binding to gp60 
receptors, resulting in endocytosis and transport across the endothelial cells [75]. Or through 
binding to osteonectin, a protein found in many cancers which causes the accumulation of 
albumin and albumin bound drugs in tumors [75-76]. A variety of alternative strategies including 
micelles, liposomes, microspheres and nanoparticles are also being investigated to deliver Ptx 
without the use of Cremophor® [77]. Nanoparticles fabricated with Poly(lactic co glycolic acid) 
(PLGA) [78] and poly(lactic acid) (PLA) [79] have been loaded with Ptx and used to passively 
target tumors [80]. Similar polymer nanoparticles have also been loaded with Dtx for passive 
targeting of tumors [81-82] and others have modified these nanoparticles to actively target cancer 
cells by using folate to target cancer cells expressing folate binding protein [83], or aptamers to 
target prostate-specific membrane antigen [84] as well as many other formulations and 
approaches. In addition to improving drug delivery to tumors, nanoparticles have also had success 
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in treating cancer cells that have developed multidrug resistance, possibly by overcoming Pgp 
pumps in the cell membrane that can efficiently remove unencapsulated drug [85-86].  
 An alternative form of targeted drug delivery uses delivery vehicles that have been 
designed to release drug at the desired location in response to internal or externally applied 
stimuli. For example, tumor hypoxia can lead to an increased production of lactic acid in the 
tumor causing the pH in the extracellular space of tumors to drop as low as 6.5 compared to 7.5 in 
normal tissue. Nanoparticles, micelles and polymer drug conjugates have been designed to  
destabilize and release drug in response to the lower pH found in tumors [87]. 
 Other delivery vehicles have been developed to release drug when triggered with an 
external stimulus such as heat, light, magnetic fields or ultrasound. Light sensitive nanoparticles 
have been developed using polymers that can be rapidly cleaved when exposed to UV light while 
in aqueous solutions, this can convert the polymer from hydrophobic to hydrophilic and 
destabilize the nanoparticle allowing the encapsulated drug to escape at the targeted region [88]. 
Alexiou et al. were able to use high powered magnetic fields focused on a tumor to improve 
delivery of drug-loaded magnetic nanoparticles. When these particles were injected through a 
femoral artery and exposed to a magnetic field they observed complete remission of a VX-2 
squamous cell carcinoma in New Zealand White rabbits [89]. Others have used ultrasound to 
trigger the release of drug from microbubbles [90]. 
 
2.1.6 Mononuclear Phagocyte System 
 One factor that has limited the success of most injectable colloidal drug delivery vehicles 
has been the mononuclear phagocyte system (MPS) and its ability to rapidly detect and remove 
injected particles from the blood. The MPS describes a group of highly phagocytic mononuclear 
cells including monocytes in the blood and macrophages in the tissues [91]. Macrophages are 
present in most organs, especially the lung, liver and spleen, and are responsible for clearing the 
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blood, lymph and tissue of dead cells, microorganisms and particles. The MPS has the ability to 
remove most foreign particles (including particles used for drug delivery) from the blood within 
minutes of being injected [92]. Peracchia et al. showed that 60% of their unpegylated 
poly(hexadecylcyanoacrylate) nanoparticles were taken up by the liver within 1 minute and 
within 30 minutes 90% of the particles had been taken up by the liver [93].  This reduces the 
amount of drug available to reach the targeted location and can also cause toxicity to the 
macrophages in the liver and spleen. When particles are exposed to blood, proteins including 
immunoglobulins, fibronectin and complement proteins such as C3b can adsorb to the surface of 
the particles. This process is called opsonization and when activated, these proteins can bind to 
receptors on the macrophages of the MPS leading to phagocytosis of the particle [94]. Serum also 
contains proteins that can suppress particle recognition by macrophages. The rate of clearance of 
particles is proposed to be a balance of the activating opsonins and suppressing proteins 
(dysopsonins) [95]. 
 Many strategies for avoiding uptake by the liver and spleen have been investigated 
including particle size and chemical makeup. By injecting large doses of placebo particles prior to 
injection of a radioactive liposome, it is possible to reduce the uptake of the radioactive particles 
by the liver and spleen from 90% to 30%, however, this increased uptake in the lung from 5% to 
60% [96-97]. Other, more clinically useful options involve designing particles that can avoid 
opsonization and enhance their circulation time. 
 The surface characteristics of a particle can determine how quickly proteins adsorb to the 
surface and also which proteins adsorb. Hydrophobic and ionic interactions can drive protein 
adsorption and are two important factors that are considered when designing stealth particles that 
can evade the immune system. Highly charged particles have been shown to rapidly bind to 
opsonins and can activate more complement proteins than neutral particles [94]. Others have 
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shown hydrophobic particles are taken up by the spleen and liver much more efficiently than 
hydrophilic particles [96]. 
 To prevent opsonization and complement activation, particles can be modified with 
polysaccharides such as heparin, or with polymers containing poly(ethylene glycol) PEG. The 
features that make PEG so effective compared to other polymers are that it is very hydrophilic, 
uncharged, has great chain flexibility and rarely elicits an immune response [94, 98-99]. PEG is 
also inexpensive and easily modified, allowing it to be conjugated to various lipids and synthetic 
polymers. The use of PEG coatings has been shown to extend the circulation time of liposomes 
and nanoparticles by reducing protein adsorption, however the length of PEG and the density of 
PEG on the particle must be carefully chosen in order to create a “brush” that can prevent protein 
adsorption through steric hindrance without chain entanglement [92, 95, 98, 100-101].  
 When PEG coated liposomes are injected intravenously, as much as 5-10% can be taken 
up by the liver and spleen within the first hour [102]. This may be the result of a heterogeneous 
population that has some particles with patchy PEG coatings that can allow opsonization and 
MPS uptake. This may explain why the PEG coated liposomes that make up Doxil can cause 
significant complement activation when incubated with serum, and why Doxil has a biphasic half 
life of 86 min and 46 hours [102].   
The size of the drug delivery vehicle also effects how it will interact with the MPS. Many 
studies have shown that larger particles are removed from circulation more quickly than smaller 
particles [94-95, 103-104].  Complement activation involves a chain reaction of multiple proteins 
and some of the convertase proteins involved can be as large as 14 x 8 nm. It may be more 
difficult for smaller particles to activate the complement system due to geometric constraints 
caused by the high radius of curvature [94]. The size of the particle can also effect the final 
biodistribution of the particles, small particles less than 30 nm can be eliminated through the renal 
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system, particles of approximately 150 nm can be taken up by the liver, spleen and bone marrow 
while particles greater than 250 nm are only taken up by the liver and spleen [104].  
The size and deformability of particles can also determine their ability to pass through the 
spleen. Particles need to be either less than 200 nm or highly deformable to avoid splenic 
filtration [95, 98]. The intercellular slits in sinusoidal spleens can be between 200 and 500 nm, 
even when blood cells are passing through [105]. Particles that are unable to pass through these 
slits will rapidly accumulate in the spleen in a process that may not depend on complement 
activation or phagocytosis [106-107]. 
 One complication that makes it difficult to interpret much of the research done on the 
MPS has been the huge differences in the MPS between species [108]. For example, the liver 
macrophages called Kupffer cells can take up particles 10 times more efficiently in mice than 
rats, and 4 times more efficiently in rats than rabbits [108]. Kupffer cells in mice livers can also 
take up particles that have not been opsonized [108]. There are also differences in how blood 
passes through the reticular mesh in the spleens of rats, rabbits and humans [95]. However, 
Walburn et al. observed no difference in the phagocytic activity of human and rat Kupffer cells in 
vitro [109]. CRIg is a complement receptor that is expressed in sinusoidal macrophages and 
participates in the internalization of C3 opsonized particles. This receptor‟s structure and function 
has also been shown to be highly conserved between mice and humans [110] 
 
2.2 Ultrasound 
 Ultrasound is one of the most widely used imaging modalities used in diagnostic 
imaging. It can be used for non-ionizing, real-time imaging and is less expensive compared to 
other modalities [111]. Ultrasound involves the transmission of a short cyclic pressure wave from 
a transducer through the body. As the acoustic wave passes through the tissue some of the energy 
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is lost to attenuation caused by scattering and friction which generates heat. The amplitude of the 
transmitted wave can be described by: 
                                                 P x =  P × eαx  ,       (1) 
where P(x) is the pressure amplitude after traveling a distance of x (cm), P (Pa) is the initial 
pressure amplitude and α (cm-1) is the attenuation coefficient for that transmission frequency in a 
specific media. The attenuation can also be estimated by: 
                                             Attenuation =  α𝐿𝑓,        (2) 
where α is assumed to be 0.3 dB/MHz cm along the beam axis for most soft tissue and L is the 
distance in cm and f is the transmission frequency in MHz. 
 When the acoustic wave reaches a boundary with an impedance mismatch, some of the 
energy will be reflected back to the transducer to generate an image while the remaining energy 
passes through the tissue until it is reflected by boundaries deeper in the tissue. The acoustic 
impedance (Z) of a material is defined as: 
                                                   Z = ρc,      (3) 
where 𝜌 is the density of the material (kg/m3) and c (m/s) is the speed of sound in that material.  
Some characteristics that can be used to describe an acoustic signal are its center 
frequency, pressure amplitude or peak negative (rarefactional) pressure (PNP) in Pa, pulse length 
(PL) in seconds, pulse repetition frequency (PRF) in Hz, duty cycle (DC) and Intensity (I) in 
W/cm
2
. Where the intensity of a continuous wave is defined as: 
                                             I =
PN P2
2Z
=
PRMS
2
Z
,         (4) 
where PRMS (Pa) is the root mean square of the pressure wave.  For pulses of ultrasound, the 
intensity can also be described as the spatial peak temporal average intensity ISPTA (W/cm
2
) and 
the spatial peak pulse average intensity ISPPA (W/cm
2
). Where for a pulse similar to one shown in 
figure 2.3, the ISPTA (W/cm
2
) would be defined as the highest intensity measured in the ultrasound 
beam averaged over the pulse repetition period [112]: 
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                                            ISPTA = I × DC.         (5) 
And the ISPPA would be defined as the highest intensity averaged over the temporal duration of the 
pulse [112]: 
                                                ISPPA = I.      (6) 
The current FDA recommendations suggest a derated maximum ISTPA of 0.72 W/cm
2
 and a ISPPA 
of 190 W/cm
2
 for diagnostic ultrasound [112]. 
 
 
 
Figure 2.3: A theoretical acoustic pulse measured at the focus of a transducer. 
 
 
 
2.3 Ultrasound Contrast Agents 
 Ultrasound can be used to detect abnormal blood flow patterns in the heart, however it is 
difficult to detect small blood volumes and slow blood flow. Small gas microbubbles can be 
introduced into the blood to improve blood and tissue delineation. The enhancement provided by 
microbubbles was first observed by a cardiologist injecting indocyanine green into the heart while 
performing an echocardiogram and it was later discovered that the ultrasound enhancement was 
due to small bubbles forming at the tip of the catheter during injection. These microbubbles can 
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reflect ultrasound due to the acoustic impedance mismatch between water and air. The reflection 
coefficient (R) describes the fraction of ultrasound that will be reflected by a boundary between 
materials with impedances of Z1 and Z2 and is defined as:  
    R =
Z2−Z1
Z2+Z1
.     (7) 
The reflection coefficient for a boundary between air (Zair=415 Pa s/m) and water (Zwater = 
1.49×10
6 
Pa s/m) (at 20 °C and 1 atm) is nearly one, indicating almost all of the energy is 
reflected back from the bubble. However, the reflection from a particle that is much smaller than 
the wavelength of the ultrasound wave is proportional to the sixth power of the size of the particle 
leading to a very small signal from micron sized particles [113]. The strong signal generated by 
microbubbles is the result of the difference in compressibility between the gas and surrounding 
fluid which allows the gas bubble to resonate and generate a signal 1000 time greater than a gas 
bubble with the same diameter but encapsulated by a completely rigid shell [114]. Each bubble 
has a natural resonance frequency that depends on the size and shell properties of the bubble. Free 
microbubbles that are 1-6 µm in diameter usually have a resonance frequency from 1-10 MHz 
which is in the range of typical ultrasound scanners used for medical imaging. A microbubble 
insonated at its resonance frequency can have a scattering and absorption cross section a thousand 
times its resting size [115].  
 The bubbles formed by injecting agitated saline into blood were clearly detectable with 
ultrasound but they would quickly disappear. The pressure drop (dP) in Pascals across a free 
bubble can be calculated using the Laplace equation: 
    dP =
2σ
r
,    (8) 
where σ is the surface tension of the gas liquid interface (N/m) and r is the radius (m) of the 
bubble. For bubbles with a small radius the pressure drop can be close to 100 kPa which drives 
the diffusion of gas from the bubble into the liquid causing the bubble to shrink and disappear. 
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The lifetime of a 2.5 µm free air bubble is less than one second [116]. In order to improve the 
lifetime of microbubbles, the air can be replaced with high molecular weight low solubility gases 
such as sulfur hexafluoride or perfluorocarbon gasses including octofluoropropane, and the gas 
can be encapsulated within a stabilizing shell.  
 
2.3.1 Existing Ultrasound Contrast Agents 
Ultrasound contrast agents (UCA) have been developed using many different materials. 
When saline was mixed with the blood from patients before injection it was able to prolong the 
lifetime of the injected bubbles and Feinstein was able to determine that albumin from the blood 
was responsible for enhancing microbubble stability and later developed Albunex an air  
microbubble stabilized with human serum albumin [114].  In 1998, albumin stabilized 
perfluorocarbon bubbles called Optison were approved by the FDA for use as an ultrasound 
contrast agent. 
 The other UCA clinically in use in the United States has been Definity, an 
octofluoropropane microbubble encapsulated within a lipid shell composed of three different 
lipids including one with PEG 5000 grafted to the end. SonoVue has been approved for use in 
Europe and China and consists of a sulfur hexafluoride microbubble encapsulated by lipids. The 
lyophilized powder contains PEG4000, lipids not containing PEG and palmitic acid. Sonazoid 
consists of hydrogenated egg phosphatidyl serine coated perfluorobutane microbubbles that have 
been lyophilized with sucrose [117]. Sonazoid has been approved for use in Japan and is a liver 
specific agent because of its ability to be rapidly taken up by macrophages in the liver (known as 
Kupffer cells) which is useful for Kupffer phase imaging. By imaging the liver 10 minutes after 
injection of Sonazoid it is possible to distinguish between hypoechoic tumors, which have no 
macrophages to accumulate the bubbles, and healthy liver tissue, which has significantly more 
contrast due to the phagocytosed UCA [118]. 
26 
 
 
2.3.2 Polymer Ultrasound Contrast Agents 
 Ultrasound contrast agents have also been made using various polymers, however no 
polymer UCA have been clinically approved yet. In the 1980‟s and 1990‟s polymer UCA were 
made with natural polymers including collagen [119] and alginate [120]. Later, 
butylcyanoacrylate, a synthetic polymer, was used to encapsulate air in a gas water emulsion 
[121]. Others have used PLGA or PLGA-PEG copolymers to encapsulate air or perfluorocarbon 
by emulsifying an ammonium acetate or ammonium bicarbonate solution with the polymer/lipid 
solution followed by spray drying and lyophilizing [122-124]. These UCA were eventually 
developed into Imagify by Acusphere but were not approved by the FDA for use as an imaging 
agent for detection of coronary artery disease. 
 The polymer UCA developed by Point Biomedical was fabricated by emulsifying PLA 
and human serum albumin solutions then repeatedly extruding the emulsion through 8 µm filters 
followed by cross linking the albumin protein coat using glutaraldehyde, then washing the 
particles and lyophilizing them in a PEG solution [125]. Polymer contrast agents have also been 
developed using other polymers including polystyrene [126] and poly(vinyl alcohol) (PVA) 
[127]. 
 The polymer UCA that have been developed in Dr. Wheatley‟s laboratory are fabricated 
using a water in oil in water emulsion to create an air filled microbubbles encapsulated by a PLA 
or PLGA shell along with residual PVA [3, 128]. These UCA have a mean diameter of less than 
2 µm and have shown acoustic enhancement of over 20 dB in vitro and in vivo [129].  
 
2.3.3 Ultrasound Induced Microbubble Behavior 
 In addition to enhancing backscatter for contrast enhanced ultrasound imaging, 
microbubbles can be used for therapeutic applications due to their unique response to ultrasound 
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and their potential to cause a physiological effect. When exposed to an acoustic pulse, the highly 
compressible gas core of an UCA will rapidly expand and contract in response to the applied 
pressure rarefaction and compression [130]. When exposed to moderate ultrasound intensities the 
UCA will undergo stable cavitation where the bubble will oscillate around a resonant 
diameter [131]. The wall of a vibrating UCA can expand and contract millions of times per 
second with wall velocities as high as 700 m/s [2]. These oscillations create a steady flow of fluid 
surrounding the UCA which is called microstreaming. With higher intensities the UCA can 
undergo inertial cavitation where the bubbles will rapidly expand due to the rarefaction phase of 
the ultrasound wave, then collapse due to the inertia of the fluid surrounding the bubbles flowing 
in during the compression phase [131]. This violent bubble collapse can generate localized 
mechanical shock waves, microstreaming, microjets, free radicals and temperatures as high as 
5000 °K [132]. 
 When a collapsing bubble is near a boundary, the collapse will be asymmetrical, the 
boundary will inhibit fluid flow and cause the bubble wall opposite the boundary to have a 
different acceleration than the bubble wall closest to the boundary causing the bubble to elongate. 
As the bubble collapses the fluid away from the boundary will be focused and accelerated 
through the bubble forming a liquid jet directed towards the boundary [130]. These liquid jets can 
travel over 20 µm with average jet velocities of approximately 80 m/s and pressures of 60 MPa 
[130, 133]. These liquids jets can be strong enough to penetrate any human cell and can act as 
micro syringes capable of injecting up to 60 femtoliters of fluid [130]. AFM images of cells that 
experienced these microjets showed deep pits indicating the permeabilization of the cell 
membrane [134]. However, formation of these jets occurred with only 39% of Optison UCA 
under conditions where the bubble‟s distance to the boundary was highly controlled with an 
optical trap holding the UCA a distance from the wall that was just beyond the measured radius 
of maximum expansion for a specific acoustic pressure [134-135]. 
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 The use of ultrasound to increase the permeability of cell membranes is known as 
sonoporation and while microjets have been shown to be capable of creating pores in cells, others 
have shown that there may be additional mechanism responsible. For example, the 
microstreaming caused by large air bubbles undergoing only controlled linear oscillations were 
capable of breaking open the membranes of unilamellar lipid vesicles [136]. Wu et al. have 
shown that the shear stress resulting from the microstreaming near an oscillating microbubble is 
strong enough to break open cell membranes [137]. High speed photography has shown that 
oscillating microbubbles close to cells were able to deform the cell membrane and allow 
propidium iodide (PI) to flow into the cell without the formation of microjets (1MHz, 0.4MPa, 
PL=10 µs, PRF=50Hz). This permeability to PI was also shown to be reversible because PI added 
to the cell culture medium one minute after ultrasound exposure was not able to pass through the 
cell membrane [138]. Others looking at the duration of the pores formed by sonoporation showed 
that when the fluorescent marker (FITC-Dextran, MW=77KDa, diameter = 17 nm) was added 5 
seconds after ultrasound exposure (2.25 MHz, 0.57 MPa, PRF=100Hz, PL=2 ms) the percentage 
of cells with enhanced uptake dropped over 90% [139]. Others have shown that a small 
fluorescent molecule Sytox Green can enter C6 glioma cells up to 24 hours after exposure to 
ultrasound (1.5 MHz, 0.88 MPa, PL = 0.2ms PRF=1kHz) with SonoVue UCA, and that the pores 
have a half life of 8 hours [140]. 
Recent studies have suggested that macromolecule entry into cells may be caused by 
enhanced endocytosis triggered by hyperpolorization of the cell membrane. Studies using patch 
clamps on human breast cancer cells have shown that low intensity ultrasound (1MHz, 200 kPa, 
10 cycles, PRF =1000 Hz) combined with microbubbles (SonoVue) in direct contact with cells 
results in membrane hyperpolarization that is synchronized with ultrasound exposure. A similar 
hyperpolarization could also be generated by mechanical pressure from a glass rod [141]. This 
lead Tran et al. to suggest that the hyperpolarization was caused by opening stretch sensitive ion 
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channels because formation of nonspecific pores would lead to depolarization of the cell [141]. 
Juffermans et al. used cardiomyoblasts exposed to ultrasound (1MHz, 0.1 and 0.5 MPa, 10 
cycles, PRF = 20 Hz) and UCA (SonoVue) to show that the hyperpolarization was localized to 
parts of the membrane adjacent to vibrating UCA [142]. They were also able to show that by 
using iberiotoxin (an inhibitor of calcium dependent big potassium channels) they could prevent 
hyperpolarization indicating that the hyperpolarization is caused by the calcium dependent 
potassium channels allowing potassium to leave the cell in response to calcium entering the cell 
[142]. Some studies have suggested that the calcium ion influx is caused by hydrogen peroxide 
generated by UCA stable cavitation. For example, Juffermans et al. observed that when cells 
were insonated in the presence of catalase (a hydrogen peroxide scavenger) there was a 
significant reduction in calcium ion influx [143], however other studies have shown that 
sonoporation is not dependent on free radical formation [144]. Calcium influx can also be caused 
by mechanical stresses on cells from direct contact or fluid flow [145-146]. This calcium ion 
influx has also been linked with rapid exocytosis and endocytosis which can increase the uptake 
of macromolecules [147-148]. Supporting this theory, Meijering et al. showed that UCA 
triggered uptake of macromolecules (4 – 500 kDa) in endothelial cells can be significantly 
decreased by inhibiting clathrin mediated enocytosis, caveolae mediated endocytosis and 
macropinocytosis [149]. 
Many studies have found evidence contradicting the role of endocytosis in sonoporation 
observed by Meijering et al. [149].  Experiments using fluorescent markers to track DNA 
internalization after ultrasound exposure with UCA showed that within 5 minutes of exposure, 
plasmid DNA was evenly dispersed throughout the cell and not localized to endosomes [150]. 
They also observed plasmid uptake with ultrasound exposure when the cells were kept at 4 °C 
suggesting endocytosis was not involved. Lentacker et al. observed UCA cavitation caused 
lipoplexes to be delivered directly to a cells cytosol, even when the cells had been treated with an 
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endocytic inhibitor (Methy-β-cyclodextrin) [151] Geers et al. have shown that ultrasound 
triggered microbubble destruction can deliver adeno-associated viruses directly to the cytosol of 
cells without endosomal internalization [152]. Schlicher et al. showed that cell uptake of calcein, 
FITC labeled albumin and dextran was dependent on both calcium and ATP which are required 
for exocytosis of lysosomes to seal the membrane [153]. They also showed that uptake of these 
molecules was not inhibited by potassium ion depletion which inhibits clathrin and caveoli 
mediated endocytosis. Schlicher et al. also stained plasma membranes before insonation and 
observed no stained membrane in the cell after insonation to further show endocytosis was not 
involved [153]. However, the rapid endocytosis that can occur in response to a large influx of 
calcium ions is dependent on dynamin (not dependent on potassium) and not clathrin [148]. 
Additionally, rapid endocytosis triggered by calcium influx is directly tied to rapid exocytosis 
where a lysosome fuses with the cell membrane but can then disconnect from the cell membrane 
in a process called cavicapture, which may explain why no fluorescently labeled membrane was 
found in the cell by Schlicher et al. [148]. 
 An alternative theory used to explain sonoporation involves the formation of nonspecific 
pores 100-1000 nm in diameter caused by the mechanical stress generated by cavitating UCA 
[154-155].  Fluorescently labeled dextran, plasmid DNA and fluorescent polystyrene 
nanoparticles can enter the cell through these large pores along with calcium ions. The calcium 
ions can trigger exocytosis by causing vesicles in the cell to fuse with the cell membrane which 
helps seal the pore formed by the cavitiating UCA [156]. Zhou et al. have used voltage clamps on 
single cells to show that UCA exposed to ultrasound can induce a transmembrane current, 
indicating the formation of pores. This current could be stopped by resealing the membrane in a 
calcium ion dependent process [157]. The rate of membrane sealing was dependent on calcium 
ion concentration, in the absence of calcium they observed no recovery in transmembrane current 
and eventually cell death. A minimum calcium concentration of 0.54 mM was required to 
31 
 
completely reseal cell membranes within minutes, while a higher concentration of 1.8 mM 
allowed the membranes to seal within 6-26 seconds [157]. 
 While the two possible mechanisms appear to contradict each other, it is important to 
note that the acoustic parameters used by Geers et al. [152], Lentacker et al. [151] and Mehier-
Humbert [158] were high enough to cause more violent microbubble  cavitation compared to the 
studies described by Juffermans et al. [142] and Meijering et al. [149].  It is possible that 
sonoporation occurs through enhanced endocytosis at lower pressures and through the formation 
of non specific pores when UCA are triggered with higher acoustic intensities. Further work is 
required to determine what conditions trigger each rout of internalization.  
 
2.3.4 Blood Vessel Permeability 
 In addition to enhancing the permeability of cells, sonoporation has also been used to 
increase the permeability of blood vessels. In vitro studies have shown that UCA triggered with 
ultrasound can create gaps in artificial endothelia and cell monolayers [159]. Song et al. observed 
discrete extravasation points created by the application of ultrasound (1MHz, 0.75 MPa, 
PL=100 µs) to skeletal muscle with Optison bubbles flowing through the capillaries. They also 
showed that 100 nm nanoparticles could escape through these pores and that extravasation of 
these particles could be enhanced by increasing the microvascular pressure [160]. A similar study 
showed that capillary rupture and also cell death was correlated with the mechanical index used 
[161]. Polymer microspheres as large as 503 nm along with red blood cells and fragments of 
Optison bubbles were able to extravasate from these capillary ruptures [161-162]. Song et al. also 
showed that this treatment may lead to arteriogenesis (the growth of preexisting collateral 
arterioles leading to formation of large conductance arteries) in muscle fibers [163]. Chappell et 
al. showed that ultrasound triggered UCA could improve extravasation of growth factor loaded 
100 nm nanoparticles into muscle fibers for therapeutic arteriogenesis [164]. 
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Ultrasound triggered UCA destruction was also able to induce Evans Blue extravasation 
from capillaries in the heart. Localized hemorrhaging was also observed in the areas of the heart 
exposed to ultrasound [165]. Bekeredjian et al. were also able to show increased extravasation of 
Evans Blue in a subcutaneous rat hepatoma when treated with ultrasound and lipid bubbles. 
However, when the Evans Blue was injected after completion of the ultrasound treatment there 
was no increase in extravasation indicating that the increased capillary permeability is very 
transient [166]. However, Bohmer et al. have shown extravasation of Evans Blue is greater when 
the dye is injected immediately after ultrasound exposure and that the pores may be open for as 
long as 60 minutes while they are slowly healed through a wound healing process involving 
platelet activation [167]. Hynynen et al. showed that UCA cavitation in the brain can allow 
marker molecules including immunoglobuilin to pass through the blood brain barrier. They also 
observed extravasation of red blood cells, widening or disintegration of tight junctions and also 
vacuoles carrying the marker molecules through the endothelial cells [168]. Caskey et al. have 
shown that UCA in a gel flow phantom were able to form small tunnels in the gel suggesting that 
the effects of cavitating UCA may extend beyond the blood vessel [169]. 
 
2.3.5 Radiation Force 
 Microbubbles placed in an acoustic field experience a primary radiation force that can 
drive the UCA in the direction of the propagating field. High-speed photography has shown that 
bubbles can be displaced as far as 5 µm during one 20 cycle pulse (2.25 MHz, 380 kPa) with an 
average velocity of 500 mm/s [170]. This radiation force is the result of a pressure gradient across 
the surface of the bubble and the primary radiation force averaged over an acoustic cycle has been 
described by Dayton et al. [171] as: 
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where δ is total damping coefficient (Ns/m), fr is the resonance frequency of the microbubble 
(Hz), f is the frequency of the driving ultrasound wave and R0 is the initial radius of the 
microbubble (m). 
When the frequency used matches the resonance frequency of the bubble the force can be 
simplified to: 
    F =
DC (P2R0)
ρc𝑓δ
.    (10) 
 The radiation force is dependent on the intensity of the applied ultrasound as well as the 
size of the particle with smaller particles experiencing less force. Additionally, smaller particles 
are expected to have larger resonance frequencies which also lead to lower radiation forces for 
smaller nanobubbles. The radiation force on a 2 µm free bubble insonated at its resonance 
frequency (3.26 MHz) would be 25 times greater than the radiation force of a 400 nm free bubble 
insonated at its resonance frequency (16.3 MHz). 
 Primary radiation forces have been used to push targeted bubbles against the vessel wall 
to improve ligand availability and binding [172-173]. Or to push drug loaded UCA against the 
vessel wall in order to deposit drug loaded particles by breaking the bubble with high intensity 
ultrasound [174]. Caskey et al. have shown that primary radiation forces can push UCA against 
vessel walls leading to an asymmetric collapse and the formation of microjets in the direction of 
the vessel wall [169]. 
 Microbubbles can also exert radiation forces on each other called secondary radiation 
forces. If two bubbles are both larger than or both smaller than the resonant size then the 
secondary forces will cause the bubbles to move towards each other leading to aggregation [130]. 
The velocity (m/s) that two identical bubbles will approach each other has been described by 
Dayton et al. [171]: 
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    v =
(2πfP )2
27ƞ
ρκ2R0
5
d2
,    (11) 
where ƞ is the shear viscosity of the fluid (Pa s), κ is the compressibility (Pa-1) of the bubble and d 
is the distance (m) between the two bubbles. When the distance is larger than a few hundred 
micrometers, the secondary forces are very small. As the bubbles get closer together the 
secondary forces increase rapidly causing the bubbles to aggregate. This can be important in 
concentrated suspensions of bubbles where the secondary forces can cause a homogenous 
suspension of bubbles to separate into discrete islands of bubbles as shown by Dayton et al. with 
high speed photography [171]. 
 
2.3.6 Ultrasound Triggered Drug Delivery 
The bioeffects induced by ultrasound have been utilized in various ways for targeted drug 
delivery. Saad et al. demonstrated a 3 fold increase in cytotoxicity in cells that were treated with 
Dox and exposed to therapeutic ultrasound (2.025 MHz, I = 1 W/cm
2
) for 30 minutes compared 
to cells that were treated with Dox with no ultrasound [175]. They concluded that the increased 
cytotoxicity was due to a net increase in drug uptake caused by enhanced cell membrane 
permeability. Escoffre et al. have shown than by combining ultrasound with UCA they were able 
enhance Dox uptake and cell death in vitro with only 30 seconds of exposure (1 MHz, 400 kPa, 
PL=40us, PRF=10000 Hz) [176]. A similar in vitro study showed melanoma cells treated with 
bleomycin in combination with ultrasound (1 W/cm
2
, DC=50%) for 60 seconds could suppress 
cell growth at concentrations 10 times lower than with bleomycin alone. This effect was further 
increased by combining ultrasound with Optison microbubbles [177]. Sonoda et al. also showed 
that ultrasound (2 W/cm
2
, DC=50%) combined with Optison microbubbles and bleomycin could 
be used to reduce the size of melanoma tumors in the eyelids of mice with bleomycin 
concentrations of 0.06 mg/ml while tumors continued to grow when treated with bleomycin 
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concentrations of 0.5mg/ml but without ultrasound [177]. Ultrasound has also been used to 
enhance the delivery of liposomes to tumors. Kheirolomoom et al. insonated (1.5MHz, 1.2 MPa, 
PL= 67 µs, PRF= 5 kHz) tumors for 2 minutes to raise the temperature in the tumor to 42 °C. 
This was shown to increase tumor blood vessel diameter by 120% and double the amount of Dox 
loaded liposomes delivered to the insonated tumor with a maximum of 10% of the injected dose 
per gram of tumor [178].  
 Drugs have also been loaded into lipid bubbles in order to be released at the desired 
location by ultrasound triggered microbubble destruction. For example, lipid bubbles loaded with 
140 µg of Dox (3.8 × 10
-8
 µg Dox/ microbubble) that were infused into rats through a jugular vein 
and combined with ultrasound (1.3MHz, 1.2MPa) focused on a subcutaneous tumor were able to 
deliver 10 µg Dox/ gram of tissue to tumors [179]. Lipid UCA have also been loaded with Ptx 
[180], Dtx [181], rampamycin [182], proteins [183-184] and fluorescently labeled lipids [185]. 
However, the thin lipid shell (<5 nm) and gas core of lipid UCA have a limited drug loading 
capacity [186]. One approach used to enhance drug loading in these UCA has been to conjugate 
drug loaded liposomes to the surface of the UCA. Kheirolomoom et al. have shown that ten 
thousand 100 nm liposomes can be loaded onto the surface of a UCA and ultrasound can be used 
to deliver those nanoparticles into cells in vitro [186]. Lentacker et al. used a similar approach to 
load 150 nm liposomes containing Dox onto the surface of lipid UCA. They were able to achieve 
a loading capacity of approximately 3.25 × 10
-8
 µg Dox/microbubble and showed significantly 
more cell death when microbubbles were triggered with ultrasound (1 MHz, DC=50% I=2W/cm
2
) 
in vitro [187]. When Klibanov et al. attached liposomes containing thrombin to the surface of 
lipid UCA they discovered that only 11% of the loaded thrombin could be released when 
triggered with ultrasound (1 MHz, 7 MPa, PL=100ms, PRF =5Hz) [188]. An alternative approach 
has been to load small lipid UCA into large liposomes containing drug in order to trigger drug 
release from the liposome with ultrasound [189]. Or by creating echogenic liposomes that can be 
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loaded with hydrophilic or hydrophobic drugs and PFC [190]. For example Unger et al. dissolved 
Ptx into soybean oil, then mixed the drug with lipids and PFC to create liposomes containing PFC 
and 15 mg Ptx/ml [191]. 
 An alternative approach developed by Rapoport et al. involves the use of liquid 600-700 
nm sized droplets of PFC that can vaporize into a gas when exposed to sufficient ultrasound 
intensity or heat. These PFC liquid droplets can be delivered along with polymeric micelles 
(<100nm) that can be loaded with Dox or Ptx [192-193]. These particles can slowly accumulate 
within a tumor through the EPR effect then be triggered with ultrasound to help improve drug 
delivery from the micelles. Acoustic droplet vaporization has also been used to trigger drug 
delivery from emulsions of liquid PFC and drugs dissolved in oil as well as water in PFC in water 
emulsions [194-195].  
As an alternative to thin shelled phospholipid ultrasound contrast agents, polymer shelled 
agents with thicker (100-400 nm) shells may be useful for targeted drug delivery [3, 196]. Lensen 
et al. have developed a series of polymer UCA made from PLA terminated with pentadecafluoro-
1-octanol. By adjusting the amount of polymer used in the fabrication process they were able to 
control the shell thickness and the acoustic pressure amplitude needed to destroy the UCA [197]. 
The gas core of these UCA can be partially replaced with hexadecane oil which can be used to 
load lipophilic drugs that can be released when the shell is cracked by ultrasound exposure 
(1 MHz, 0.51 MPa) [196]. 
Polymer ultrasound contrast agents with a poly(lactic acid) shell and a gas core consisting 
of air have also been developed in Dr. Wheatley‟s laboratory [128]. Doxorubicin has been 
successfully loaded into the polymer shell of these agents while maintaining the agents acoustic 
properties [3]. In vitro, these agents have shown significantly greater anti tumor activity when 
triggered with ultrasound [198]. When exposed to ultrasound, these agents have been shown to 
significantly reduce in size to below 400 nm [4] presumably due to fragmentation of the shell 
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induced by cavitation. These resulting nanoparticles are capable of escaping the leaky vasculature 
of the tumor and accumulating within the interstitium where the polymer fragments can degrade 
and provide a sustained, localized release of doxorubicin as illustrated in figure 2.4. Prior to 
triggering, these agents retain their size, thus restricting them to the vasculature and minimizing 
systemic toxicity. In a VX2 rabbit liver cancer model, a 110% increase in doxorubicin delivered 
to the tumor was observed when the agent was triggered with 5 MHz Doppler ultrasound relative 
to a non-insonated control [4].  
 
 
 
Figure 2.4: Schematic of targeted drug delivery with polymer microbubbles. The drug loaded 
microbubbles can be injected intravenously and flow freely through the vasculature until exposed to 
ultrasound where they will experience 1) primary radiation forces that will push the bubbles to the vessel 
wall. The ultrasound pressure wave will cause 2) microbubble cavitation as the gas in the bubble rapidly 
expands and contracts in response to the changes in pressure. When exposed to ultrasound with sufficient 
intensity the microbubble will undergo 3) inertial cavitation, destroying the polymer shell resulting in drug 
loaded polymer fragments less than 400 nm in diameter. The energy released by the inertial cavitation is 
capable of breaking apart cell junctions, creating pores and 4) enhancing the permeability of the blood 
vessel. The polymer fragments can then 5) escape the leaky vasculature of the tumor and accumulate within 
the tumor interstitium. The polymer fragments will then degrade over the course of weeks providing 6) a 
sustained release of drug at the tumor. This diagram is not drawn to scale. 
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2.4 Gene Delivery 
 Gene therapy requires the transfer of genetic material into targeted cells followed by 
sufficient levels of gene expression to treat disease. Over 80% of gene therapy clinical trials have 
been focused on treating cancer, cardiovascular disease or inherited genetic disorders [199]. In 
anti-cancer gene therapy, apoptotic and anti-oncogenic genes can be an effective treatment. 
Another common approach has been to transfect cancer cells with a suicide gene encoding an 
enzyme that can convert a non-toxic prodrug into a cytotoxic chemical within transfected cells. 
Cancer cells can also be transfected with genes encoding cytokines such as interleukin-12 which 
can stimulate T lymphocytes and natural killer cells to proliferate and attack a growing tumors 
blood supply [200]. Peripheral blood lymphocytes can also be harvested from a cancer patient 
and transfected in vitro with genes that allow it to recognize and attack cancer cells [201]. While 
these strategies have shown potential to help treat cancer, the main challenge that limits the 
effectiveness of gene therapy has been the lack of safe and efficient methods for delivering genes 
into cells.  
 
2.4.1 Viral Vectors 
 Viruses have been the most commonly used vectors for gene therapy [199]. The viruses 
used in gene therapy have been genetically modified by removing pathogenic genes and inserting 
the desired therapeutic gene. Retroviral vectors were the first viruses used in gene therapy and are 
capable of transfecting dividing cells during mitosis and can integrate DNA into the transfected 
cells genome. This can lead to stable gene transfer but the DNA insertion has also been shown to 
cause mutations that can lead to cancer [202]. Adenoviruses can transfect dividing and non 
dividing cells and do not insert DNA into the genome. The first gene therapy treatment to be 
approved in China uses an adenoviral vector to deliver a p53 tumor suppressor gene in order to 
treat head and neck squamous cell carcinoma [203]. Adenoviruses have been the most commonly 
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used viral vector but they are limited by their immunogenicity and were responsible for the first 
gene therapy related death [204]. Other viral vectors include the herpes simplex virus, adeno 
associated virus and poxvirus. These and other viral vectors continue to be studied and modified 
to reduce immunogenicity, improve specificity and limit mutagenesis while maintaining 
transfection efficiency [205-206]. 
 
2.4.2 Non Viral Vectors 
 The limitations of viruses have created a need for the development of non viral vectors. 
The most common non viral method of gene delivery has been the direct injection of naked DNA 
into tissue [199]. Free plasmid DNA is non immunogenic and has shown moderate success in 
muscle tissue but is limited by its low efficiency and a lack of spatial specificity [207]. Plasmids 
are not rapidly taken up by most cells due to their large size and negative charge. Plasmid DNA 
has a half life of approximately ten minutes in whole blood [207] and unprotected plasmids that 
are taken into the cell by endocytosis can be degraded by the low pH of lysosomes [208]. 
Plasmids that escape the lysosomes are subjected to nucleases that give plasmids a half life of 50-
90 minutes in the cytosol [209]. Finally, for efficient transfection to take place, the plasmids must 
enter the nucleus [210]. The nuclear envelope is freely permeable to molecules of up to 9 nm (40 
– 60 kDa) but larger molecules such as plasmids must be actively transported through nuclear 
pores or wait for the nuclear envelope to dissolve during mitosis [211]. One strategy for 
improving non viral transfection has been to improve plasmid design. Nuclear localization signal 
peptides can be added to DNA in order to improve transport into the nucleus through nuclear 
pores and improve gene expression 10 to 1000 fold in some cell types [211]. However, others 
have shown that in some cell lines resistant to transfection, DNA can enter the nucleus but is then 
rapidly removed [208]. Finn et al. have developed plasmids containing cytoplasmic expression 
systems that can bypass the requirement for plasmid DNA to enter the nucleus [212]. Others have 
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developed plasmids that can be inserted into specific sites of the target cell‟s genome that can 
allow stable transfection without causing mutations that could lead to oncogenesis [213].  
Synthetic vectors have been developed to improve to improve the transfection efficiency 
of naked DNA without generating the safety concerns associated with viral vectors. Cationic 
lipids and cationic liposomes are the most efficient and widely used synthetic vectors for gene 
delivery [214]. Cationic lipids can decrease the negative charge of plasmid DNA allowing it to 
interact with negatively charged cell membranes. Helper lipids such as dioleoylphosphatidyl-
ethanolamine (DOPE) can be combined with cationic lipids to create liposomes that can help 
DNA escape from endosomes by weakening lipid bilayers [214-215]. Cationic liposomes 
including Lipofectamine 2000 have shown transfection efficiencies as high as 85% in vitro [216]. 
These cationic liposomes have shown some success in trasfecting the nasal epithelia without any 
adverse effects in phase I clinical trials [214]. However, these liposomes can be unstable when 
administered systemically and have caused highly toxic side effects [217].  
Cationic polymers such as polyethyleneimine (PEI), poly-L-lysine and chitosan can 
condense DNA much more effectively than cationic lipids. PEI can be used to condense plasmid 
DNA into PEI/DNA complexes less than 100 nm in diameter [218]. PEI/DNA complexes can 
enter cells through endocytosis 2-3 hours after binding to the surface [219]. The complexes then 
accumulate in lysosomal compartments before they are released into the cytoplasm through small 
local membrane damage [220]. The PEI/DNA complex can then enter the nucleus where 
transcription can begin immediately [219]. Bieber et al. showed that transcription can occur even 
with PEI still closely associated with the template DNA [220]. The main limitations of 
DNA/polycationpolyplexes have been their toxicity [221], targeting difficulties and limited 
stability. PEI/DNA complexes can aggregate into particles greater than 900 nm depending on 
incubation time, surface charge and ionic strength [218]. Polyplexes administered systemically 
will interact with negatively charged proteins such as albumin which will bind to the positively 
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charged PEI/DNA complex leading to an increase in size, reduction in charge and drop in 
transfection efficiency [218]. To prevent aggregation, PEI can be grafted onto hydrophilic 
polymers such as PEG or N-(2-hydroxypropyl)methacrylamide which can stabilize the complex 
and prevent self or protein induced aggregation or complement activation. PEGylation also 
shields the positive charge of the complex and reduces internalization and transfection efficiency 
[222]. Cationic polymers have also been used to help load plasmid DNA onto polymer 
nanoparticles. Zhang et al. have shown that PLGA particles can be loaded with PEI/DNA 
complexes through a double emulsion technique, entrapping DNA in a PLGA/PEI blend that is 
less toxic than PEI alone [223]. Similar studies have used chitosan and 6-lauroxyhexyl lysinate to 
load DNA onto PLA/PLGA nanoparticles [224-225].  
 Gene therapy can also be achieved through physical delivery methods that can create 
transient holes in the plasma membrane allowing DNA to enter the cell. Microinjection, particle 
bombardment, electroporation, laser irradiation, magnetofection and sonoporation have been 
investigated as alternatives to viral and synthetic gene delivery vectors. Microinjection can 
achieve transfection efficiencies of up to 100% in vitro but this cannot be translated to in vivo 
applications. Particle bombardment has been useful for immunization and delivery of DNA to the 
skin but has poor penetration through deep tissues. Similarly, laser irradiation can achieve high 
levels of transfection in vitro but can damage tissue and has limited penetration depth. 
Magnetofection uses a magnetic field to pull magnetic nanoparticles loaded with DNA to the 
desired target and can help improve uptake of the particles. Electroporation involves applying 
high intensity electrical pulses that can cause transient permeabilization of the cell membrane. 
Electroporation can achieve high levels of transfection (up to 50% of tissue in the heart), 
however, cell survival can range from 10 to 70% and application of the electrodes can be invasive 
[158]. 
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2.4.3 Ultrasound and Ultrasound/UCA Assisted Gene Delivery 
 Ultrasound without the addition of any microbubbles has had some success in enhancing 
gene delivery. In vitro studies with vascular smooth muscle cells have shown that exposing cells 
to naked DNA along with ultrasound (1 MHz, 110 kPa, DC=100%, I=0.4 W/cm
2
) for 60 seconds 
(without UCA) can increase transfection efficiency by 7.5 fold compared to naked DNA alone 
[226]. Similar in vitro studies have shown cancer cells exposed to ultrasound (1 MHz, 160 kPa, 
DC=30%, I=2 W/cm
2
) for 20 minutes [227] and mouse brain cells exposed to ultrasound (210 
kHz, 5 W/cm
2
) for 5 seconds [228] both have significantly greater gene expression compared to 
uninsonated cells. In a rabbit carotid artery that had been clamped and infused with plasmid 
DNA, high intensity focused ultrasound (0.85 MHz, 15 MPa, PL=50 ms, PRF=1 Hz) was able to 
enhance gene expression as much as eight fold without causing any visible damage to the vessel 
[229]. The enhanced transfection is believed to be caused by cavitation of gas bubbles that are 
formed from gas dissolved in the liquid coming out of solution due to the negative pressure of the 
ultrasound cycle. Supporting this hypothesis, when ultrasound was combined with Optison 
microbubbles, they observed significantly higher transfection efficiencies with lower pressures 
[229]. 
 Application of ultrasound in combination with microbubbles and free plasmid DNA 
provides greater transfection efficiency compared to plasmid alone and plasmid with ultrasound 
without UCA. Ultrasound combined with Optison microbubbles was able to increase transgene 
expression by 300 fold compared to free plasmid DNA in vascular smooth muscle cells in vitro 
[230]. Similar in vitro studies have shown UCA combined with ultrasound can improve 
transfection of many different cell lines including Chinese hamster ovary cells [231], 
cardiomyocytes [232] and cancer cells [233].  
Microbubble enhanced sonoporation has also been used to improve transfection of naked 
plasmid DNA in vivo.  Microbubbles and free plasmid DNA encoding angiogenic genes have 
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been injected directly into skeletal muscle, followed by ultrasound exposure in order to promote 
blood vessel growth in ischemic muscle [234]. Intratumoral and intrahepatic injections of DNA 
mixed with UCA were also able to enhance transfection in the desired tissue when combined with 
ultrasound [227, 235]. Free plasmid DNA mixed with albumin UCA has also been injected 
intravenously [236] or intraportaly [237] then insonated for transfection of the heart and liver. 
However, some have observed albumin UCA injected into skeletal muscle can enhance uptake of 
DNA even without ultrasound but this has not been observed in other tissues or with any other 
microbubble formulations [238]. 
 One interesting target for gene therapy that has gained attention over the past 15 years is 
the salivary gland. Currently there are no effective treatments for the two main clinical disorders 
affecting the salivary gland (Sjorgen‟s syndrome and xerostomia caused by radiation damage 
from head and neck cancer treatment) [239]. The salivary gland also has the ability to secrete 
proteins directly into the bloodstream, giving them the potential to be endogenous bioreactors for 
systemic gene therapy [240]. The need for effective treatments in this area has recently resulted in 
a clinical trial using viruses to deliver genes to the salivary gland [241]. As an alternative to 
viruses, ultrasound triggered microbubble destruction has recently been introduced as an option 
for gene delivery to the salivary gland [242].  
 Microbubbles have also been loaded with DNA to help protect plasmid DNA from 
degradation by nucleases in the body and to help deliver plasmid to the desired target [243]. Fujii 
et al. showed that Definity microbubbles incubated with plasmid DNA encoding VEGF for 20 
minutes achieved a 72% loading efficiency and were capable of enhancing angiogenesis in the 
hearts of rats exposed to ultrasound [244]. Some studies have used albumin UCA to load viruses 
that were then delivered to the heart with ultrasound [245]. Significantly higher levels of 
transfection were achieved by using ultrasound to deliver the viral particles compared to naked 
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DNA, however, higher transfection levels in non targeted organs such as the liver were also 
observed [246].   
 To improve loading of plasmid DNA onto lipid UCA, some microbubbles have been 
made with cationic lipids capable of loading negatively charged DNA. Phillips et al. have 
developed cationic lipid UCA capable of loading up to 10 µg DNA per billion microbubbles. 
These UCA were able to transfect vascular smooth muscle cells both in vitro and in vivo, 
however, the maximum transfection efficiency achieved in vitro was less than 1% [247]. Similar 
cationic-lipid UCA have been used to deliver fluorescently labeled plasmid to skeletal muscle. 
When these UCA were injected through the jugular vein they observed a 200 fold reduction in 
transfection compared to UCA injected through the carotid artery suggesting either the 
microbubbles were not able to pass through the rat‟s circulatory system or DNA did not remain 
attached to the UCA [248]. Lipid UCA have also been loaded with commercial cationic 
liposomes such as Lipofectaime. Chen et al. made lipid UCA loaded with Lipofectamine 2000 (a 
cationic liposome) containing DNA, injected them through the jugular vein of rats and triggered 
the UCA with ultrasound as they reached the pancreas in order to deliver insulin producing genes 
to islet cells [249]. Lentacker et al. have developed lipid UCA conjugated to PEGylated 
lipoplexes loaded with DNA and have shown that they can transfect cells in vitro when triggered 
with ultrasound [151]. A similar study by Sirsi et al. conjugated PEI/DNA/PEG nanoparticles to 
lipid UCA and demonstrated enhanced gene delivery to a rat kidney tumor model in vivo [250].  
 Polymer UCA can also be used for ultrasound triggered gene delivery, however they have 
been used much less frequently than lipid and albumin microbubbles. Mehier-Humbert et al. have 
shown that the properties of the gas and shell of UCA can influence their ability to transfect cells 
[126]. Polymer shelled UCA made from polystyrene were shown to transfect cells only when 
insonated with pressures greater than 600 kPa compared to 200 kPa for lipid UCA [126]. PLGA 
UCA can also be loaded with DNA by incorporating plasmid DNA within the shell, or by 
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allowing PEI/DNA complexes to adsorb to the surface of the microbubble [251]. Seemann et al. 
developed PLGA microbubbles loaded with either naked DNA or poly-L-lysine/DNA complexes 
[252] and showed that they could be used to transfect liver tumors in rats leading to tumor growth 
inhibition [253]. 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 UCA Fabrication Materials 
Poly(lactic acid) (PLA) 100 DL MW=83 kDa was purchased from Lakeshore 
Biomaterials, (Birmingham, AL). Ammonium carbonate was purchased from J.T. Baker 
(Phillipsburg, NJ). Poly(vinyl alcohol) (MW = 25 kDa, 88mol% hydrolyzed) (PVA) was 
purchased from Polysciences (Warrington, PA). Methylene chloride, isopropyl alcohol (IPA) and 
hexanes were purchased from Fisher Scientific (Waltham, MA). Radio labeled (
14
C) Doxorubicin 
HCl (1.25 µCi/mg) was purchased from GE Healthcare (Piscataway, NJ), non radio labeled 
Doxorubicin HCl was purchased from Sigma-Aldrich (St. Louis, MO). Paclitaxel and Docetaxel 
were purchased from LC Laboratories (Woburn, MA). Camphor, deoxyribonucleic acid sodium 
salt from salmon testes and branched polyethyleneimine (PEI, MW=25 kDa) were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
3.1.2 Cell Culture Materials 
The human breast cancer cell lines MCF7 and MDA MB 231 were obtained from 
American Type Culture Collection (Manassas, VA) and the Morris hepatoma 3924a cell line was 
provided by Dr. Uwe Haberkorn at the German Cancer Research Center (Heidelberg, Germany). 
Bovine aortic endothelial cells (BAEC) were provided by Dr. Ken Barbee. RPMI 1640 with L-
Glutamine, DMEM (with L-Glutamine, sodium pyruvate and 1.0g/L glucose) and Trypsin EDTA 
1x were purchased from Mediatech Inc. (Manassas, Va). Thiazoyl blue tetrazolium bromide 
(MTT), an antibiotic solution (10,000 units penicillin and 10 mg streptomycin per ml), sodium 
chloride, potassium chloride, magnesium chloride hexahydrate, calcium chloride dihydrate, 
sodium mono-phosphate, potassium bi-phosphate, ethylenediaminetetracetic acid (EDTA), 
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hydroxyurea, Poloxamer 188 and propidium iodide (PI) were purchased from Sigma-Aldrich. 
USDA tested Fetal bovine serum (FBS) was purchased from HyClone (Waltham, MA). 
  
3.1.3 Plasmid Preparation Materials  
 Glycerol, Luria Bertani broth (LB) powder, kanamycin, magnesium sulfate, agar, agarose 
type 1 low EEO, boric acid, ethidium bromide and sodium acetate were purchased from Sigma-
Aldrich. Ethanol (200 proof) was purchased from Decon Laboratories (King of Prussia, PA). 
Blue/orange 6x DNA loading dye and a 1 kb DNA step ladder (1000 to 10,000) were purchased 
from Promega (Madison, WI). Tris(hydroxymethyl) aminomethane (Tris) was purchased from 
Fisher Scientific.  
 
3.1.4 Other Materials  
ScintiSafeEcono 2 liquid scintillation counting (LSC) fluid, hydrogen peroxide (30%), 
optimum cutting temperature (OCT) medium, hydrochloric acid, sodium hydroxide and 
acetonitrile were purchased from Fisher Scientific. Soluene-350 was purchased from Perkin 
Elmer (Waltham, MA). 
 
3.2 Methods 
3.2.1 Contrast Agent Fabrication 
Poly (lactic acid) ultrasound contrast agents were fabricated using a double emulsion 
technique previously developed in our lab [128]. Five hundred milligrams of PLA were dissolved 
in 10 ml of methylene chloride along with 50 mg of camphor. When the polymer was completely 
dissolved, 1 ml of an ammonium carbonate solution (4% w/v) was added to the polymer solution 
then immediately sonicated on ice for 30 seconds (10 pulses of 3 seconds each separated by 1 
second) with 110 W applied power (Misonix Inc. CL4 tapped horn probe with 0.5 inch tip, 
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Farmingdale, NY). The resulting water in oil emulsion was immediately added to 50 ml of a cold 
(4°C) 5% w/v PVA solution and homogenized for 5 minutes at 9500 rpm with a Brinkman PT 
3100 homogenizer and a Polytron PT-3020/2 saw tooth homogenizer probe (Brinkmann 
Instruments, Westbury, NY). Immediately following homogenization, 100 ml of 2% v/v IPA was 
added to the emulsion then stirred (approximately 400 rpm) on a magnetic stir plate for 1 hour to 
allow the methylene chloride to evaporate. The particles were then collected by centrifugation at 
2500 g for 5 minutes and washed three times with hexane. The residual hexane was allowed to 
evaporate in the fume hood for 20-30 minutes until the particle suspension become thick enough 
to coat the sides of the centrifuge tube. The particles were washed in deionized (DI) water then 
frozen in liquid nitrogen and lyophilized for 48 hours with a VitrisBenchtop freeze dryer 
(Gardiner, NY) with the chambers exposed to room temperature and a pressure of 10-30 µbar. 
The water and ammonium carbonate from the core of the particles and the camphor from the 
polymer shell were allowed to sublime during lyophilization to create a porous polymer shell 
encapsulating a void. 
 
3.2.2 Drug Loaded Contrast Agent Fabrication 
Ultrasound contrast agents loaded with 
14
C labeled Dox for in vivo testing were fabricated 
by Dr. John Eisenbrey using an incorporation method previously described by Eisenbrey et al. 
[3]. The standard UCA fabrication procedure was modified by suspending 15 mg (18.75 µCi) 
(3% w/w) of 
14
C labeled Dox (the loading concentration that achieved the maximum payload for 
Dox) in the polymer solution before the primary emulsion.   
Paclitaxel and docetaxel loaded UCA were also fabricated using an incorporation method 
by dissolving the chemotherapeutic agent in the PLA solution at concentrations of 0, 3, 6, 12, 18 
or 24% (mg drug / mg PLA) before the first emulsion, then proceeding with the standard 
procedure.   
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3.2.3 Nanoparticle Fabrication 
 Doxorubicin loaded 200 nm polymer nanoparticles were fabricated by Dr. John 
Eisenbrey using a single emulsion method followed by surface adsorption of doxorubicin. Two 
hundred milligrams of PLA were dissolved in 5 ml of methylene chloride then sonicated in an ice 
water bath at 20 kHz for 30 seconds (10 pulses of 3 seconds each separated by a 1 second pause) 
at 75 W of applied power. After sonication, the emulsion was formed by adding the polymer 
solution to 100 ml of a 1% w/v solution of PVA and homogenizing at 12,500 rpm for 7.5 min 
with a saw tooth homogenizer blade. Following homogenization, the emulsion was stirred with a 
magnetic stir plate at room temperature for 12 hours to allow methylene chloride evaporation. 
The nanoparticles were then collected by centrifugation at 12,500 g for 1 hour (SorvallWX 
ultracentrifuge, AH-629 rotor, Thermo Electron Corp, Waltham, MA). The supernatant was 
discarded and the pellet was flash frozen and lyophilized for 48 hours. Following freeze drying, 
nanoparticles were suspended in a 3% w/v 
14
C labeled Dox solution in PBS and stirred end over 
end at 4 °C for 24 hours. The nanoparticles were then washed 3 times with deionized water, 
collected by centrifugation and lyophilized. Drug loading of Dox loaded UCA and NP was 
quantified by 
14
C activity with the method described for quantifying Dox found in the organs and 
tumor.  
 
3.2.4 In Vitro UCA Characterization 
3.2.4.1 Size and Zeta Potential Measurements 
The size distribution of PLA UCA was measured by dynamic light scattering using a 
Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). One milligram of dry contrast 
agent was suspended in 1.5 ml PBS by vortexing for 10 seconds then transferred into a disposable 
cuvette and allowed to equilibrate for 3 minutes before taking measurements. The samples were 
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then measured in triplicate and particle sizes were reported as peak % number. Zeta potential 
measurements were taken by suspending 1 mg of UCA in 1 ml of deionized water then loading 
the suspension into a Malvern disposable capillary cell to take measurements in triplicate. A one 
way ANOVA was used to compare the size of particles made with each loading concentration. 
 
3.2.4.2 Drug Encapsulation Measurements 
The final encapsulated drug payload of Ptx and Dtx loaded UCA was quantified by using high 
performance liquid chromatography (HPLC) based on a protocol adapted from Xie et al. [79]. 
Three milligrams of UCA were dissolved in 1 ml of methylene chloride. The drug was then 
extracted into 3 ml of the running buffer (acetonitrile/water, 50:50, v/v). The methylene chloride 
was then allowed to evaporate under a nitrogen stream. A reverse phase Inertsil ODS-3 column 
(150 × 3 mm internal diameter, 5 µm pore size, GL Sciences, Tokyo, Japan) was used for HPLC 
analysis. The mobile phase (acetonitrile/water, 50:50, v/v) was delivered at a flow rate of 
1ml/min with a Waters 1525 binary pump (Milford, MA). Paclitaxel and Dtx were detected by 
UV absorbance at λ = 227 nm (Waters 2487, Milford, MA). The area under the curve for the peak 
corresponding to Ptx or Dtx was calculated and the drug concentration loaded into the ultrasound 
contrast agent was calculated based on a linear calibration curve. The drug payload achieved with 
each loading concentration was compared with a one way ANOVA. The encapsulation efficiency 
was defined as:  
 
Encapsulation efficiency  % =  
Amount  of  drug  in  UCA  (µg)
Initial  amount  of  drug  (µg) 
× 100% .            (12) 
 
3.2.4.3 Acoustic Testing In Vitro 
Acoustic testing was performed in vitro to determine the ability of UCA samples to 
reflect ultrasound. An in vitro acoustic setup was used with a 5 MHz, 0.5 inch diameter 
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transducer (Panametrics-NDT Waltham, MA) with a focal length of 45 mm and a -6dB 
bandwidth of 89.3% placed in a 37 °C water bath and focused through the acoustically 
transparent window of an acrylic sample holder containing 50 ml of 37 °C PBS, pH = 7.4 
continuously stirred on a magnetic stir plate. The transducer was connected to a pulser/receiver 
(Panametrics Waltham, MA) to generate an acoustic pulse with a pulse repetition frequency of 
100 Hz and a peak negative pressure amplitude of 0.45 MPa measured with a 0.5 mm 
polyvinylidene fluoride needle hydrophone (Precision Acoustics, Dorset, UK). The reflected 
signal was detected with the transducer and amplified 40 dB by the pulser receiver then displayed 
by an oscilloscope (Lecroy 9350 A Chestnut Ridge, NY). Labview 7 Express (National 
Instruments, Austin, TX) was used for data acquisition and processing.  
Acoustic backscattering enhancement was used to measure the agent‟s ability to respond 
to ultrasound for imaging and drug delivery applications. A cumulative dose response of acoustic 
enhancement was performed by suspending 3 mg of dried UCA in 0.8 ml of PBS (3.75 mg/ml) 
then adding 20 µl aliquots of the microbubble suspension to the buffer in the sample holder and 
allowing them to mix for 10 s before recording the acoustic backscatter between 51.3 mm and 
52.8 mm from the transducer. An additional aliquot was added to the chamber every 30 seconds. 
The acoustic backscattering enhancement was defined as: 
Enhancement = 20 log  
rms  UCA  
rms [Blank ]
 ,                                         (13) 
where rms[UCA] is the root mean square of the backscatter signal given by the UCA and 
rms[Blank] is the root mean square of the backscatter signal given by the solution alone prior to 
the addition of UCA. The enhancements achieved with the initial dose (1.5 µg UCA/ml) for each 
initial drug loading concentration were compared to each other with a one way ANOVA. The 
enhancements achieved with the highest dose (15 µg UCA/ml) for each initial drug loading 
concentration were compared to each other with a one way ANOVA and the maximum 
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enhancements achieved with each initial drug loading concentration were also compared to each 
other with a one way ANOVA.  
 The acoustic stability of UCA exposed to ultrasound was measured to determine the 
effect of drug loading on shell stability. Three microgram of UCA per milliliter of PBS was 
added to the sample holder and insonated continuously with a pulse repetition frequency of 
100 Hz and a peak negative pressure amplitude of 0.45 MPa. Acoustic enhancement was 
measured every one minute over the course of 15 min and normalized with respect to the initial 
enhancement. The normalized enhancements after 15 minutes for each set of initial drug loading 
concentrations were compared to each other with a one way ANOVA. 
 
3.2.4.4 In Vitro Drug Release 
 Drug loaded UCA loaded with 18% Ptx or 18% Dtx (the loading concentration that 
provided the maximum drug payload without a significant drop in enhancement) were suspended 
in PBS at 37 °C with a concentration of 0.2 mg/ml and placed into the acoustic sample holder 
described above with stirring. The previously described acoustic setup was used to insonate the 
UCA with a frequency of 5 MHz, peak negative pressure amplitude of 0.94 MPa and a PRF of 
5000 Hz (the highest pressure amplitude and PRF possible with the pulser receiver) for 25 
minutes. Controls were preformed with no insonation. Ten milliliters of the suspension was then 
transferred to centrifuge tubes and incubated at 37 ° C while being rotated end over end. At 
selected time intervals the samples were centrifuged at 48,000 g for 20 min (SorvallWX 
ultracentrifuge, AH-629 rotor, Thermo Electron Corp, Waltham, MA). The pellet was suspended 
in fresh PBS at each time interval (to maintain sink conditions) and placed in the incubator to 
continue the release. The collected supernatants were extracted two times with 1 ml of methylene 
chloride. The methylene chloride was then allowed to evaporate under a stream of nitrogen and 
the drug was dissolved in 1 ml of the mobile phase and measured using the HPLC protocol 
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described above.  The extraction efficiency was calculated in triplicate using 10 ml solutions with 
known concentrations of Ptx or Dtx in PBS and put through the same extraction procedure. The 
percentage of drug released at each time point from microbubbles triggered with ultrasound was 
compared to microbubbles not triggered with ultrasound with Student‟s t-test. 
 
3.2.5 Characterization of Nano Shard Behavior 
3.2.5.1. Potential for Nanoparticle Extravasation  
The ability of drug loaded ultrasound contrast agents to be triggered by ultrasound to break into 
fragments capable of escaping the leaky vasculature of tumors was modeled in vitro with Corning 
Transwell inserts with a polyester membrane containing 400 nm pores with a density of 4 × 10
6
 
pores/cm
2 
(approximately 0.5% by area) (Corning Incorporated, Corning, NY). An insert was 
placed in a 6 well plate containing 3 ml of phosphate buffered saline with 1 mg of Ptx or Dtx 
loaded ultrasound contrast agent. The insert was then filled with 1 ml of phosphate buffered 
saline and the plate was partially submerged in at 37 °C water bath. A 5 MHz spherically focused 
transducer was placed 1.75 inches from the bottom of the membrane (to keep the focus of the 
transducer aligned with the membrane located approximately 2.5 mm from the bottom of the 6 
well plate) and the sample was insonated for 20 minutes with a peak negative pressure of 0.94 
MPa and a pulse repetition frequency of 5000 Hz. A 0.5 ml sample was carefully taken from 
above the membrane using a 1 mL pipetteman, and replaced with 0.5 ml fresh PBS at 37 °C prior 
to insonation and at 5 minute intervals to measure the amount of drug forced across the 
membrane. The 0.5 ml sample was mixed with 0.5 ml acetonitrile to give a 50:50 
acetonitrile/PBS solution. Docetaxel and Ptx levels were quantified with HPLC using the protocol 
described previously. Tests were performed in triplicate and controls were performed with no 
insonation.  The amount of drug transported across the membrane with and without ultrasound 
exposure after each time point was compared using Student‟s t-test. 
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3.2.5.2 In Vitro Tumoricidal Activity 
 MCF7 human breast cancer cells were grown in RPMI medium supplemented with 10% 
(v/v) FBS and 1% (v/v) antibiotic. The cells were maintained in a humidified incubator at 37 °C 
with a 5 % CO2 atmosphere. The effect of drug loaded microbubbles on the viability of cells was 
tested in vitro with an assay adapted from Fonseca et al. [254]. Cells were seeded on 48 well 
plates with a density of 2.5 × 10
4
 cells per well in 500 µl of media and incubated overnight to 
allow cells to attach. Ultrasound contrast agents initially loaded with 0% and 18% of Ptx or Dtx 
(weight drug/weight PLA) were insonated in media for 20 minutes with a frequency of 5 MHz, a 
peak negative amplitude of 0.94 MPa and a PRF of 5000 Hz. After insonation, the samples were 
filtered through 0.45 µm filters to simulate leaky tumor vasculature and allow only nanoparticles 
to pass through. The samples were then diluted in media and added to the attached cells. Controls 
were performed without insonation. Cells were incubated with the treatment for 72 hours and 
tumoricidal activity was evaluated with an MTT assay. Culture media was removed and cells 
were washed with PBS then incubated with 500 µl of the MTT solution (0.5 mg MTT/ml serum 
free RPMI) for 3 hours at 37 °C. The solution was then aspirated and the formazan crystals were 
dissolved in 1 ml of an acidic isopropyl alcohol solution (isopropyl alcohol – 0.04 M HCl). The 
absorbance of the solution was then measured at 570 nm with a Tecan Infinite M200 plate reader 
(Männedorf, Switzerland). Cells that were not treated with MTT were used as a blank to calibrate 
absorbance measurements and untreated cells were used as controls. The cell viability was 
calculated as: 
 
                           Cellviabilitiy % =
Absorbance  sample  −Absorbance (blank )
Absorbance  control  −Absorbance (blank )
× 100.  (14) 
The viability of cells treated with each condition was compared with a one way ANOVA for each 
concentration of microbubbles tested.  
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3.2.6 In Vivo Doxorubicin Delivery to a Rat Hepatocellular Carcinoma 
 ACI rats purchased from Harlan Laboratories (Somerville, NJ) implanted with Morris 
3924a hepatomas (provided by Dr. Uwe Haberkorn at the German Cancer Research Center,  
Heidelberg, Germany) were treated with Dox loaded PLA UCA, Dox loaded NP, free Dox or a 
combination of UCA and NP. The biodistribution and efficacy of each treatment was compared 
over 14 days. 
 
3.2.6.1 Establishment of Rat Liver Cancer Model 
Cell Culture 
A rat hepatocellular carcinoma cell line, Morris 3924a was cultured in BD Falcon 75 cm
2
 
cell culture flasks with RPMI 1640 medium supplemented with 20% (v/v) FBS. The cells were 
maintained in a humidified incubator at 37 °C with a 5 % CO2 atmosphere. The medium was 
changed every day and cells were passaged every 3 days. Testing for pathogens was performed 
by Research Animal Diagnostic Laboratory (Columbia, MO) to show the cell line was pathogen 
free before being used in animals. 
 
Tumor Inoculation 
 Drug delivery was evaluated in vivo in a rat hepatocellular carcinoma model using 200-
300 g ACI rats. A subcutaneous tumor was induced in the hind limbs of carrier rats. Rats were 
anesthetized with 2% isoflurane, both flanks were then shaved and cleaned with alcohol wipes. 
Morris 3924a cells were harvested from culture plates by removing the culture media and 
washing the attached cells one time with sterile PBS without magnesium or calcium, 3 ml of 
trypsin (37 °C) was then added to the cells which were then placed in the incubator for 3 minutes 
to allow cells to detach, 7 ml of media with FBS was then added to the cells which were then 
collected in a sterile 15 ml centrifuge tube and centrifuged for 5 minutes at 1000 rpm (~120g), 
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then washed three times with serum free RPMI 1640 medium. The cells were then suspended at a 
concentration of 5 × 10
6
 cells per 100 µl of serum free RPMI 1640 and transported in sterile tubes 
at 37 °C (the sterile cell storage tubes were sealed in an empty 50 ml centrifuge tube placed into a 
one liter glass bottle containing water at 37 °C in order to transport the cells from Drexel to 
Penn).  Approximately 0.1 ml of the cell suspension was then slowly injected subcutaneously into 
the flanks of carrier rats as described by Maataoui et al. [255]. Implanted animals were returned 
to their cages in the animal facility.  
 
Establishment of Hepatic Tumors 
The subcutaneous tumors were removed after 2-3 weeks when they reach approximately 
1-1.5 cm in diameter and minced into cubes approximately 1-2 mm
3
. Tumor implantation was 
performed by Dr. Soulen as described by Yang et al .[256]. Under inhalation anesthesia with 
isoflurane, rats underwent a15 mm subxiphoid midline abdominal incision. The left lateral lobe of 
the liver was retracted out of the abdominal cavity and a small stab wound was made with a 
scalpel. A small piece of gelatin sponge (Pfizer Inc, NY, NY) was inserted into the cavity for 1-2 
min while manual compression was held to attain hemostasis. The gelatin sponge was then 
removed and a 1-2 mm
3
 piece of tumor was gently inserted into the cavity. The left lobe was then 
returned to the peritoneal cavity and the abdominal wall and skin were closed primarily with 
sutures. Tumors were then allowed to grow for two to three weeks prior to treatment. 
 
3.2.6.2. In Vivo Comparison between Ultrasound Contrast Agents, Nanoparticles and Free 
Doxorubicin  
Two to three weeks after tumor implantation, when the tumors had grown to a diameter 
of 5-10mm, the rats were anesthetized with isoflurane and the abdomens were shaved and treated 
with a depilatory cream. The rats were then scanned with an ATL/Philips HDI-5000 scanner 
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(Bothel, WA) using a linear 12-5 MHz transducer. An initial tumor measurement was obtained in 
both the transverse and sagittal planes. With the transducer focused on the tumor, a 1 ml aliquot 
of saline containing a suspension of one of the four treatments was injected through an 
intravenous catheter placed in the tail vein, followed by 0.2 ml of a saline flush. The tumor was 
continuously insonated following the injection for 20 min with Doppler ultrasound at a 
mechanical index of 0.40-0.45 and a pulse repetition frequency of 1000 Hz. The treatments 
consisted of 12 mg of UCA containing 167 µg 
14
C labeled Dox, 12 mg of nanoparticles 
containing 34 µg 
14
C labeled Dox, a combination of 6 mg UCA and 6 mg nanoparticles 
containing 100 µg 
14
C labeled Dox, or 112 µg of free 
14
C labeled Dox. Quantities were chosen to 
ensure equal weights of polymer injected into the blood stream in each treatment. The number of 
rats in each group is shown in Table 3.1. The number of rats included in each treatment group 
was limited by the funding available for this project. The small sample size used in these 
experiments limits the power and reliability of the study.  
 
 
 
Table 3.1: Number of Animals Receiving Each Treatment  
 UCA NP COM Free Dox 
4 Hours 4 5 5 2 
7 Days 5 5 4 3 
14 Days 7 7 6 3 
 
 
 
3.2.6.3 Biodistribution 
Quantification of 
14
C Labeled Doxorubicin in Plasma 
 Doxorubicin levels in blood plasma were measured at 5, 15 and 30 minutes after injection 
of the vehicle.  Blood samples of approximately 0.5 ml were collected through the tail vein 
catheter at each time point. Samples were centrifuged (in an Eppendorf centrifuge 5415D, 
Hamburg Germany) for 3 min at 2000 g in BD Microtainer® tubes (Franklin Lakes, NJ) to isolate 
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plasma. Two hundred microliters of plasma were added to 1 ml of a 1:1 mixture of Soluene-350 
tissue solvent and isopropyl alcohol in glass scintillation vials and incubated at 60 °C for 2 hours. 
The vials were gently swirled every 60 minutes. Samples were then allowed to cool to room 
temperature before 200 µl of 30% v/v hydrogen peroxide was added to the mixture to remove any 
color that could absorb light emitted from the scintillation fluid. The mixture was gently shaken 
for 30 min to allow the gas to escape before the vials were closed and incubated at 60 °C for an 
additional 30 min. The samples were then cooled to room temperature and 15 ml of liquid 
scintillation counting cocktail was added to the mixture.  After 1 hour in the dark at room 
temperature, samples were read in a 1500 TRI-CARB liquid scintillation analyzer (Packard 
Instruments Company, Downers Grove, IL). Disintegrations per minute were converted to 
14
C 
activity in µCi, which were then converted to µg of Dox. The concentrations of Dox in the 
plasma of animals treated with each delivery vehicle were compared at each time point with a one 
way ANOVA.  
 
Quantification of 
14
C Labeled Doxorubicin in Tumors and Organs 
 Doxorubicin levels in the organs and tumor were measured at 4 hours, 7 days or 14 days 
after treatment. Rats were sacrificed by CO2 inhalation. The spleen, heart, lungs, right and left 
lobes of the liver and the tumor were removed. From each harvested organ and tumor, three 50-
100 mg sections were collected. Each sample was weighed and added to 2 ml of Soluene-350 
tissue solvent in a scintillation vial and incubated for 3.5 hours (with gentle shaking every 60 
minutes) at 60 °C to dissolve the tissue. The solution was cooled to room temperature and 200 µl 
of 30 % v/v hydrogen peroxide was added to the mixture and gently swirled with the cap open to 
allow the gas to escape. The vials were then sealed and incubated at 60 °C for 30 min. The 
solution was brought back to room temperature before 10 ml of liquid scintillation counting 
cocktail was added and measurements were carried out using the same scintillation counting 
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method described for blood plasma. The amount of drug found in each of the three 50-100 mg 
sections divided by the mass of each section was averaged to calculate the concentration of drug 
found in each organ for each animal. The concentrations of drug found in the tumor, heart, spleen, 
liver and lungs of animals treated with each delivery vehicle were compared to each other at each 
time point with a one way ANOVA. 
 
3.2.6.4 Tumor Growth 
Initial tumor size measurements were obtained by ultrasound from transverse and sagittal 
planes at the time of treatment. At 4 hours, 7 days and 14 days after treatment, tumors were 
harvested and measured by hand. The largest diameter measured at the time of sacrifice was 
normalized to the largest diameter measured by ultrasound at the time of treatment. Tumors 
measured at sacrifice 4 hours after measurement by ultrasound were on average 90.4 ± 8.8% of 
the size estimated by ultrasound. The normalized diameters of tumors treated with each delivery 
vehicle were compared with each other at each time point with a one way ANOVA. 
 
3.2.6.5 Autoradiography 
Remaining sections of the tumors not used to quantify Dox concentrations were 
embedded in optimal cutting temperature media and frozen on dry ice then stored at -80 °C. 
Sections (10 µm) from tumors were used for autoradiography. Autoradiography was performed to 
determine the drug distribution within the sections. A phosphor plate (Fujifilm, Valhalla, NY) 
was exposed to tumor sections for 3 weeks. The phosphor plates were read with a Fujifilm FLA-
7000 digital imager (Valhalla, NY). 
 
3.2.7 Escherichia Coli (E. Coli) and Plasmid Preparation 
3.2.7.1 E. Coli Transformation 
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E. coli samples were transformed using the protocol provided by Invitrogen (Grand 
Island, NY). A 1.5 ml micro centrifuge tube containing 50 µl of frozen DH5α Competent Cells 
(provided by Dr. Saunders) was allowed to thaw on ice. When completely thawed, 4 µl of 
plasmid DNA encoding enhanced green fluorescent protein (EGFP), a GFP derivative that allows 
for use in mammalian cells, with kanamycin resistance and controlled by a CMV promoter 
(provided by Dr. Saunders) was gently added to the bacteria and incubated on ice for 30 minutes. 
The tube was then heat shocked for 25 seconds in a 42 °C water bath then immediately placed 
back in an ice water bath for 2 minutes. The centrifuge tube was then removed from ice and 950 
µl of LB broth containing no antibiotic was added to the bacteria and incubated at 37 °C with 
shaking for 60 minutes. After incubation, 200 µl of bacteria was plated onto LB agar plates 
containing kanamycin (50 µg/ml). The plates were placed upside down in an incubator at 37 °C 
and incubated overnight. A sterile micro pipette tip was used to select a colony which was then 
transferred into a sterile test tube containing 5 ml LB broth with kanamycin (50 µg/ml). The tube 
was loosely covered with foil and incubated for 18 hours with shaking at 37 °C. The LB broth 
containing bacteria was then diluted (1:1) with the E. coli freezing media (65% glycerol, 0.1 M 
MgSO4, 25 mMTris, pH 8.0). The samples were mixed well and transferred into 2 ml 
cryopreservation vials then frozen and stored at –80 °C. 
 
3.2.7.2 Plasmid DNA Preparation 
 Plasmid DNA was prepared based on a protocol recommended by the manufacturer of 
the Gene Elute HP Plasmid Maxiprep Kit (Sigma Life sciences, St. Louis MO). A sterile micro 
pipette tip was used to scratch the surface of a frozen stock sample of EGFP expressing E coli (to 
transfer a sample of the frozen stock without letting it thaw). The pipet tip was then placed into an 
autoclaved test tube (with a loose top for gas exchange) containing 5 ml of LB broth containing 
kanamycin (50 µg/ml).  The tube was then incubated at 37 °C for 8 hours and shaken at 250 rpm. 
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The starter culture was then diluted (1:500) in LB broth containing kanamycin (50 µg/ml) and 
100 ml were added to autoclaved 250 ml Erlenmeyer flasks and incubated for 16 hours at 37 °C 
while being shaken at 250 rpm in a G24 Environmental Incubator Shaker (New Brunswick 
Scientific Company Inc., Edison NJ) located in the 6
th
 floor teaching lab of Bosone. The 
overnight culture was then poured into 50 ml tubes and centrifuged at 5000 g for 10 min. The 
supernatant was discarded and the bacterial pellets from 150 ml of overnight culture were pooled 
for plasmid extraction using the GenElute
TM
 HP Plasmid Maxiprep Kit (Sigma Life Sciences, St. 
Louis, MO).  
To create a more concentrated DNA solution, the plasmid DNA was then precipitated by 
adding 80 µl of 3 M sodium acetate (pH 5.2) and 560 µl of isopropyl alcohol to 800 µl of the 
plasmid DNA eluted from the kit in a 2 ml micro centrifuge tube. The contents were then mixed 
by gently inverting then incubated in a -20 °C freezer overnight. The samples were then 
centrifuged for 30 minutes at 16,100 g at 4 °C. The supernatant was removed and 2.0 ml of cold 
70% ethanol was added to the DNA pellet and centrifuged for 10 minutes at 16,100 g in order to 
wash away residual isopropyl alcohol. The supernatant was discarded and the pellet was allowed 
to dry for 5-10 minutes to remove any residual ethanol. The pellet was then gently dissolved in 
100 µl of 10 mM Tris (pH 8.0).  
 
3.2.7.3 Quantifying Plasmid DNA Concentration 
 Plasmid DNA concentration was measured by diluting 5 µl of the final plasmid solution 
in 345 µl of Tris (pH 7.0) and measuring the absorbance of all 350 µl in a 96 well plate (UV 
transparent) using a Tecan Infinite M200 plate reader with a wavelength of 260 nm (350 µl 
provides a path length of 1 cm in a 96 well plate). The absorbance of a blank sample containing 
only Tris was also measured and subtracted from the absorbance of the samples containing 
plasmid DNA. The plasmid DNA concentration (for all absorbance values between 0.1 and 1.0) 
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was calculated with the Beer-Lambert Law with a path length of 1 cm and an extinction 
coefficient of 1/(50 µg/ml *cm) or: 
 
 DNA =  Abs260 (Sample) − Abs260 (Blank) × 50
ug
ml
× Dilution Factor.      (15) 
 
3.2.8 Nucleic Acid Loading 
 Nucleic acids were loaded into polymer microbubbles through both incorporation and 
surface adsorption. Deoxyribonucleic acid sodium salt from salmon testes (sDNA) was used as a 
model nucleic acid to test the loading efficiency of DNA into and onto polymer microbubbles. 
sDNA was weighed out then dissolved in DI water at a concentration of 10 mg/ml by gently 
stirring in a 60 °C water bath for 3 hours or until completely dissolved. 
 
3.2.8.1 Incorporation 
 Branched polyethyleneimine (PEI) 1% (w/v) (pH adjusted to 7.0 with HCl) with one 
positively charged amine group per 43.4 mg of PEI was used to create PEI/DNA complexes with 
sDNA containing one negatively charged phosphate group per 330 mg of sDNA. The PEI/DNA 
complexes were formed with amine to phosphate (N:P) ratios of 0:1, 1:1, 2.5:1, 5:1, 10:1 and 
20:1 by incubating 2.5 mg sDNA with PEI in 1 ml of 150 mM NaCl for 15 minutes to form a 
cloudy suspension of PEI/DNA complexes. Polyethyleneimine was used as polycation in these 
experiments because of its high density of positive charges compared to other polycations such as 
polylysine. Sodium chloride was included to increase the ionic strength and slow the formation of 
large complexes. 
Microbubbles were loaded with sDNA by dissolving 40 mg of ammonium carbonate in 
1 ml of the PEI/DNA complex suspension and using this as the aqueous phase of the first 
emulsion in the UCA fabrication process, all other steps remained the same.  
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To determine the amount of sDNA incorporated, 3 mg of UCA was added to 600 µl of 
NaOH (200 mM) then incubated at 60 °C for 20 minutes. The solution was then centrifuged at 
16,000 g for 5 minutes and 150 µl of the supernatant was transferred to a UV transparent 96 well 
plate. The absorbance was measured at 260 nm, the absorbance of blanks (UCA not loaded with 
DNA) was subtracted and the amount of sDNA was calculated using a linear standard curve. The 
concentration of plasmid DNA was calculated based on the widely used constant of 50 µg/ml for 
an absorbance of 1 AU, a path length of 1 cm and a pH of 7.0 because it was not possible to make 
a standard curve. For quantifying concentrations of sDNA, sufficient dried material was available 
to make standard curves with the pH and buffer that the samples were measured in. 
 
3.2.8.2 Surface Loading 
In order to load negatively charged DNA onto the surface of UCA, microbubbles with a 
positive surface charge were made. PEI was dissolved in 5% PVA to create PVA solutions with 
0, 0.5, 1, 2 and 4 % (w/v) PEI. The solutions were kept at 4 °C and used as the aqueous phase of 
the second emulsion in the UCA fabrication process. All other steps remained the same.  
Freeze dried UCA (2mg) were then suspended in 1 ml of sDNA and incubated in a 1.5 ml 
centrifuge tube at 4 °C while being rotated end over end for 2 hours. After 15 minutes, 1 hour or 
2 hours the tubes were centrifuged for 5 minutes at 5000 g, 350 µl of the supernatant was 
transferred to a clean tube. The tubes were centrifuged at max speed to remove any remaining 
polymer debris and150 µl of the supernatant was transferred into a UV transparent 96 well plate. 
The absorbance of each sample was measured at 260 nm and the sDNA concentration in the 
supernatant was calculated using a linear standard curve. The total amount of sDNA loaded onto 
the UCA was calculated by subtracting the amount of sDNA in solution after incubation with the 
UCA from the initial amount of sDNA. The effect of PEI concentration, DNA loading 
concentration, DNA molecular weight, sodium chloride concentration and incubation time on the 
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final DNA payload were all studied. The DNA payloads within each study were compared to 
each other at each incubation time with a one way ANOVA. 
Plasmid DNA loading was confirmed by agarose gel electrophoresis. Two milligrams of 
UCA made with 1% PEI (PEI-UCA) were incubated in 0.5 ml of 10 mM NaCl containing 100, 
50, 25, 12.5 6.25, 3.13 and 1.56 µg of plasmid DNA. The suspension was incubated at 4 °C for 
1 hour then centrifuged. The supernatant was removed and 10 µl of the supernatant was mixed 
with 2 µl of a 6x loading buffer and added into a 0.7 % agarose gel in 0.5x TBE with 0.5 µg/ml 
ethidium bromide to stain the DNA. The gel was run at 100 V for 100 minutes. An Alpha 
Innotech FluorChem SP MultiImage Light Cabinet (Santa Clara, CA) with UV illumination was 
used to image gels. An identical gel was run with plasmid DNA not incubated with PEI-UCA and 
imaged with the same exposure and gain to compare the intensity of each band. 
 
3.2.9 DNA Integrity 
 The effect on the integrity of DNA of loading plasmid DNA onto the surface of PEI-
UCA was determined by using agarose gel electrophoresis to separate the supercoiled, open 
circular (nicked) and linear plasmid DNA. Two milligrams of 1% PEI-UCA and 2 mg of control 
UCA with no PEI were each incubated with 50 µg of plasmid DNA in 0.5 ml of 10 mM NaCl for 
1 hour. The supernatant was removed and the pellet was washed with 0.8 ml of di-water. The 
pellet was then suspended in 0.25 ml of 5 M NaCl and incubated at room temperature for 2 hours 
to release the DNA and PEI from the UCA. The suspension was then centrifuged again and the 
supernatant was collected.  
 The effect of ultrasound on plasmid DNA integrity was determined by insonating 1% 
PEI-UCA loaded with DNA with a Model SYL-06 1MHz transducer (Sylvan Inc. North Myrtle 
Beach, SC) for 30 seconds on high (I = 4.8 W/cm
2
, PRF = 150 Hz, PL = 5 ms). Control UCA not 
coated with PEI were also incubated with plasmid DNA and insonated with the same conditions. 
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Control plasmid DNA, plasmid DNA incubated with control UCA with no PEI, and 
plasmid DNA insonated with control UCA were run on 0.7% agarose gels at 100 V. Control 
plasmid DNA in 5 M NaCl, plasmid DNA loaded onto PEI-UCA then released with 5 M NaCl 
and plasmid DNA loaded onto PEI-UCA then insonated then released with 5 M NaCl were run on 
0.7% agarose gels at a higher voltage of 125 V in order to help separate the PEI from the DNA 
before the NaCl diffused away. The gels were imaged and the intensity of the bands 
corresponding to supercoiled plasmid DNA, open circular plasmid DNA and linear plasmid DNA 
were quantified in each lane. The intensities of each band for each treatment were compared to 
each other with a one way ANOVA. 
 
3.2.10 Microbubble Triggered Gene Delivery In Vitro 
 The ability of PLA UCA to enhance gene delivery when triggered by ultrasound was 
examined in vitro. MCF 7 human breast cancer cells were grown in an Opticell (Thermo Fisher 
Scientific, Rochester NY) with RPMI 1640 containing 10% FBS and 1% antibiotic until 80-90% 
confluent. The medium was then removed and replaced with warm (37
o
C) RPMI 1640 containing 
10% FBS, plasmid DNA encoding EGFP (10 µg/ml) and polymer UCA (0 - 1 mg/ml). No 
antibiotic was used in the transfection medium to reduce toxicity. The Opticell was then 
submerged in a 37 °C water bath and clamped in a vertical position with an unfocused, single 
element, 0.5 inch diameter ultrasound transducer (1.0, 2.25 or 5 MHz, with a -6 dB bandwidth of 
58.9, 89.2 and 70.5% Panametrics-NDT, Waltham, MA) aligned perpendicularly to the Opticell 
at a distance from the Opticell equal to the natural focus of the transducer (the distance at which 
the transducers were calibrated using a hydrophone). The position of the transducer was adjusted 
manually with a xyz stage and the distance from the transducer to the outer membrane of the 
Opticell was measured using an oscilloscope (Lecroy 9350A, Chestnut Ridge, NY) to determine 
the time required for sound to be reflected from the membrane. The transducers were calibrated 
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with a Precision Acoustics HP series hydrophone by Dr. John Eisenbrey at Thomas Jefferson 
University. The transducer was excited by an 8116A Pulse/Function Generator (Hewlett-Packard 
Company, Palo Alto, CA) used to gate a Wavetek 5 MHz Lin/Log Sweep Generator Model 185 
(San Diego, CA) which was amplified by an ENI model A150 (55dB) RF Power Amplifier 
(Rochester, NY) connected to the transducer. The pulse/function generator was used to generate a 
triangle wave with a high output level set to 4.7 V, a low output level set to 0.7 V and a frequency 
set to the desired PRF of the final signal. The duty cycle was controlled by adjusting the threshold 
for the Wavetek generator. The Wavetek generator was used to generate a sign wave with the 
desired frequency, pulse length, PRF and amplitude which was confirmed using a Hewlett-
Packard 54602B oscilloscope then attached to the amplifier. The attenuation caused by the 
membrane of the Opticell has been shown to be less than 1% when being insonated with a 1 MHz 
transducer [231] however the attenuation at 2.25 and 5 MHz were not measured. After insonation, 
the Opticell was gently removed from the water bath and dried, then placed in the incubator. 
After 4 hours, the medium and bubbles in the Opticell were removed and replaced with fresh 
RPMI 1640 with 10% FBS and 1 % antibiotic. The medium was not removed until 4 hours after 
insonation in order to allow viable cells that have detached from the Opticell to reattach to the 
plate before non viable cells were removed when the medium was changed. The cells were then 
placed back in the incubator at a temperature of 37 °C, humidity of 99% and carbon dioxide 
concentration of 5% for 24 hours.  
 
3.2.11 Imaging and Quantification  
 Twenty four hours after insonation, EGFP expression was quantified. The cells were 
stained with propidium iodide with a final concentration of 2 µg/ml to label dead cells, then 
imaged with an Olympus IX71 microscope using a FITC and TRITC filter along with phase 
contrast. Five images were taken across each insonated region along with five images across an 
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uninsonated region (at least 250 cells were included in each image). The cells were counted and 
the percentage of cells expressing EGFP was calculated as: 
 
Transfection efficiency =  
Number  of  viable  cells  expressing  EGFP  per  image
Total  number  of  cells  per  image
× 100%    (16) 
 
and the cell viability was calculated as: 
 
Cell viability =  
Number  of  viable  cells  per  image
Number  of  cells  per  image  in area  not  exposed  to  ultrasound
× 100%      (17) 
 
The total fluorescence intensity was also quantified to measure differences in total EGFP 
expression. The total EGFP expression in each image is expected to be affected by the 
transfection efficiency, number of plasmids delivered to each cell [257] as well as the health of 
the cells. Cells were imaged with a FITC filter with a constant gain and exposure. Five images 
were taken across each insonated region and 5 images across an uninsonated region. The 
background was subtracted and the fluorescence intensity of each image was calculated using 
ImageJ (National Institutes of Health, Bethesda, Maryland) and is reported as relative 
fluorescence units (RFU). Quantifying the percentage of cells expressing EGFP and the total 
fluorescence provide information about the relative influence of each variable tested in these 
experiments however it is difficult to determine what transfection efficiencies could be achieved 
in vivo or what transfection efficiencies would be needed for a therapeutic effect. The most 
common methods for measuring transfection efficiency in vivo are to quantify protein expression, 
measure the functional effect on the desired target or to quantify luminescence relative to controls 
after transfection with luciferase.  
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3.2.12 Ultrasound Exposure Conditions 
 The effects of the following parameters on transfection efficiency, total fluorescence 
intensity and cell viability were examined: center frequency, pressure amplitude, PRF, PL, duty 
cycle (DC), PLA microbubble concentration, exposure time, buffer used during transfection, 
timing of ultrasound exposure and cell cycle.  
 
Pressure amplitude 
 Cells were insonated at three different center frequencies (1, 2.25 and 5 MHz) and peak 
negative pressure amplitudes of 0, 0.1, 0.25, 0.5, 1 and 2 MPa. A constant PRF of 3000 Hz, PL of 
20 µs and exposure time of 15 seconds were used to insonate cells with RPMI 1640 and 10% 
FBS containing 10 µg/ml plasmid DNA and 0.25 mg/ml PLA UCA. The center frequencies were 
limited to 1, 2.25 and 5 MHz because a hydrophone calibrated at 0.5 MHz was not available to us 
and the function generator had a maximum frequency of 6 MHz. The PRF of 3000 Hz and PL of 
20 µs were chosen as a starting point based on the conditions described by Karshafian et al. 
[258]. The results at each pressure were compared to each other for the same frequency with a 
one way ANOVA and the results for each frequency at the same pressure were compared to each 
other with a one way ANOVA.  
 
Duty cycle 
 Cells were insonated with a center frequency of 1 MHz and peak negative pressure 
amplitude of 500 kPa. A constant PL of 20 µs was maintained as the DC was adjusted to 0.02, 
0.06 and 0.18 by using a PRF of 1000, 3000 and 9000 Hz. The DC was also adjusted by 
maintaining a constant PRF of 3000 Hz and adjusting the PL to 7, 20 and 60 µs. A constant 
exposure time of 15 seconds was used to insonate cells with RPMI 1640 and 10% FBS containing 
10 µg/ml plasmid DNA and 0.25 mg/ml PLA UCA. The maximum DC of 0.18 used in this 
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experiment with a pressure amplitude of 500 kPa was chosen to prevent overloading and 
damaging the transducer. The results with each PL and PRF were compared to each other with a 
one way ANOVA. 
 
Pulse repetition frequency and pulse length 
 Cells were insonated with three different center frequencies (1, 2.25 and 5 MHz) and a 
constant peak negative pressure amplitude of 1 MPa. A constant DC of 0.06 was maintained 
while simultaneously adjusting the PRF to 5, 20, 200, 3000 and 20000 Hz and the PL to 12000, 
3000, 300, 20 and 3 µs. A constant exposure time of 15 seconds was used to insonate cells in 
RPMI 1640 with 10% FBS containing 10 µg/ml plasmid DNA and 0.25 mg/ml PLA UCA. The 
results each frequency were compared to each other for each combination of PRF and PL with a 
one way ANOVA and the results from each combination of PRF and PL were compared to each 
other for each frequency. 
 
Pressure and pulse length 
 Cells were insonated with three center frequencies (1, 2.25 and 5 MHz) and a constant 
ISPTA of 2.0 W/cm
2
 or 0.33 W/cm
2
. A constant PRF of 3000 Hz was maintained while 
simultaneously adjusting the PL to 5, 20 and 80 µs and pressure amplitude to 2.0, 1.0 and 
0.5 MPa in order to maintain an ISPTA of 2.0 W/cm
2
. It was not possible to continue to decrease 
the pressure amplitude to 0.25 MPa while increasing the DC to 0.96 because of the limitations of 
the amplifier. To maintain a constant ISPTA of 0.33 W/cm
2
, the PL was adjusted to 62.5, 250 and 
1000 ms and the pressure amplitude was changed to 400, 200 and 100 kPa while maintaining a 
constant PRF of 1 Hz. The PRF was lowered to 1 Hz in this experiment in order to use the longest 
PL possible. A constant exposure time of 15 seconds was used to insonate cells with RPMI 1640 
with 10% FBS containing 10 µg/ml plasmid DNA and 0.25 mg/ml PLA UCA. The results from 
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each frequency were compared to each other for each PL and pressure amplitude combination 
with a one way ANOVA. 
 
Microbubble concentration 
 Cells were insonated with a center frequency of (1, 2.25 and 5 MHz), pressure amplitude 
of 1 MPa, PL of 12 ms and PRF of 5 Hz. A constant exposure time of 15 seconds was used to 
insonate cells in RPMI 1640 with 10% FBS and 10 µg/ml plasmid DNA. Microbubble 
concentrations of 0, 0.025, 0.05, 0.25 and 1.0 mg/ml UCA were tested. The results from each 
frequency were compared to each other for each UCA concentration with a one a one way 
ANOVA and the results from each microbubble concentration were compared to each other at 
each frequency. 
 
Exposure time 
 Cells were insonated with a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL 
of 12 ms and PRF of 5 Hz. Cells were incubated with RPMI 1640 with 10% FBS and 10 µg/ml 
plasmid DNA and 0.05 mg/ml UCA then insonated for 0, 2, 15 or 30 seconds. The lowest 
exposure time of 2 seconds was limited by the ability to manually start and stop the exposure 
accurately. The results of each insonation time were compared to each other with a one way 
ANOVA. 
 
Radiation force 
 Cells were insonated as above. A constant exposure time of 15 seconds was used to 
insonate cells in RPMI 1640 with 10% FBS, 10 µg/ml plasmid DNA and 0.05 mg/ml UCA. An 
Opticell with cells growing in a monolayer on one membrane of the chamber was placed in the 
water bath so that the primary radiation forces from the ultrasound would push the microbubbles 
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towards the cells or away from the cells. The results from each direction were compared to each 
other with Student‟s t-test. 
 
Calcium and magnesium ion concentrations 
 Cells were insonated as above. A constant exposure time of 15 seconds was used to 
insonate cells in 4 ml of PBS with 10 µg/ml plasmid DNA and 0.05 mg/ml UCA. A constant 
magnesium chloride concentration of 0.49 mM was added to PBS along with calcium chloride 
concentrations of 0, 0.25, 0.5, 1, 1.5 or 2 mM. Or, the calcium chloride concentration was held 
constant at 1 mM as the magnesium chloride concentration was changed to 0, 0.5 and 1 mM. Two 
minutes after cells were exposed to ultrasound, 6 ml of RPMI 1640 with 10% FBS was added the 
Opticell which was then placed in the incubator for 4 hours before the media was replaced with 
complete media containing 10% FBS and 1% antibiotic. The initial concentrations of 0.49 mM 
magnesium chloride or 1 mM calcium chloride were based on the standard concentrations of 
magnesium and calcium found in PBS. The results from each concentration were compared to 
each other with a one way ANOVA. 
 
Multiple exposures 
 Cells were insonated as above. A constant exposure time of 15 seconds was used to 
insonate cells in RPMI 1640 with 10% FBS, 10 µg/ml plasmid DNA and 0.05 mg/ml UCA. After 
the first ultrasound exposure, cells were placed back in the incubator. After 4 hours, one group of 
Opticells (0 h 4 h) was removed from the incubator and the media was replaced with RPMI 1640 
with 10% FBS and fresh plasmid DNA and UCA at the same concentration used in the first 
treatment. The Opticell was placed into the water bath in the same position and treated with the 
same ultrasound exposure. A second group (0 h 12 h) was exposed to a second identical 
ultrasound treatment 12 hours after the initial treatment. A third group (1x) was exposed to only a 
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single treatment. Four hours after each treatment the media was replaced with complete media 
containing 10% FBS and 1% antibiotic. The minimum of 4 hours between the first and second 
treatment was limited by the need to allow cells to reattach before replacing the media to avoid 
cell loss. The results from each condition were compared to each other with a one way ANOVA. 
 
Poloxamer 188 
 Poloxamer 188 (P188) is a surface active agent that can prevent cell death by sealing cell 
membranes. To determine the effect of P188 on ultrasound triggered transfection efficiency, cells 
were insonated with a single exposure of 15 seconds at 1 MHz, 1 MPa, with a PL of 12 ms and 
PRF of 5 Hz. Cells were insonated in RPMI 1640 with 10% FBS, 0.05 mg/ml UCA, 10 µg/ml 
plasmid DNA and 100 µM P188 (dissolved in medium and filtered through a sterile 0.22 µm 
syringe filter). After 4 hours, the medium was replaced with complete medium containing 1% 
antibiotic and no P188.The results with and without P188 were compared with a one way 
ANOVA. 
 
Transfection with DNA loaded UCA 
 To determine if DNA loaded onto cationic microbubbles were able to transfect cells in 
vitro cells were insonated as above with 0.25 mg/ml UCA made with 1% PEI and loaded with 
22.8 ± 0.1 µg DNA/mg in RPMI 1640 with 10% FBS. The DNA loaded UCA were compared 
with control UCA combined with the same concentration of free DNA (5.5 µg/ml). These were 
also compared with DNA loaded UCA that were first suspended in RPMI 1640 with 10% FBS 
then immediately centrifuged for 5 minutes at 5000 g. The washed DNA loaded PEI-UCA were 
then collected and suspended in fresh media and insonated with cells using the same conditions as 
above. The results from each group were compared to each other with a one way ANOVA. 
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3.2.13 Cell Cycle Synchronization 
 Exponentially growing MCF 7 cells were synchronized at the G1/S boundary by a double 
hydroxyurea block as described by Lin et al. [259-260]. Cells were incubated in RPMI 1640 with 
10% FBS, 1% antibiotic and 1.5 mM hydroxyurea for 16 hours to stop DNA synthesis. Cells in 
any part of S phase would remain in S phase or progress very slowly through S phase. Cells in 
other stages of the cell cycle would progress at the normal rate until stopping at the G1/S phase 
boundary. After 16 hours the cells were washed twice with PBS then incubated in medium 
without hydroxyurea for 13 hours to allow all cells to escape S phase. The cells were then 
incubated in medium containing 1.5 mM hydroxyurea for 16 hours to synchronize all cells at the 
G1/S phase boundary (figure 3.1). The cells were then washed twice with PBS and incubated in 
medium without hydroxyurea. To determine how well cells were synchronized, at 0, 4, 8, 12 and 
16 hours after the hydroxyurea was removed, cells were detached with trypsin and washed with 
cold PBS. The cells were then suspended in 0.5 ml cold PBS and fixed by the addition of 4 ml of 
ice cold 95% ethanol and stored at -20 °C overnight. The cells were then washed with cold PBS 
and incubated in PBS containing PI (50 µg/ml, to bind stoichiometrically to DNA), RNAse 
(50 µg/ml, to remove all RNA) and Triton X-100 (0.05% to permeableize the membrane) at 
37 °C for 2 hours. The cells were then imaged with a TRITC filter using a constant gain and 
exposure time. The total PI fluorescence in each cell was quantified and plotted in a histogram to 
determine the percentage of cells containing 1x DNA (cells in G0 or G1), 2x DNA (cells in G2 or 
M phase) or between 1x and 2x (cells in S phase). 
To determine if cell cycle had an influence on the transfection efficiency, cells 
synchronized as described above were treated with ultrasound 0, 4, 8 or 12 hours after hydroxurea 
was removed. Cells were insonated for 15 seconds, with a center frequency of 1 MHz, pressure 
amplitude of 1 MPa, PRF of 5 Hz and PL of 12 ms in RPMI 1640 with 10% FBS, 10 µg/ml 
plasmid DNA and 0.05 mg/ml UCA. 
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Figure 3.1: Cell cycle of MCF 7 cells. 
 
3.2.14 Statistical Analysis 
All data are expressed as a mean value ± standard error of the mean. Statistically 
significant differences for multiple groups were determined using a one way ANOVA with 
Tukey‟s multiple comparison post test. Statistical significance was defined as p < 0.05. Individual 
p values were calculated with a Student‟s t-test. All testing was done using Prism 5 (GraphPad, 
San Diego, CA). 
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4. RESULTS AND DISCUSSION 
 
4.1 In Vivo Delivery of Dox Loaded UCA to Morris 3924a Tumor Model  
 The Dox biodistribution and tumor response of four different drug delivery platforms 
were examined in a rat HCC model. Dox loaded UCA were compared with unencapsulated Dox 
(Free Dox), Dox loaded nanoparticles (NP) and a combination of Dox loaded UCA and Dox 
loaded NP (COM).  
 
4.1.1 Ultrasound Image Enhancement 
Doppler imaging of Morris 3924a hepatomas in the liver of ACI rats after the injection of 
each treatment was performed using an ATL/Philips HDI-5000 scanner with a linear 12-5 MHz 
transducer. The same conditions and filters were used to image each tumor. Enhancement was 
observed along the rim of tumors treated with UCA (A) while enhancement in tumors treated 
with the combination of UCA and NP (B) was considerably diminished and those treated with NP 
(C), or free Dox (D) showed little or no enhancement as shown in figure 4.1. Doppler imaging 
without contrast can detect vessels as small as 200-300 mm in diameter while adding contrast can 
detect vessels as small as 30 µm [261]. These images help confirm that the drug loaded UCA can 
enter the tumor and respond to ultrasound, they also show that the majority of the microbubbles 
flow through the periphery of the tumor and may not have access to the center of the tumor due to 
the heterogeneous vasculature and high interstitial pressure of the tumors.  
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Figure 4.1: Doppler ultrasound images of Morris 3924a tumors (shown within the green boxed region) in 
the livers of ACI rats after the injection of A) 12 mg ultrasound contrast agent, B) a combination of 6 mg 
nanoparticles and 6 mg ultrasound contrast agent, C) 12 mg nanoparticles and D) free doxorubicin. All 
images were taken with identical machine settings 
 
 
 
4.1.2 Plasma Doxorubicin Levels 
Plasma was separated (by centrifugation for 3 min at 2000 g in BD Microtainer® tubes 
(Franklin Lakes, NJ)) from whole blood samples taken from the tail vein of rats prior to the 
treatment and at 5, 15 and 30 minutes after the injection of each treatment. Dox levels in plasma 
were calculated based on the total 
14
C activity in each sample and are reported as the percentage 
of injected drug per milliliter (%ID/ml). Dox levels in plasma are shown in figure 4.2 for each of 
the four treatments. Plasma drug levels were highest, as measured at the 5 minute sample for all 
four treatments with a significantly higher percentage of the total dose for unencapsulated free 
Dox (3.033 ± 0.612 %ID/ml plasma, compared to UCA (0.466 ± 0.068 %ID/ml plasma), NP 
(1.650 ± 0.294 %ID/ml plasma) and the combination of UCA and NP (0.632 ± 0.046 %ID/ml 
plasma, p<0.0470). Doxorubicin loaded nanoparticles also lead to a significantly greater 
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percentage of injected drug in the plasma after 5 minutes compared to drug encapsulated within 
UCA (1.650 ± 0.294 %ID/ml plasma vs. 0.466 ± 0.068 %ID/ml plasma, p<0.01). The higher 
percentage of drug found in plasma after treatment with NP may have been caused by insufficient 
removal of the nanoparticles by centrifugation or by a greater burst release from NP compared to 
UCA. Loading the NP by surface adsorption of Dox can lead to weak bonds between the drug and 
surface of the NP that can be disturbed in the presence of the salts and negatively charged 
proteins found in blood.   
 After 15 minutes plasma drug levels remained significantly greater for free doxorubicin 
compared to drug encapsulated within UCA 1.151 ± 0.422 %ID/ml plasma, vs. 0.242 ± 
0.030 %ID/ml plasma, p= 0.0395).  This is one important advantage of encapsulating Dox within 
UCA because reducing peak plasma concentrations of Dox has been shown to be essential for 
reducing cardiotoxicity and improving the therapeutic index [44]. 
 
 
 
 
Figure 4.2: Effect of delivery vehicle on the concentration of doxorubicin in plasma. Vehicles include: 12 
mg ultrasound contrast agent , 12 mg nanoparticles , a combination of 6 mg nanoparticles and 6 
mg ultrasound contrast agent  or free doxorubicin . After 5 minutes plasma drug concentrations 
were significantly greater in rats treated with free doxorubicin compared to all other treatments (p<0.0470) 
and concentrations were significantly greater in rats treated with nanoparticles compared to ultrasound 
contrast agents (p=0.0052) n=5. 
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4.1.3 Organ and Tumor Doxorubicin Levels 
 Organs and tumors harvested from rats sacrificed 4 hours, 7 days and 14 days after 
treatment were processed and used to determine the Dox biodistribution and persistence for each 
of the four treatments. After 14 days, Dox levels in the spleen remained significantly greater for 
rats treated with UCA 4.833 ± 1.00 %ID/g tissue and for the combination of nanoparticles and 
UCAs 6.842 ± 1.280 %ID/g compared to rats treated with free doxorubicin 0.283 ± 0.006 %ID/g  
(p<0.0210) as shown in figure 4.3. Drug levels in the right and left lobes of the liver are shown in 
figures 4.4a and 4.4b respectively. After 14 days, drug levels in the liver were greater for rats 
treated with UCA 2.381 ± 0.458 %ID/g  and the combination of nanoparticles and UCAs 2.945 ± 
0.465 %ID/g (compared to rats treated with free doxorubicin 0.177 ± 0.006 %ID/g (p<0.0159).  
 
 
 
Figure 4.3: The effect of vehicle type on the percentage of doxorubicin taken up by the spleen. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment. 
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Figure 4.4: The effect of vehicle type on the percentage of doxorubicin taken up by the left liver (a) and 
right liver (b). Vehicle consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a 
combination of 6mg UCA and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were 
quantified at 4 hours , 7 days  and 14 days  after treatment. 
 
 
 
This accumulation of UCA within the spleen and liver is believed to be caused by a rapid 
uptake of particles by the mononuclear phagocyte system [262]. This phenomenon is common 
among nanoparticles and liposomes less than 5 µm with unmodified surfaces [263-265]. 
Opsonins can adsorb to the surface of particles where they interact with macrophage surface 
receptors and trigger phagocytosis, leading to rapid particle uptake in the liver and spleen [262]. 
Some studies have shown that the uptake of drug loaded particles in the spleen does not result in 
significant toxicity, for example, Rahman et al. have reported that mice treated with doxorubicin 
loaded liposomes have drug levels in the spleen 10 fold greater than those treated with free 
doxorubicin but with no difference in spleen toxicity compared to free doxorubicin [265]. 
However others have observed that Dox loaded liposomes can be toxic to the mononuclear 
phagocyte system causing macrophage toxicity and depletion [266]. It may be advantageous in 
the future to modify the surface of the ultrasound contrast agents used in this study with 
poly(ethylene glycol), poloxamer or vitamin E TPGS, to prevent opsonization and thus slow 
down uptake by the mononuclear phagocyte system [262]. This strategy potentially would lead to 
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increased drug carriers in circulation and ultimately higher tumoral delivery. However, the 
benefits of PEGylation may be limited by the size and stiffness of polymer UCA, some studies 
have shown particles need to be either less than 200 nm or highly deformable to avoid splenic 
filtration [95, 98]. 
Drug levels in the lungs were also examined after 14 days, with no significant differences 
in Dox levels for any of the treatments (figure 4.5). This indicates that drug loaded UCA are able 
to pass through the lungs without getting trapped in the pulmonary capillaries, a key requirement 
for an ultrasound contrast agent [267]. 
 
 
 
Figure 4.5: The effect of vehicle type on the percentage of doxorubicin taken up by the lungs. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment. 
 
 
 
After 14 days, the percentage of injected doxorubicin in the hearts of rats treated with 
nanoparticles remained significantly higher than those treated with free doxorubicin (0.736 ± 
0.097 %ID/g tissue, vs. 0.320 ± 0.054 %ID/g tissue, p=0.0292) while those treated with UCA 
were significantly lower compared to free doxorubicin (0.168 ± 0.017 %/g tissue, vs. 0.320 ± 
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0.054 %/g tissue, p=0.008) as shown in figure 4.6. Reducing peak plasma concentrations of 
doxorubicin has been shown to be essential for reducing cardiotoxicity and improving the 
therapeutic index [44]. Drug loaded ultrasound contrast agents are also able to significantly 
reduce the amount of doxorubicin accumulated within the heart compared to free doxorubicin 
confirming the benefits of encapsulation. 
 
 
 
Figure 4.6: The effect of vehicle type on the percentage of doxorubicin taken up by the heart. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment. 
 
 
 
Doxorubicin loaded UCAs resulted in the most efficient delivery of drug into the tumor, 
with significantly greater levels of doxorubicin in tumors treated with UCA compared to tumors 
treated with free doxorubicin as shown in figure 4.7 (2.491 ± 0.501 %/g tissue, vs. 0.373 ± 
0.087 %/g tissue, p= 0.0472). This is over 10 times greater than the delivery efficiency found by 
Stables et al. who used ultrasound to trigger Dox release from micelles in tumors and achieved a 
maximum delivery of 0.12%ID to the tumor [268]. However, other studies using Dox loaded lipid 
microbubbles triggered with ultrasound [179] or Dox loaded liposomes combined with ultrasound 
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[178] have been able to deliver 9-15% of the injected dose per gram of tissue to the insonated 
tumor.  
 
 
 
Figure 4.7: The effect of vehicle type on the percentage of doxorubicin delivered to the tumor. Vehicle 
consists of ultrasound contrast agent (UCA; 12mg), nanoparticles (NP; 12 mg), a combination of 6mg UCA 
and 6 mg NP (COM) and free doxorubicin (free Dox; 112 µg). Drug levels were quantified at 4 hours , 
7 days  and 14 days  after treatment (n=3 for all except free dox at 4 hours 7 and 14 days due to 
lack of tumor growth in some animals). 
 
 
 
 The biodistribution of Dox loaded UCA is shown below in figure 4.8. The drug levels 
were highest for all organs in the 4 hour samples with 13.29 ± 0.884 %ID/g in the spleen, 5.118 ± 
0.704 %ID/g in the right lobe of the liver, 5.75 ± 0.774 %ID/g in the left lobe of the liver, 1.507 ± 
0.496 %ID/g in the lungs, 0.33 ± 0.021 %ID/g in the heart and 2.49 ± 0.501 %ID/g in the tumor 
as shown in figure 4. After 14 days, drug levels in the spleen, liver, lungs and heart were all 
significantly lower compared to samples taken at 4 hours (p<0.0212) while drug levels in the 
tumor showed no significant drop from day 0 to day 14 2.49 ± 0.501 %ID/g  vs 2.08 ± 
1.079 %ID/g, p=0.7. 
While drug levels within the spleen, liver, heart and lungs all decreased significantly 
from day 0 to day 14, drug levels within the tumor showed no significant decrease (figure 4.8), 
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presumably a result of the tumor‟s limited lymphatic drainage. The sustained presence of Dox 
supports the hypothesis that drug loaded polymer fragments can accumulate within the tumor 
interstitium, presumably a combined consequence of both the EPR effect and biophysical effects 
of cavitating UCA. The concentration of Dox in tumors treated with ultrasound contrast agents 
was 5.7 µM after 14 days indicating this platform is able to maintain tumoricidal drug 
concentrations over an extended time frame [41], however, it is not clear how much of the drug 
remains attached to the polymer fragments and how much is available to the tumor. It is also 
important to note that Dox levels were measured by 
14
C activity, however, the radioactive carbon 
in Dox is also part of the degradation products of Dox (as shown in figure 2.1) [269], making it 
difficult to determine if the drug detected after 14 days was still active. 
 
 
 
 
Figure 4.8: The biodistribution of doxorubicin loaded ultrasound contrast agents. Samples were quantified 
at 4 hours , 7 days  and 14 days  after treatment. Drug levels in the spleen, liver, lungs and 
heart all peaked at 4 hours and dropped significantly after 14 days (p<0.0212) while drug levels in the 
tumor showed no significant drop in drug levels from day 0 to day 14 (p=0.7447). 
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4.1.4 Tumor Growth 
 The effect of each treatment on tumor growth was also examined and is shown in 
figure 4.9. There were no significant changes in tumor size from the time of treatment to 7 days 
for any of the four treatments. Tumors treated with ultrasound contrast agents showed no 
significant change in size from day 0 to day 14 (p=0.3214). After 14 days, tumors treated with 
ultrasound contrast agents were significantly smaller than tumors treated with free doxorubicin 
(p=0.0390). Tumors treated with nanoparticles or the combination of ultrasound contrast agents 
and nanoparticles showed no significant difference compared to tumors treated with free 
doxorubicin (p=0.0964 and p=0.2862). This helps support the hypothesis that drug loaded 
polymer fragments can provide a sustained release of Dox in the tumor to help stop tumor 
growth. However it is difficult to make comparisons between groups because ultrasound contrast 
agents had a greater drug carrying capacity compared to equal polymer weights of nanoparticles 
(167, 34, and 100 µg total doxorubicin for contrast agent, nanoparticle and combination platforms 
respectively).   
 
 
 
 
Figure 4.9: Effect of vehicle on tumor growth in rats.  Vehicles include; 12 mg ultrasound contrast agent 
, 12 mg nanoparticles , a combination of 6 mg nanoparticles and 6 mg ultrasound contrast agent 
 or free doxorubicin . All rats were insonated for 20 minutes after injection.  Tumors treated with 
ultrasound contrast agent did not show a significant increase in size over 14 days (p=0.3214) and had 
significantly less growth than rats treated with free doxorubicin after 14 days (p=0.0390). n = 3 for all 
except free dox at 4 hour 7 and 14 days due to lack of tumor growth in some animals. 
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4.1.5 Autoradiography  
 Autoradiography was performed on frozen sections of tumors treated with UCA, NP, free 
Dox and the combination of UCA and NP. Autoradiography images of frozen tissue sections 
from each treatment and time point are shown in figure 4.10. Tumors treated with UCA showed 
the greatest accumulation of drug at 4 hours, predominantly around the periphery, while tumors 
treated with nanoparticles or free Dox showed no detectable drug at any time point. Tumors 
treated with UCA and the combination of nanoparticles and contrast agent maintained detectable 
drug levels after 14 days. As shown by the error bars in figure 4.7 there was a large variability in 
the drug uptake found in the tumors which is also shown in the drug uptake of individual tumors 
in figure 4.10. 
 The penetration of ultrasound contrast agents into the center of the tumor may have been 
restricted by poor vascularization of necrotic regions within the tumor. The agent‟s penetration 
into the tumor may also be enhanced by using a more sophisticated ultrasound regimen [174, 
270]. It may be advantageous to track contrast agents with low intensity ultrasound as they 
perfuse through the tumor vasculature, then emit a high intensity destructive pulse to destroy the 
agent throughout the tumor similar to flash replenishment sequences used for perfusion imaging 
[270]. This process may allow intact contrast agents to reach deeper into the tumor before they 
are activated with ultrasound, and thus increase the amount of drug deposited within the tumor. 
Others have shown that ultrasound can be used to increase the temperature in the tumor to 42 °C, 
this hyperthermia has been shown to enhance blood flow to the tumor, reduce interstitial fluid 
pressure and enhance drug delivery to the tumor [31]. 
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Figure 4.10: Autoradiography images of tumors treated with 12 mg ultrasound contrast agent (UCA), 12 
mg nanoparticles (NP), a combination of 6 mg nanoparticles and 6 mg ultrasound contrast agent (COM) or 
free doxorubicin (Free Dox) and sacrificed after 4 hours, 7 days or 14 days. 
 
 
 
4.1.6 In Vivo Delivery of Dox Loaded UCA Conclusions 
 Doxorubicin loaded UCA were compared with three other delivery vehicles in their 
ability to provide targeted drug delivery to a rat liver cancer model. Dox loaded UCA delivered 
significantly more drug to the tumor than free Dox, however there was also significantly more 
drug in the liver and spleen of rats treated with UCA compared to free Dox. The results support 
the hypothesis that Dox loaded polymer UCA can deliver Dox to the targeted tumor when 
triggered with ultrasound while more work must be done to reduce drug uptake by the 
mononuclear phagocyte system and determine how drug uptake by the spleen and liver affects the 
health of the macrophages and immune system. It may also be useful to show this platform can 
carry higher payloads of drugs that are more hydrophobic than Dox including Ptx and Dtx. 
 
4.2 Characterization of Paclitaxel and Docetaxel Loaded UCA 
The maximum amount of Dox loaded into the polymer UCA tested in vivo was 13.9 µg 
Dox/mg UCA. The loading capacity for Dox may have been limited by the drug‟s hydrophilic 
nature when the primary amine group is charged (pKa ~ 8.4). Paclitaxel and docetaxel are 
anticancer drugs that are much more hydrophobic than Dox which may allow more drug to be 
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incorporated within the hydrophobic PLA shell. Ptx and Dtx are ideal candidates for targeted 
delivery using UCA due to the side effects caused by the current formulations of Cremophor or 
polysorbate 80 and ethanol. The following section examines the effects of loading Ptx and Dtx 
into PLA UCA on the total drug payload, in vitro acoustic properties and in vitro drug release.  
 
4.2.1 Effect of Ptx Loading on Acoustic Enhancement and Stability 
 The effect of Ptx loading on the in vitro acoustic properties of PLA UCA was examined. 
The effect of Ptx loading concentration on the agent‟s acoustic enhancement and acoustic 
stability are shown in figure 4.11a and b. Paclitaxel loading did not result in any significant 
differences in maximum acoustic enhancement compared to unloaded control UCA (21.2 ± 0.7 
dB, 19.7 ± 0.5 dB, 19.3 ± 1.2 dB, 19.5 ± 0.2 dB, 19.7 ± 0.6 dB and 22.6 ± 0.9 dB for 0, 3, 6, 12, 
18 and 24% (mg Ptx/ mg PLA) initial loading  p>0.076), however UCA loaded with 12% Ptx or 
greater did show significantly more shadowing at a dose of 15 µg/ml compared to unloaded 
controls (p<0.0058). It is also possible that higher Ptx loading concentrations affected the 
alignment of the polymer chains in the shell, altering the properties of the microbubble wall, or 
creating walls with a greater thickness, causing a change in the microbubble resonance frequency.  
UCA loaded with 24% Ptx also had significantly (p=0.028) greater enhancement than unloaded 
UCA at the first dose of 1.5 µg/ml (22.0 ± 0.7 dB vs. 16.5 ± 1.5 dB), suggesting the acoustic 
response from larger UCA is greater [271] or that the shell of the drug loaded UCA is more 
flexible due to the addition of Ptx allowing greater oscillations but also lower stability.  
 Effects of Ptx loading on the agent‟s acoustic stability during insonation were measured 
and are shown in figure 4.11b. Unloaded UCA maintained 78% of their initial enhancement after 
15 minutes, while UCA loaded with 3% Ptx or more, maintained significantly less enhancement 
(p<0.034) less than 70% of their original enhancement after 15 min (77.9 ± 1.4%, 70.4 ± 1.9%, 
67.9 ± 2.7%, 68.7 ± 1.4%, 62.4 ± 4.8% and 59.3 ± 4.6% for 0, 3, 6, 12, 18 and 24% (mg Ptx/ mg 
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PLA) initial loading after 15 minutes). This suggests that incorporation of the drug into the shell 
may affect the interactions between the polymer chains, making the agent more likely to rupture 
in response to the stresses caused by ultrasound [3]. This decrease in stability may be 
advantageous for the purpose of ultrasound targeted drug delivery.  
 
 
Figure 4.11: Effects of Ptx loading concentration on the acoustic behavior, (a) enhancement and (b) 
acoustic stability in vitro of UCA loaded with (0% , 3% , 6% , 12% , 18%  and 24% 
Ptx). No significant difference in maximum enhancement was observed at any loading concentration 
(p>0.076), however samples loaded with 12% Ptx or greater showed significantly more shadowing at a 
dose of 15 µg/ml  (*p<0.0058). All samples loaded with 3% Ptx or greater showed significantly less 
stability than unloaded UCA after 15 minutes (**p<0.034). 
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4.2.2 Effect of Ptx Loading on Microbubble Size 
 The effect of Ptx loading concentration on microbubble size was examined and is shown 
in figure 4.12. Particles were loaded with initial concentrations up to 6% Ptx without any 
significant difference in particle size compared to unloaded control particles (1.38 ± 0.06 µm, 
1.61 ± 0.13 µm and 1.74 ± 0.15 µm for UCA initially loaded with 0, 3 or 6% Ptx,  p>0.0653). 
However, particles loaded with 12% Ptx or greater showed a significant increase in particle size 
compared to unloaded UCA (1.86 ± 0.13 µm vs. 1.38 ± 0.06 µm, p<0.0197) supporting the 
hypothesis that increasing UCA size is responsible for the increased shadowing observed. It is 
possible that the addition of hydrophobic molecules to the organic phase can affect the viscosity 
or surface tension of the polymer solution during the emulsion process which may lead to 
differences in particle size. It has also been observed that the concentration of camphor in the 
organic phase can also affect particle size (unpublished results). The observed increase in size of 
Ptx loaded UCA corresponds with the significant increase in acoustic shadowing of UCA loaded 
with greater than 12% Ptx. This is expected as larger UCA have larger attenuation coefficients 
[271]. It has also been shown by Gorce et al. that with SonoVue, larger microbubbles can 
dominate the acoustic signal with bubbles less than 2 µm accounting for 60% of the microbubble 
population by number but only 5% by volume and contribute less than 20% of the acoustic signal 
while 80% of the signal is from UCA larger than 3 µm [271].  
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Figure 4.12: Effect of Ptx loading concentration on UCA size. Unloaded contrast agent had a diamter of 
1.38 ± 0.06 µm, UCA loaded with 12, 18 and 24% were significantly larger (p<0.0197) with diamters of 
1.86 ± 0.13 µm, 2.02 ± 0.39 µm and 2.83 ± 0.67 µm respectively.  
 
 
 
4.2.3 Paclitaxel Payload and Encapsulation Efficiency 
 Paclitaxel encapsulation was quantified with HPLC and is shown in figure 4.13a over a 
range of loading concentrations, along with the encapsulation efficiency shown in figure 4.13b. 
Final drug payload increased significantly with each increase in initial loading concentration up 
to 18% Ptx (p<0.001) while particles loaded with the highest initial loading concentration of 24% 
Ptx did not have a significantly greater final payload compared to particles loaded with 18% Ptx 
(131.12 ± 10.94 µg Ptx/mg PLA (24%) vs. 129.46 ± 1.80 µg Ptx/mg PLA (18%) p =0.88). The 
encapsulation efficiency of UCA loaded with 3, 6 and 12% Ptx were approximately 75% and 
were not significantly different from each other. However the increase in loading from 12 to 18% 
Ptx resulted in a significantly lower encapsulation efficiency (76.07 ± 1.33 % vs 64.73 ± 0.90 % 
p<0.01) and the encapsulation efficiency of particles loaded with 18% Ptx was significantly 
greater than particles loaded with 24% Ptx (64.73 ± 0.90 % vs. 49.21 ± 4.10 % p<0.05). An initial 
loading of 18% Ptx was selected for future experiments because it achieved the highest total Ptx 
payload without the significant increase in size observed with microbubbles loaded with 24% Ptx. 
This agent‟s maximum payload of Ptx is 20 times greater than its maximum payload of Dox (6.2 
µg/mg) while maintaining an encapsulation efficiency three times greater than the encapsulation 
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efficiency of Dox (20.5%) [3], (or almost 10 times greater than the Dox payload (13.9 µg/mg) 
used for the in vivo experiments). When compared to Dox, paclitaxel is much more hydrophobic, 
and its low solubility in water (3 µg/ml) [58] and greater solubility in the organic phase (50 
mg/ml) of the water/oil/water emulsion make it possible for this platform to carry a much greater 
payload of Ptx with higher encapsulation efficiencies compared to hydrophilic drugs. This Ptx 
payload is over 3 times greater than the Ptx payload achieved by Yan et al. with lipid 
microbubbles [180] and over 6 times greater than the Ptx payload found in lipid microbubbles 
developed by Xing et al. [272]. This difference in drug payload is most likely due the greater 
loading capacity of the thicker shell in polymer UCA compared to the thin shells of lipid 
microbubbles.  
 
 
 
 
Figure 4.13: Final Paclitaxel payload as a function of initial loading concentration (a) and encapsulation 
efficiency (b). Paclitaxel loaded UCA approached their maximum payload of 129.46 µg/mg (encapsulation 
efficiency of 64.73%) at an initial loading concentration of 18% Ptx with no significant increase in payload 
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when the initial loading concentration was increased to 24% Ptx (p=0.8807). Numbers above bars represent 
payload in µg Ptx/mg UCA. 
 
 
 
4.2.4 In Vitro Paclitaxel Release 
 The release profiles of Ptx loaded UCA exposed to ultrasound and uninsonated controls 
were examined in vitro and are shown in figure 4.14. The in vitro release profile of Ptx from 
polymer UCA when triggered by ultrasound closely matched the uninsonated controls over the 
first week of release. After 48 hours there was no significant difference in the percentage of total 
Ptx released from insonated and uninsonated UCA (24.76 ± 2.59 % vs. 24.21 ± 2.87 % p=0.89). 
After 21 days, the release of Ptx from insonated UCA became significantly greater than 
uninsonated controls (51.66 ± 2.45% vs. 40.05 ± 3.11% p<0.5) and remained significantly greater 
at all additional time points. This portion of the release profile is believed to be dominated by 
polymer degradation [273]. The increased Ptx release may be caused by the ultrasound triggered 
destruction of UCA resulting in polymer fragments that would expose a grater surface area for 
hydrolysis, as well as accelerated polymer degradation [274]. As UCA cavitate in response to 
ultrasound, the high strain rate can fracture polymer chains, this polymer scission can reduce the 
polymer molecular weight and increase polymer degradation [275]. This enhanced polymer 
degradation has also been observed in contrast agents fabricated with poly (lactic co glycolic 
acid) [276]. 
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Figure 4.14: In vitro drug release profile of Ptx from drug loaded UCA exposed to ultrasound   and 
uninsonated UCA  . The release profile of insonated UCA closely matched the release of uninsonated 
UCA over the first week of release (p>0.56). After 21 days significantly more Ptx had released from 
insonated UCA compared to UCA not exposed to ultrasound (*p<0.05). 
 
 
 
4.2.5 Nanoparticle Extravasation Potential of Ptx Loaded Microbubbles 
 Corning transwell inserts with a thin polyester membrane containing pores 400 nm in 
diameter were used to model the leaky tumor vasculature and to determine if delivery of Ptx 
through the pores using Ptx loaded UCA can be triggered with ultrasound. The delivery of Ptx 
through the pores over 20 minutes with and without ultrasound is shown in figure 4.15.  After 
5 minutes, significantly more drug was forced through the membrane when the Ptx loaded UCA 
were triggered with ultrasound compared to samples not exposed to ultrasound (1.3 ± 0.13 µg Ptx 
vs. 0.80 ± 0.8 µg Ptx, p<0.05). After 20 minute, 75% more drug was forced through the 400 nm 
pores when the agent was exposed to ultrasound compared to uninsonated controls (4.77 ± 0.09 
µg Ptx vs. 2.74 ± 0.17 µg Ptx, p<0.001). This system was limited by a lack of circulation which 
only exposed UCA within the focus of the transducer to sufficient energy to result in cavitation. 
The -6 dB focal zone of the transducer used was 3.19 mm while the diameter of the insert was 24 
mm, resulting in only 1.8% of the total area being included in the focal zone in this stagnant 
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system, however a significant increase in delivery through the 400 nm pores was still observed 
when UCA were triggered with ultrasound. 
 
 
 
 
Figure 4.15: Transport through membranes with 400 nm pores of Ptx loaded UCA exposed to ultrasound 
 and uninsonated UCA . After twenty minutes of insonation, 75% more Ptx was forced through the 
400 nm pores than uninsonated controls (p<0.001).  
 
 
 
4.2.6 In Vitro Tumoricidal Activity of Ptx Loaded Microbubbles 
Human breast cancer cells were exposed to both unloaded and Ptx loaded UCA that were 
exposed to ultrasound as well as uninsonated controls over a range of concentrations from 0 to 10 
µg UCA/ml (UCA were insonated then passed through 0.45 µm filters before being exposed to 
cells to allow only the free drug and polymer fragments less than 450 nm to pass through). After 
72 hours cell viability was measured with a MTT assay to determine the anti tumor activity of the 
triggered particles as shown in figure 4.16. 
 Ultrasound contrast agents loaded with 18% Ptx triggered by ultrasound resulted in a 
significant increase in tumoricidal activity compared to uninsonated controls at concentrations 
greater than 0.1 µg UCA/ml (p<0.01). The cell viability of samples treated with 1 µg/ml of Ptx 
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loaded UCA was significantly lower when triggered with ultrasound (49.81 ± 3.28%) compared 
to uninsonated controls (89.69 ± 4.09%) p<0.001. Unloaded UCA did not have any effect on cell 
viability at any concentration tested up to 10 µg/ml, both UCA exposed to ultrasound and 
uninsonated UCA did not reduce cell viability compared to controls (p> 0.5), indicating that all 
tumoricidal activity can be attributed to the Ptx loaded within the agent. It is possible that the 
drop in viability is the result of free drug that was slowly released from the polymer fragments 
that passed through filter or that the polymer fragments themselves were taken into the cells by 
endocytosis. In cells treated with uninsonated Ptx loaded UCA diluted to a concentration of 
10 µg/ml the drop in cell viability may have been caused by a burst release of Ptx from the UCA 
as they were suspended in media before filtration through the 440 nm filter. A burst of 17% 
observed from uninsonated UCA (in the first 6 hours shown in figure 4.14) results in a Ptx 
concentration of approximately 250 nM at this dilution and is above the 50 nM concentration that 
causes cell death in MCF 7 cells [50]. In comparison, at a dilution of 0.1 µg UCA/ml the burst 
release from uninsonated UCA that would be able to pass through the filter would be 
approximately 2.5 nM and was not observed to have an effect on cell viability while there was a 
significant drop in the viability of cells treated with insonated UCA, supporting the hypothesis 
that insonating the microbubbles allows drug loaded polymer fragments to carry drug through the 
450 nm pores in the filter.  
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Figure 4.16: Effect of treatment regime on tumoricidal activity of UCA. Samples were either not insonated 
(patterned) or insonated at 5 MHz for 20 minutes (solid) and assayed 72 hours post treatment.  Unloaded 
UCA not exposed to ultrasound , unloaded UCA exposed to ultrasound , 18% Ptx loaded UCA 
not exposed to ultrasound  and 18% Ptx loaded UCA exposed to ultrasound . Unloaded UCA 
exposed to ultrasound and uninsonated loaded UCA showed no significant decrease in cell viability at any 
concentrations tested (p>0.4827).  Ultrasound contrast agents loaded with 18% Ptx and exposed to 
ultrasound showed significantly greater anti tumor activity at concentrations of 0.1, 1.0 and 10 µg/ml  
compared to uninsonated controls (p<0.01). 
 
 
 
4.2.7 Effect of Docetaxel Loading on Acoustic Enhancement and Stability  
 Docetaxel (Dtx), a more hydrophilic derivative of Ptx was also loaded into polymer 
microbubbles. The effect of docetaxel loading on the acoustic enhancement and stability was 
examined. Figure 4.17a shows the effect of Dtx loading on the ability of the ultrasound contrast 
agent to reflect ultrasound which is measured in decibels relative to the enhancement provided 
with no contrast agent. Ultrasound contrast agents were loaded with up to 18% Dtx with no 
significant drop in maximum acoustic enhancement compared to unloaded control microbubbles 
(18.38 ± 1.8 dB vs. 21.13 ±  1.1 dB, p=0.11). However, microbubbles loaded with 24 % docetaxel 
showed a significant drop in maximum acoustic enhancement compared to unloaded 
microbubbles (16.8 ±  1.0 db vs. 21.13 ±  1.1 dB, p=0.02). This drop in acoustic enhancement 
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was not observed in Ptx loaded UCA and may be the result of the more hydrophilic Dtx 
interfering with the formation of UCA at higher concentrations. This was not expected after 
observing Ptx loading appeared to increase the backscatter enhancement and shadowing, possibly 
by increasing the particle size.  
 The effect of docetaxel loading on the ultrasound contrast agents‟ stability while exposed 
to ultrasound was also examined and is shown in figure 4.17b. The enhancement decreases over 
time as the microbubbles pass though the ultrasound beam and the polymer shell is destroyed, 
generating nanoparticles and allowing the gas core to diffuse into solution. Unloaded 
microbubbles were able to maintain 78% of their acoustic enhancement after 15 minutes of 
insonation while microbubbles loaded with 12% docetaxel or greater had significantly lower 
acoustic enhancement (77.9 ± 1.4%, 68.6 ± 1.6%, 73.7 ± 5.3%, 71.3 ± 0.3%, 51.3 ± 0.7% and 
54.3 ± 6.3% for initial Dtx loadings of 0, 3, 6, 12, 18 and 24%, p<0.04). This is similar to the 
trends observed with both Dox and Ptx loading.  
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Figure 4.17: Effect of docetaxel loading on the acoustic enhancement (a) and acoustic stability (b) in vitro 
of polymer ultrasound contrast agents loaded with 0% , 3% , 6% , 12% , 18%   and 
24% docetaxel. A significant decrease in maximum acoustic enhancement was observed in samples 
loaded with 24% docetaxel (*p<0.05) while samples loaded with 18% or less showed no significant 
change. A significant decrease in acoustic stability was observed in all samples loaded with 12% docetaxel 
or greater (*p<0.05). 
 
 
 
4.2.8 Effect of Dtx Loading on Microbubble Size 
 The effect of Dtx loading on particle size was examined and is shown in figure 4.18. 
Unloaded ultrasound contrast agents had a peak particle diameter of 1.38 ± 0.06 µm. No 
statistically significant change in particle size was observed (1.38 ± 0.06 µm, 1.60 ± 0.09 µm, 
1.59 ± 0.26 µm, 1.32 ± 0.08 µm, 1.42 ± 0.04 µm and 1.38 ± 0.06 µm)  for ultrasound contrast 
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agents loaded with any of the tested concentrations of Dtx (0 – 24%),  p>0.5. This is also 
different from the trend observed with Ptx loaded UCA suggesting the difference between Ptx 
and Dtx result in very different interactions with the polymer shell. 
 
 
 
 
Figure 4.18: Effect of docetaxel loading on ultrasound contrast agent size. Unloaded contrast agent had an 
average diameter of 1.38 ± 0.06 µm with no significant change in size observed with docetaxel loading. 
 
 
 
4.2.9 Docetaxel Payload and Encapsulation Efficiency 
 Docetaxel encapsulation was measured using HPLC and is shown in figure 4.19a. Final 
drug payload increased significantly with each increase in initial loading concentration with a 
maximum drug payload of 106.9 ± 12.7 µg docetaxel/mg contrast agent corresponding to an 
initial loading of 24%. The drug payload was used to calculate the encapsulation efficiency 
shown in figure 4.19b. Ultrasound contrast agents loaded with 24% docetaxel had an 
encapsulation efficiency of 44 ± 5%. Ultrasound contrast agents loaded with 18% docetaxel had a 
final payload of 80.8 ± 2.97 µg/mg UCA and encapsulation efficiency of 44 ± 2%. This payload 
of docetaxel is over twelve times greater than the maximum payload of the more hydrophilic 
chemotherapeutic drug Dox (6.2 µg doxorubicin/mg contrast agent) [3] but 38% less than the 
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payload of the more hydrophobic taxane paclitaxel (129.46 µg Ptx/ mg contrast agent) [277]. This 
suggests that the loading capacity of these polymer contrast agents is dependent on the ability of 
the drug to interact with the shell consisting of the hydrophobic polymer poly(lactic acid). In vitro 
studies have shown the IC50 of docetaxel to be near 100 nM corresponding to approximately 80 
ng of docetaxel/ml [49], suggesting the docetaxel loaded ultrasound contrast agents are capable of 
delivering sufficient drug levels to inhibit tumor cell growth. 
 
 
 
 
Figure 4.19: Docetaxel payload (a) and encapsulation efficiency (b) as a function of initial loading 
concentration. A maximum docetaxel payload of 106.9 ± 22.0 µg docetaxel/mg contrast agent was 
observed with an initial loading of 24% resulting in an encapsulation efficiency of 40 ± 8%. 
 
 
 
4.2.10 In Vitro Docetaxel Release 
 The release of docetaxel from ultrasound contrast agents loaded with 18% docetaxel was 
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examined in vitro for both insonated and uninsonated microbubbles and is shown in figure 4.20. 
After 6 hours there was no significant difference in release from insonated compared to 
uninsonated microbubbles (25.8 ± 1.5 % vs. 22.5 ± 4.8 %, (20.9 vs. 18.2 µg Dtx/mg UCA), p = 
0.5). After 24 hours significantly more docetaxel had been released from insonated microbubbles 
compared to the uninsonated samples (40.1 ± 2.1 % vs. 30.3 ± 3.7%, (32.4 vs 23.5 µg 
docetaxel/mg UCA)  p<0.05). After 40 days a total of 70.2 ± 1.2% (56.7 µg docetaxel/mg UCA) 
of docetaxel had been released from insonated samples compared to only 57.8 ±  2.8% (46.7 µg 
docetaxel/mg UCA) of uninsonated samples. One potential advantage of this delivery vehicle is 
the ability to provide a sustained release of docetaxel at the tumor as the polymer degrades. While 
over 51% (41.6 µg docetaxel/mg UCA) of the loaded docetaxel is released over the first 4 days 
there is still a continuous release over at least 40 days with a 1 mg dose being capable of releasing 
over 150 ng of docetaxel per day for the first 35 days. The percentage of Dtx released from 
insonated UCA over 40 days is also significantly greater than the percentage of Ptx released over 
40 days (70.2 ± 1.2% vs 61.4 ± 1.2%, p<0.05). This suggests that the more hydrophobic Ptx is 
held within the polymer fragments more tightly than Dtx. 
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Figure 4.20: In vitro drug release profile from polymer ultrasound contrast agents loaded with 18% 
docetaxel that were either insonated   or uninsonated  . After 24 hours, significantly more docetaxel 
had been released from the insonated samples compared to uninsonated microbubbles (p<0.05). Inset: 
docetaxel release over first 6 days. 
 
 
 
4.2.11 Nanoparticle Extravsation Potential of Dtx Loaded Microbubbles 
 The leaky vasculature of a tumor was modeled with Corning transwell inserts with a thin 
membrane containing pores 400 nm in diameter to determine if docetaxel can be forced through 
the pores when the drug loaded microbubbles are triggered with ultrasound. The delivery of 
docetaxel through the porous membrane over 20 minutes of insonation was quantified with HPLC 
and is shown in figure 4.21 compared with uninsonated microbubbles. After 5 minutes 
significantly more docetaxel had been forced through the membrane when the samples were 
triggered with ultrasound compared to uninsonated controls (0.38 ± 0.04 µg Dtx vs. 0.14 ± 0.01 
µg Dtx, p<0.01). After 20 minutes nearly three times more docetaxel had been forced through the 
pores compared to uninsonated controls (1.99 ± 0.28 µg Dtx vs. 0.67 ± 0.4 µg Dtx). This helps 
support the hypothesis that ultrasound can be used to enhance drug delivery through leaky blood 
vessels. 
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Figure 4.21: Transport through membranes with 400 nm pores of ultrasound contrast agent loaded with 
18% docetaxel that were insonated    or uninsonated  . After 20 minutes of exposure to ultrasound, 
significantly more docetaxel had been forced through the pores compared to the uninsonated samples 
(p<0.05). 
 
 
 
4.2.12 In Vitro Tumoricidal Activity of Docetaxel Loaded Microbubbles 
 The MCF7 human breast cancer cell line was used to determine the tumoricidal activity 
of docetaxel loaded microbubbles in vitro. Cells were incubated with insonated and uninsonated 
ultrasound contrast agents that were loaded with 18% docetaxel or unloaded controls. After 72 
hours cell viability was measured with an MTT assay as shown in figure 4.22. Incubating cells 
with unloaded ultrasound contrast agent that were insonated or uninsonated had no effect on cell 
viability for any of the concentrations tested (p=0.5). However, treating cells with ultrasound 
contrast agent loaded with 18% docetaxel and triggered with ultrasound was able to cause a 
significant drop in cell viability at concentrations greater than 0.1 µg ultrasound contrast agent/ml 
compared to uninsonated cells (50.3 ± 5.4%, 31.5 ± 2.1%, and 31.1 ± 3.9% vs. 96.4 ± 2.1, 69.5 ± 
0.2% and 50.3 ± 2.5% , for concentrations of 0.1, 1.0 and 10 µg/ml, p<0.01). Despite the lower 
payload of Dtx loaded UCA compared to Ptx loaded UCA, the effects on cell viability were very 
similar, this may be the result of Dtx‟s 1.9 fold higher affinity for microtubules and its ability to 
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induces microtubule polymerization at 2.1 fold lower concentrations compared to paclitaxel 
[278]. 
 
 
 
 
Figure 4.22:Tumoricidal activity of docetaxel loaded microbubbles. MCF 7 breast cancer cells were 
treated with unloaded microbubbles that were not exposed to ultrasound , unloaded microbubbles 
exposed to ultrasound , microbubbles loaded with 18% docetaxel and not exposed to 
ultrasound  and microbubbles loaded with 18% docetaxel and exposed to ultrasound . Cell 
viability 72 hours post treatment showed that unloaded microbubbles had no effect on cell viability while 
docetaxel loaded microbubbles exposed to ultrasound had significantly greater antitumor activity compared 
to unloaded bubbles and drug loaded bubbles that had not been exposed to ultrasound at concentrations 
greater than 0.1 µg contrast agent/ml. 
 
 
 
4.2.13 Paclitaxel and Docetaxel Loading Conclusions 
 The acoustic and drug loading properties of UCA loaded with Dox, Ptx and Dtx are 
summarized in table 4.1. Polymer microbubbles have been loaded with up to 129.46 ± 1.80 µg 
Ptx/mg PLA and 80.8 ± 2.97 µg Dtx/mg PLA without a significant drop in the peak acoustic 
enhancement measured in vitro. Both taxanes were incorporated into polymer microbubbles at 
significantly higher levels than the more hydrophilic doxorubicin, supporting the hypothesis that 
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drug is primarily incorporated within the polymer shell of the microbubbles and more 
hydrophobic molecules can be entrapped within the hydrophobic polymer shell more efficiently. 
Consistent with this hypothesis, Dtx loading was lower than Ptx and a significantly higher 
percentage of Dtx was released over 40 days compared to Dtx, suggesting a weaker interaction 
with the polymer shell.  
 
 
Table 4.1: Effect of Drug Loading on UCA Properties. 
  Dox Ptx Dtx 
Initial loading 
(3% w/w) 
Peak Enhancement (dB) 18.3 19.6 19.7 
Enhancement after 15 min (%) 60 70 69 
Size (µm) 1.87 1.61 1.60 
Payload (µg Drug/mg PLA) 6.2 24.7 21.1 
Encapsulation Efficiency (%) 20.5 82.4 70.37 
     
Initial loading 
(18% w/w) 
Peak Enhancement (dB)  19.7 18.4 
Enhancement after 15 min (%)  62 61 
Size (µm)  2.02 1.42 
Payload (µg Drug/mg PLA)  129.5 80.8 
Encapsulation Efficiency (%)  71.9 44.9 
 
 
 
4.3 Development of Nucleic Acid Loaded UCA for Gene Delivery 
 Two methods have been developed for adding negatively charged nucleic acids to PLA 
microbubbles. Microbubbles were first loaded with DNA by incorporation, where the nucleic acid 
was dissolved in the ammonium carbonate solution used in the first emulsion of the microbubble 
fabrication process. The total DNA payload, UCA size and microbubble enhancement achieved 
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with this method were compared with loading DNA onto the surface of modified PLA UCA. 
Linear DNA from salmon testes (sDNA) was used as a model nucleic acid to quantify DNA 
loading due to its availability and similarity to plasmid DNA in loading [279]. Initially 
uncomplexed sDNA was incorporated, but this was replaced by use of sDNA complexed with 
PEI in an attempt to increase the payload. 
 
4.3.1 DNA Loading by Incorporation 
 Microbubbles loaded with naked sDNA by incorporation had a total payload of 
0.34 ± 0.02 µg DNA/mg UCA with an encapsulation efficiency of only 6.75 ± 0.43%. The ability 
to increase the payload of DNA by starting with higher concentrations of sDNA was limited by 
the viscosity of solutions of 10 mg/ml and greater.  
 To improve DNA loading, sDNA was incubated with the highly positively charged 
polymer, poly(ethyleneimine) (PEI) to create positively charged PEI-DNA complexes that can 
bind to the negatively charged polymer wall. Condensing DNA with PEI also can have a 
significant effect on the size and shape of these particles which may influence loading [280]. The 
effect of the molar ratio of positively charged amine groups from PEI to negatively charged 
phosphate groups of sDNA (N:P ratio) on the size and zeta potential of the PEI-DNA complex 
was examined first.  
 PEI-DNA complexes with N:P ratios of 1:1 and 2.5:1 resulted in the rapid formation of 
large aggregates of 7.4 ± 1.7 µm and 2.6 ± 0.9 µm in diameter and the size of PEI-DNA 
complexes with a 1:1 N:P ratio were significantly larger than all other N:P ratios (p<0.01) as 
shown in figure 4.23a. At a N:P ratio of 5:1 the size of particles dropped to 0.4 ± 0.04 µm in 
diameter. These results are similar to other studies that have seen PEI-DNA complex particle 
sizes ranging from 300 to 400 nm [281]. This drop in aggregation may have been the result of a 
more positive overall charge of the particles causing them to repel each other and reduce 
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aggregation. Zeta potential measurements of these particles showed a similar trend with particles 
made with a 1:1 ratio having a nearly neutral charge of 1.75 ± 5.14 mV and a increasingly 
positive charge as the N:P ratio was increased, however  there was no significant difference in 
zeta potential between N:P ratios of 2.5:1 and 20:1 (figure 4.23b) suggesting that continuing to 
increase the N:P ratio does not add significantly more PEI chains to the complex. The strong 
positive charge and limited aggregation of PEI-DNA complexes made with N:P ratios of 5, 10 
and 20:1 made them the most promising choices for loading DNA into polymer UCA by 
incorporation. 
 
 
Figure 4.23: Effect of N:P ratio on size (a) and zeta potential (b) of PEI-DNA complexes made in 150 mM 
NaCl at a pH of 7.0 and a maturation time of 15 minutes (n=3). 
 
 
 The effect of the N:P ratio on the total payload of sDNA loaded into polymer UCA by 
incorporation was measured by dissolving unloaded (blank) and loaded microbubbles in sodium 
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hydroxide solutions, then measuring the concentration of sDNA by absorbance at 260 nm 
compared to a standard curve of sDNA in the same buffer with the absorbance of blank UCA 
subtracted to account for the absorbance of the polymer. Loading of naked DNA alone (N:P ratio 
of  0:1)  was only 0.34 ± 0.02 µg/mg corresponding to an encapsulation efficiency of 6.75 ± 
0.43%. When PEI-DNA complexes made with an N:P ratio of 1:1 were incorporated in the first 
emulsion, the amount of DNA loaded increased significantly to 2.51 ± 0.26 µg/mg (p<0.05) as 
shown in figure 4.24. The DNA payload also increased significantly when the N:P ratio was 
raised to 5:1, with a payload of 3.07 ± 0.23 µg/mg and an encapsulation efficiency of 61.4 ± 
4.6%. However, when the N:P ratio was increased to 20:1, DNA loading dropped significantly to 
2.04 ± 0.14 µg/mg. It is possible that this drop in loading is caused by an excess of PEI 
competing with PEI-DNA complexes for binding locations on the negatively charged polymer 
surface of UCA which may explain why there were only small changes in the zeta potential of 
microbubbles as the N:P ratio was increased. To test this, sDNA with a 10:1 N:P ratio was added 
to the first emulsion of the UCA fabrication process and 1% PEI was added to the 5% PVA 
solution used in the second emulsion. The total sDNA loaded into these UCA dropped 
significantly (p<0.05) from 3.13 ± 0.14 µg/mg when 1% PEI was not included in the second 
emulsion, to 1.90 ± 0.14 µg/mg with PEI. This drop in loading suggests that excess positive 
charges from PEI are capable of displacing PEI-DNA complexes loaded on the surface of 
polymer UCA.  
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Figure 4.24: Effect of N:P ratio on the total DNA payload of UCA loaded by incorporation. DNA loading 
increased significantly with increasing N:P ratios up to 2.5:1, remained unchanged at 5:1 and 10:1 ratios 
and then dropped significantly when the N:P ratio increased from 10:1 to 20:1 (*p<0.05, n=3). 
 
 
 
 The effect of loading sDNA complexes by incorporation on the size of the resulting UCA 
was also examined. Loading uncomplexed DNA (N:P of 0:1) resulted in UCA with a mean 
diameter of 2.2 ± 0.1 µm. It has been noted in figure 4.23 that the N:P ratio had a significant 
effect on the size of the PEI-DNA complexes formed at a pH of 7, with an N:P ratio of 1:1 
creating complexes over 7 µm in diameter (much larger than the normal 2 µm UCA). 
Surprisingly, the N:P ratio had no significant effect on the size of UCA loaded with these DNA-
PEI complexes as shown in figure 4.25a. The UCA made with a 1:1 N:P ratio were much smaller 
than the PEI-DNA complexes themselves which were formed at a pH of 7 and measured 7.4 µm. 
This drop in size may have been caused by the higher pH of the ammonium carbonate solution 
(pH = 8.7) in the w/o/w emulsion, which deprotonates the amine groups of PEI, reducing the 
charge of the polymer and weakens the PEI-DNA complex. When the size of the PEI-DNA 
complexes were measured in an ammonium carbonate the size dropped from 7.4 ± 1.7 µm and 
2.6 ± 0.9 µm for a N:P ratio of 1:1 and 2.5:1 measured in DI water to 0.99 ± 0.18 µm and 1.1 ± 
0.26 µm for the same N:P ratios (1:1 and 2.5:1) measured in a 4% w/v solution of ammonium 
carbonate. The diameters of these particles are similar to the sizes of the microbubbles themselves 
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suggesting it may be possible for the DNA/PEI particles to be in suspension with the 
microbubbles and not loaded into the shell but are never washed away from the UCA because 
they are removed from the supernatant along with the microbubbles during centrifugation. It is 
also possible that the energy from sonication in the first emulsion of the UCA fabrication process 
causes the PEI-DNA particles to break down further into particles small enough to be 
incorporated within the microbubble. Others have shown that complexing DNA with cationic 
polymers can protect the plasmid DNA from degradation caused by sonication [282], this is a key 
advantage of complexing DNA with PEI in order to protect the plasmid from the high energies of 
sonication during the first emulsion of the UCA fabrication process. 
 The zeta potential of UCA loaded with PEI-DNA complexes showed a similar trend to 
the zeta potential of the PEI-DNA complexes in solution (figure 4.25b). Incorporating PEI-DNA 
complexes with a 1:1 N:P ratio that had a nearly neutral charge had no significant effect on the 
zeta potential of microbubbles compared to UCA loaded with uncomplexed DNA (-23.0 ± 3.3 
mV vs. -20.0 ± 0.4 mV). When UCA were loaded with PEI-DNA complexes with increasing N:P 
ratios, the zeta potential increased significantly (p<0.05) with 2.5:1 being significantly more 
positive than 1:1 (6.4 ± 0.6 mV vs. -23.0 ± 3.3 mV)  and 5, 10 and 20:1 all having zeta potentials 
(18.1 ± 1.8 mV, 22.4 ± 0.8 mV and 21.4 ± 1.4 mV) significantly more positive than 2.5:1. This 
change in zeta potential supports the possibility that the PEI-DNA complexes are included in the 
microbubble shell, at least at the higher N:P ratios, although the nearly neutral 1:1 ratio would not 
be expected to impact the zeta potential compared to empty UCA.  
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Figure 4.25: Effect of N:P ratio of DNA-PEI complexes loaded into UCA on the size (a) and zeta potential 
(b) of UCA (n=3). 
 
 
 
4.3.2 DNA Loading by Surface Adsorption 
 While DNA loading by incorporation of PEI-DNA complexes was able to provide an 
encapsulation efficiency of over 60%, the maximum payload was limited by the concentration of 
DNA that could be included in the ammonium carbonate solution of the primary emulsion. As an 
alternative approach, PLA microbubbles were incorporated with a PEI by including PEI in the 
PVA solution used in the second emulsion in order to provide a positively charged surface 
capable of loading negatively charged nucleic acids. The effect of PEI concentration on the in 
vitro acoustic enhancement, stability, size and DNA payload were examined to help choose the 
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formulation that would allow maximum DNA payload while maintaining the microbubble‟s 
acoustic properties and ability to pass through blood vessels.  
 Polymer UCA were made with concentrations of PEI in the PVA solution from 0 to 4 % 
(w/v) with no significant effect on the acoustic enhancement measured in vitro. The peak 
enhancement ranged from 20.06 ± 1.5 dB for UCA made with 0.5% PEI to 22.11 ± 0.8 dB for 
UCA made with 1% PEI with no significant difference between any of the groups (p>0.1) as 
shown in figure 4.26a. A similar trend was found for the acoustic stability, UCA were emulsified 
in PVA solutions containing up to 4% PEI without causing a significant change in acoustic 
stability (p>0.25) compared to UCA made without PEI as shown in figure 4.26b. 
 
 
 
Figure 4.26: Effect of PEI concentration in the second emulsion on the acoustic enhancement (a) and 
stability (b) of polymer microbubbles (n=3). 
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 While including PEI in the second emulsion had no effect on the acoustic enhancement or 
stability, there was a significant effect on particle size with higher concentrations of PEI causing 
an increase in particle size. Microbubbles made with 2% and 4% PEI had average particle 
diameters of 3.9 ± 0.4 µm and 3.6 ± 0.5 µm compared to 1.9 ± 0.3 µm for particles made without 
PEI (p<0.05) as shown in figure 4.27a. In addition to doubling the peak particle diameter, 
increasing the concentration of PEI also resulted in a higher percentage of UCA larger than 
6.5 µm as shown in figure 4.27. Particles larger than 6 µm may not be able to pass through small 
capillaries and are also more likely to be trapped in the spleen and lung [104] making them more 
dangerous for systemic delivery. It is possible that the increased microbubble size may have been 
caused by the higher viscosity of the 5% PVA 4% PEI solutions compared to 5% PVA alone. 
However, it is not clear why microbubbles made with 4% PEI which appeared to be significantly 
larger showed no difference in acoustic enhancement compared to smaller UCA made with no 
PEI. It is possible the addition of PEI resulted in microbubble clumps that were not easily 
dispersed but responded to ultrasound as individual microbubbles.  
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Figure 4.27: Effect of PEI concentration in the second emulsion on microbubble diameter (a) and 
percentage of microbubbles larger than 6.5 µm (b) (n=3). 
 
 
 
 The effect of including PEI in the second emulsion on the zeta potential of UCA was also 
examined. Adding 0.5 % (w/v) PEI resulted in a complete reversal in charge to 31.3 ± 1.2 mV 
compared to -24.9 ± 2.6 mV for control UCA emulsified in a PVA solution without PEI. As the 
PEI concentration was increased up to 4%, the zeta potential became less positive, decreasing to 
27.6 ± 2.6 mV, 23.0 ± 2.0 mV and 19.2 ± 2.1 mV for UCA made with 1, 2 and 4% PEI as shown 
in figure 4.28. This reversal of zeta potential can provide a positive surface charge capable of 
loading DNA.  
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Figure 4.28: Effect of PEI concentration in the second emulsion on zeta potential of PLA microbubbles 
(n=3). 
 
 
 
 The DNA loading capacity of these PLA microbubbles coated with PEI was determined 
by incubating the microbubbles in a solution of sDNA and quantifying the amount of sDNA 
adsorbed to the microbubbles. To determine if the molecular weight of the nucleic acid had an 
effect on loading, intact salmon DNA was compared with sDNA that had been sonicated in order 
to generate DNA fragments with lower molecular weights. The effect of sonication (with a 20 
kHz sonication probe set at 30% for 3 minutes) on the molecular weight of sDNA is shown in 
figure 4.29. Uninsonated DNA ranged in size from greater than 10,000 base pairs to less than 
1000 base pairs while sonicated DNA was broken into fragments less than 2000 base pairs.  
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Figure 4.29: Agarose gel electrophoresis (0.7% agarose gel run at 100 V for 100 minutes) comparing 
uninsonated salmon DNA (B) with salmon DNA insonated for 3 minutes (C). A 1kBp ladder is shown in 
lane (A).  
 
 
 
4.3.2.1 Effect of DNA Molecular Weight on DNA Loading 
 To determine if DNA molecular weight had an effect on the DNA loading capacity of 
positively charged UCA loaded by surface adsorption, microbubbles made with 1% PEI were 
incubated at 4 
o
C with sonicated and unsonicated sDNA (in diH2O). The amount of sDNA 
adsorbed to the UCA was measured after 15, 60 and 120 minutes and is shown in figure 4.30. 
Microbubbles made with a PEI concentration of 1% were chosen for this adsorption study 
because this was the highest PEI concentration that did not result in a large increase in 
microbubbles greater than 6 µm. There was no significant difference in the DNA payloads of 
UCA loaded with unsonicated DNA compared to sonicated DNA (11.6 ± 1.8 µg DNA/mg vs. 
12.24 ± 0.7 µg DNA/mg PEI-UCA after 15 min, 12.6 ± 1.8 µg DNA/mg vs. 12.8 ± 0.8 µg 
DNA/mg PEI-UCA after 60 min and13.2 ± 1.5 µg DNA/mg vs. 13.8 ± 0.4 µg DNA/mg PEI-
UCA after 2 hours, p=0.7). There was also no significant difference in loading after 15 minutes 
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compared to 2 hours. The similar loading capacity suggests that loading is independent of the 
nucleic acid molecular weight and the DNA payloads measured with sDNA should be similar for 
plasmid DNA or other nucleic acids as also claimed by Borden et al [279]. Unsonicated sDNA 
was used for all other DNA loading experiments.  
 
 
 
Figure 4.30: Effect of DNA molecular weight on DNA payload of 1% PEI coated PLA UCA after 
incubating UCA with DNA for 0.25, 1 and 2 hours (n=3). 
 
 
 
4.3.2.2 Effect of PEI Concentration on DNA Loading 
 The effect of PEI concentration on the microbubble DNA loading capacity is shown in 
Figure 4.31. Increasing the concentration of PEI used in the second emulsion was able to 
significantly increase the DNA payload of the resulting microbubbles. Control microbubbles 
made without PEI had almost no DNA attached after 15 minutes (0.91 ± 0.7 µg DNA/mg UCA) 
but each increase in PEI concentration provided a significant increase in DNA payload (p<0.01), 
with 7.2 ± 0.3 µg DNA, 14.5 ± 0.9 µg DNA, 19.3 ± 0.8 µg DNA and 25.7 ± 1.0 µg DNA loaded 
per mg of UCA made with 0.5, 1, 2 and 4% PEI. The increased DNA loading capacity when PEI 
is added agrees with the reversal of zeta potential from negatively charged control UCA to 
positively charged PEI coated UCA shown in Fig. 4.28. However, in figure 4.18 the zeta potential 
became less positive with increasing PEI concentrations but the DNA loading of these UCA 
demonstrated in figure 4.31 continued to increase with increasing PEI. The higher DNA loading 
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capacity suggests that more PEI also adsorbs to the surface with higher PEI concentrations, but it 
is not clear why this would cause the zeta potential to decrease.  
 The total payload of UCA made with 2% and 4% PEI increased with incubation time 
from 15 min to 2 hours, rising from 19.3 ± 0.8 µg DNA/mg PEI-UCA to 24.0 ± 1.9 µg DNA/mg 
PEI-UCA at 2% PEI and from 25.7 ± 1.0 µg DNA/mg PEI-UCA to 34.7 ± 1.0 µg DNA/mg PEI-
UCA at 4% PEI. It is possible that more time is required for additional DNA to adsorb to the 
surface as the total payload of DNA is increased, possibly because of additional negative charges 
from DNA weakening the attraction to the microbubble. It is also possible that microbubbles 
made with higher concentrations of PEI will release free PEI polymer when incubated with DNA, 
these PEI and DNA molecules can then slowly aggregate in a process called “ripening” into 
particles that are large enough to be removed from the solution by centrifugation along with the 
microbubbles, creating a mix of DNA loaded UCA and PEI/DNA complexes. 
 The loading capacity of UCA made with 2% and 4% PEI (19.3 ± 0.8 µg DNA and 25.7 ± 
1.0 µg DNA/mg UCA) (figure 4.31) was significantly greater than the loading capacity of UCA 
made with 1% PEI (14.5 ± 0.9 µg DNA/mg UCA). However, due to the significant increase in 
particle size and the increase in the percentage of particles greater than 6.5 µm in the diameter 
(figure 4.27b) of UCA made with 2% and 4% PEI only UCA made with 1% PEI were examined 
further. 
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Figure 4.31: Effect of PEI concentration used in the second emulsion on DNA payload of UCA incubated 
in 100 µg/ml sDNA dissolved in diH2O (n=3).  
 
 
 
4.3.2.3 Effect of Ionic Strength on DNA Loading 
 Microbubbles made with 1% PEI (PEI-UCA) were incubated with sDNA in NaCl 
concentrations from 0 to 1000 mM in order to measure the effect of ionic strength on DNA 
loading. Increasing the NaCl concentration from 0 mM to 10 mM resulted in a significant 
increase in sDNA payload after two hours (15.4 ± 1.6 µg DNA/mg vs 21.1 ± 1.5 µg DNA/mg, 
p<0.05). Continuing to increase the salt concentration to 100 and 1000 mM caused a significant 
decrease in sDNA loading to 15.3 ± 0.7 µg DNA/mg and 5.8 ± 0.3 µg DNA/mg (p<0.05) as 
shown in figure 4.32. The ionic strength of a solution can affect the conformation of 
polyelectrolyte molecules [283]. At low ionic strengths the negative charges along the backbone 
of DNA molecules can repel each other and prevent the chain from bending freely. As the ionic 
strength is increased, the salt ions can shield the charges and allow the DNA to form folds and 
coils, generating a more compact structure that can be loaded more efficiently. At higher ionic 
strengths, the charge shielding can be enough to reduce the attraction between PEI and DNA 
resulting in lower loading. Other groups have also seen a relationship between ionic strength and 
DNA loading on various cationic surfaces but the optimal NaCl concentrations found in different 
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studies have had a wide range from 1 to 500 mM [279, 283].The hypothesis is that loading DNA 
in a solution with an ionic strength that allows maximum binding will result in tightly bound 
DNA and this stabilized complex will resist release when exposed to physiological conditions.  
 
 
 
 
Figure 4.32: Effect of ionic strength on DNA payload of PLA PEI-UCA made with 1% PEI (n=6). 
 
 
 
4.3.2.4 Effect of DNA Concentration on DNA Loading 
 The effect of loading concentration on DNA payload of microbubbles was measured for 
sDNA concentrations from 0 to 180 µg DNA/mg PEI-UCA. Two milligrams of microbubbles 
made with 1% PEI were incubated in 1 mL of sDNA with 10 mM NaCl for 15 minutes, 1 or 2 
hours. Microbubbles incubated in 22.5 µg DNA/ml quickly adsorbed over 90% of the sDNA 
from solution with a total loading of 10.4 ± 0.1 µg DNA/mg after 15 minutes and no significant 
increase after 2 hours (10.7 ± 0.02 µg DNA/mg, figure. 4.33). When the loading concentration 
was doubled to 45 µg DNA/ml the sDNA payload also doubled to 21.1 ± 0.3 µg DNA/mg PEI-
UCA after 15 minutes with no significant increase after 2 hours (22.1 ± 0.01 µg DNA/mg PEI-
UCA). An additional increase in loading concentration to 90 µg DNA/ml resulted in a drop of 
DNA payload to 19.0 ± 0.3 µg DNA/mg PEI-UCA after 15 minutes but increased significantly to 
24.8 ± 0.1 µg DNA/mg PEI-UCA after 2 hours and was not significantly different from the 
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loading achieved with an initial loading concentration of 180 µg DNA/ml (24.2 ± 0.6 µg 
DNA/mg PEI-UCA after 2 hours) indicating the loading capacity was not dependent on the initial 
loading concentration as long as the concentration used contained enough sDNA to saturate the 
adsorption sites on the UCA.  
 
 
 
Figure 4.33: Effect of initial loading concentration of sDNA on DNA payload of UCA made with 1%PEI 
(n=3). 
 
 
 
4.3.2.5 Plasmid DNA Loading 
 Plasmid DNA loading was confirmed by agarose gel electrophoresis as shown in 
figure 4.34. Microbubbles made with 1% PEI that were incubated with 25 µg DNA/mg UCA 
were able to adsorb nearly all of the DNA from solution leaving only a faint band in lane 2 in 
figure 4.34b indicating only a small amount of free DNA remained in solution, in agreement with 
the maximum DNA payload of 24.8 ± 0.1 µg DNA/mg measured with sDNA. A DNA payload of 
24.8 µg DNA/mg UCA corresponds to 0.053 pg DNA/µm
2
. The loading capacity of most lipid 
UCA have been reported to be from 0.001 to 0.02pg DNA/µm
2 
[248, 279, 284]. The loading 
capacity of these microbubbles can be limited by the amount of positively charged lipids that can 
be included in the lipid shell. Borden et al. found that increasing the percentage of positively 
charged lipid from 0 to 20% caused a significant reduction in bubble production yield [279] 
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which limited the maximum cationic lipid concentration to 40% of the lipid used for the UCA 
shell. The cationic lipids used in most positively charged UCA only have one tertiary amine per 
lipid which may also limit the total binding capacity of each microbubble. For each positively 
charged lipid (dioleoyl -3-trimethyl ammonium propane) there is only one positive charge per 
approximately 697 Daltons compared to one positive charge for every 43 Daltons found in PEI. 
Branched PEI also has a mixture of primary, secondary and tertiary amines which may also help 
improve DNA binding. The benefits of PEI are limited by its low biodegradability and high 
cytotoxicity [285] but this toxicity can be reduced by conjugating chains of PEG to PEI [286]. 
 
 
 
Figure 4.34: Plasmid DNA before (A) and after (B) incubating 2 mg of 1% PEI UCA with 100 (1), 50 (2), 
25 (3), 12.5 (4), 6.25 (5), 3.13 (6) and 1.56 µg plasmid DNA (7).  
 
 
 
4.3.2.6 Effect of Surface Adsorption on Microbubbles 
 The effect of loading sDNA by surface adsorption on microbubble size and zeta potential 
is shown in figure 4.35. Loading 1% PEI UCA with sDNA resulted in microbubbles that were 
larger than unloaded UCA (made with 1% PEI) and significantly (p<0.05) larger than control 
UCA made without PEI (3.6 ± 0.30 µm , 2.8 ± 0.2 µm and 1.9± 0.33 µm). This increase in size 
may have been caused by the formation of PEI/DNA complexes around the surface of the surface 
of the microbubble.  
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 Loading DNA onto the surface of UCA also caused a reversal of zeta potential as shown 
in figure 4.35b. The addition of 1% PEI to the surface of UCA created positively charged 
microbubbles with a zeta potential of 27.6 ± 2.6 mV. Incubating these UCA with DNA was able 
to reverse the zeta potential to -18.0 ±1.4 mV, supporting the hypothesis that negatively charged 
DNA is attaching to the surface of these microbubbles.  
 
 
 
Figure 4.35: Effect of DNA loading by surface adsorption on the size (a) and zeta potential (b) of UCA 
made with 1% PEI (n=3). 
 
 
 
 Loading DNA onto the surface of 1% PEI UCA did not have a significant effect on the 
acoustic enhancement of the lowest dose of 1.5 µg UCA/ml (20.8 ± 0.7 dB vs 21.8 ± 0.9 dB, 
p>0.1) (figure 4.36a). However, at the highest dose of 15 µg UCA/ml, DNA loaded UCA 
provided significantly greater acoustic enhancement than unloaded UCA (24.7 ± 1.3 dB vs. 22.2 
± 1.1 dB, p<0.05) compared to a peak enhancement of 22.3 ± 0.3 dB for UCA made with 0% 
PEI. This change in acoustic enhancement was not expected because the total mass of DNA 
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loaded onto the microbubbles was approximately 2% of its total mass. The DNA loaded UCA 
were also slightly but not significantly more stable than unloaded UCA as show in figure 4.36b. 
 
 
 
 
Figure 4.36: Effect of DNA loading by adsorption on the acoustic enhancement (a) and stability (b) of 
polymer microbubbles made with 1% PEI (n=3). 
 
 
 
4.3.2.7 Effect of DNA Loading on Plasmid Integrity 
 Plasmid DNA can exist in multiple conformations including supercoiled, open circular 
and linear plasmid DNA. The topology of plasmid DNA has been shown to affect transfection 
efficiency with supercoiled DNA being the most efficient, followed by open circular and linear 
plasmid DNA [287-289]. The conformation of plasmid DNA can determine the molecules 
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electrophoretic mobility allowing supercoiled DNA to travel through a gel the fastest, followed 
by linear then open circular (nicked) DNA as shown in figure 4.37. 
 
 
Figure 4.37: Effects of plasmid DNA integrity on agarose gel electrophoresis migration. 
 
 
 
 Agarose gel electrophoresis was used to determine the effect of DNA loading on the 
integrity of plasmid DNA. Plasmid DNA was incubated with UCA made with 1% PEI and 
control UCA with no PEI. The effect of microbubble cavitation on loaded plasmid DNA and free 
plasmid DNA was also examined. In figure 4.38 the gel shows no significant difference in the 
amount of supercoiled, linear, or nicked DNA between control plasmid DNA (A) and plasmid 
incubated with control microbubbles (C) or plasmid incubated with UCA that were then exposed 
to ultrasound (D) meaning that the process of incubating DNA with UCA and even microbubble 
cavitation in the presence of DNA did not affect DNA integrity. When plasmid DNA was 
incubated with 1% PEI UCA (B) most of the DNA remained attached to the UCA making it 
difficult to examine the integrity of the loaded plasmid. A small band can also be observed at the 
top of the gel close to the well in lane B which may represent plasmid DNA complexed with PEI 
that had detached from the PEI-UCA. 
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Figure 4.38: Effect of loading and ultrasound on integrity of plasmid DNA. Control plasmid DNA (A) was 
compared with the supernatant after DNA was incubated with 1% PEI UCA (B) or with control UCA 
without PEI (C). Plasmid DNA incubated with control UCA that were then insonated were also examined 
(D).  
 
 
 
 To examine the integrity of DNA loaded onto PEI-UCA, the DNA was first released by 
incubating the loaded UCA with a 5 M NaCl solution to increase the ionic strength and weaken 
the ionic bonds between the plasmid and PEI. The voltage used to run the gel was also increased 
to allow the DNA to migrate away from the PEI before the salt diffused away (however, it is 
possible that not all of the PEI was removed from the DNA resulting in the smeared bands 
observed in lanes B and C). Control plasmid DNA incubated with 5 M NaCl shown in figure 4.39 
in lane (A) did not form clear bands due to the increased ionic strength, however the ratio of 
supercoiled to linear and nicked DNA remained the same as control plasmid without salt. DNA 
released from 1% PEI-UCA in lane (B) had a significantly lower percentage of supercoiled DNA 
compared to unloaded UCA, with a corresponding increase in nicked or open circular DNA and 
no change in linear plasmid DNA this drop in supercoiled DNA may reduce the transfection 
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efficiency of the loaded DNA [287-289]. When loaded UCA were exposed to ultrasound (C) 
there was also no effect of microbubble cavitation on the integrity of loaded DNA, but it is 
possible that the degree of cavitation was reduced by the addition of DNA to the microbubble. In 
both loaded samples (B) and (C) a large percentage of the loaded DNA remained at the top of the 
gel near the well indicating that PEI/DNA complexes were released from the surface of the UCA 
when exposed to high salt concentrations, however the ionic bonds between PEI and DNA may 
be more difficult to disrupt. An Alpha Innotech FluorChem SP MultiImage Light Cabinet (Santa 
Clara, CA) with UV illumination was used to image gels (Dr. Clyne‟s lab, Department of 
Mechanical Engineering at Drexel).  The band density (quantified with Image J) of each plasmid 
DNA isoform was quantified as a percentage of total DNA in each lane and is shown in 
figure 4.40.  
 
 
 
Figure 4.39: Effect of loading and ultrasound on integrity of plasmid DNA. Control plasmid DNA  
incubated with 5M NaCl (A) was compared DNA released from 1% PEI UCA (B) or with DNA exposed to 
ultrasound while loaded onto PEI UCA then released with 5 M NaCl. The high NaCl concentration used to 
load these samples resulted in the „U‟ shaped bands (“smiling”). 
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Figure 4.40: Effect of loading and ultrasound on integrity of plasmid DNA (n=3). Lower levels of 
supercoiled DNA may have lower transfection efficiencies [287-289].   
 
 
 
 The effect of cell culture media and fetal bovine serum on DNA loaded 1% PEI-UCA 
was also examined and is shown in figure 4.41. When DNA loaded UCA were incubated in water 
for 15 minutes, very little DNA was released from the surface. However, when DNA loaded UCA 
were incubated in cell culture media approximately 50% of the loaded DNA was released into 
solution. This could be caused by the ionic strength of the media allowing the DNA that was most 
loosely bound to release. The addition of 10% serum to the culture media caused a total of 60% 
of the loaded DNA to release within 15 minutes. This additional release of DNA may have been 
caused by the negatively charged proteins in serum, especially albumin, which will compete with 
DNA for binding sites, eventually displacing bound DNA. Lane (G) in figure 4.41 shows that 
more DNA released from UCA incubated with media containing 10%  serum stays high in the gel 
close to the loading well. This suggests that more PEI was released from the microbubble surface, 
along with the plasmid. The released PEI can reattach to the plasmid as the salts and albumin 
diffuse away, this can reduce the charge and increase the molecular weight of the DNA, 
preventing it from migrating down the gel.  
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Figure 4.41: Agarose gel electrophoresis examining the effect of growth media and serum on plasmid 
DNA loaded 1% PEI UCA. The gel was loaded with a 1kb ladder (A), control plasmid DNA (B), the 
supernatant after incubating plasmid with PEI UCA (C), the supernatant after incubating DNA loaded UCA 
with water (D) RPMI (E) RPMI + 1% FBS (F) RPMI + 10% FBS. Lanes (H), (I) and (J) contain RPMI 
with 0%, 1% and 10% FBS.  
 
 
 
4.3.3 DNA Loaded UCA Conclusions 
 Loading naked plasmid DNA into unmodified polymer UCA by incorporation or surface 
adsorption was inefficient, with loading efficiencies less than 10%. To improve loading, DNA 
was complexed with the polycation PEI to increase incorporation loading efficiencies up to 60% 
and surface adsorption efficiencies up to 90%. Addition of PEI to the second emulsion of the 
microbubble fabrication process was an effective method of reversing the surface charge of 
microbubbles and increasing plasmid DNA loading but also resulted in significantly larger 
microbubbles. DNA loading onto PEI coated microbubbles also caused a significant drop in the 
percentage of supercoiled plasmid DNA which may reduce the transfection efficiency. Incubating 
plasmid loaded UCA in medium containing serum resulted in the rapid release of up to 60% of 
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the loaded DNA within 15 minutes suggesting that DNA will be rapidly released from these 
microbubbles in vivo.  
 
4.4 Ultrasound Triggered Gene Delivery In Vitro 
The ability of microbubbles triggered with ultrasound to enhance cell uptake of 
macromolecules can be utilized to deliver plasmid DNA to the cytoplasm of cells as a form of 
non viral gene delivery. While the mechanism involved in this process is still under debate, it is 
important to understand how the acoustic parameters used with polymer microbubbles will 
control their ability to transfect cells. To determine the effects of the acoustic exposure on 
transfection efficiency, polymer UCA along with free plasmid DNA were exposed to various 
ultrasound conditions in vitro with MCF 7 cells.  
 
4.4.1 Pressure Amplitude 
The effect of acoustic pressure amplitude on transfection efficiency and cell viability was 
examined first to determine if a pressure threshold exists for these PLA UCA and how it 
compared with other polymer and lipid UCA [126, 167]. Cells were insonated with three different 
center frequencies (1, 2.25 and 5 MHz) using a constant PL of 20 µs, constant PRF of 3000 Hz 
and a constant exposure time of 15 seconds. PLA UCA with a diameter of (1.6 ± 0.2 µm) were 
used at a concentration of 0.25 mg/ml and free plasmid DNA encoding EGFP was used at a 
concentration of 10 µg/ml. Exposing UCA to an acoustic pressure amplitude of 100 kPa provided 
no significant increase in transfection compared to uninsonated cells with any of the frequencies 
tested (p<0.05) from 0.09 ± 0.02% with no ultrasound to 0.15 ± 0.06%, 0.17 ± 0.4% and 0.14 ± 
0.04% at 100 kPa using center frequencies of 1, 2.25 and 5 MHz. This indicates that there is a 
pressure threshold greater than 100 kPa required for transfection with these PLA UCA. Increasing 
the pressure amplitude from 100 to 250 kPa resulted in a significant increase in transfection for 
cells insonated with 1 MHz (10.2 ± 0.8%, p<0.05) and 2.25 MHz (10.7 ± 1.1%, p<0.05), but not 
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5 MHz (0.3 ± 0.1%, p>0.05) as shown in figure 4.42a. Increasing the pressure amplitude to 
500 kPa resulted in a significant increase in transfection efficiency for 1 MHz (15.3 ±1.5, p<0.05) 
and 5 MHz (8.3 ± 1.0%, p<0.05) compared to 250 kPa but no significant increase in transfection 
was achieved by further increasing the pressure amplitude to 1000 kPa (17.3 ± 1.2%, 11.8 ± 1.0% 
and 10.1 ± 0.6% for 1, 2.25 and 5 MHz, p>0.05). The maximum transfection efficiency achieved 
with these conditions was 17.3 ± 1.2% with 1 MHz and 1 MPa. A similar trend was observed 
with the total EGFP-derived fluorescence intensity of these cells as shown in figure 4.42b, with 
the highest fluorescence intensity occurring at 1 MPa for all three frequencies (4.3  10
6
 ± 0.4  
10
6
 RFU, 3.3  10
6
 ± 0.1  10
6 
RFU and 2.8  10
6
 ± 0.2  10
6
 RFU for 1, 2.25 and 5 MHz). This 
suggests that microbubbles triggered with lower frequencies of ultrasound were more effective at 
creating pores in cells compared to the higher 2.25 and 5 MHz frequencies. 
In previous studies the resonance frequency of these PLA UCA has been measured to be 
in the range of 2.28 – 3.2 MHz. However, here the transfection efficiency was significantly 
greater when using 1 MHz compared to 2.25 or 5 MHz for pressure amplitudes of 500 kPa or 
greater. The threshold for transfection at 1 and 2.25 MHz (100-250 kPa) was also lower than the 
threshold for 5 MHz (250-500 kPa). This agrees with other studies using lipid and albumin UCA 
that have observed improved sonoporation and lower pressure thresholds with lower frequencies 
[258, 290-291]. The acoustic pressure amplitudes necessary for ultrasound triggered gene 
delivery with lipid microbubbles can range from 130 to 500 kPa [126, 231, 292], similar pressure 
thresholds from 120 to 400 kPa were observed for albumin microbubbles [293-295]. One study 
found the pressure amplitude threshold of polymer UCA, consisting of air filled polystyrene 
microbubbles, to be between 400 and 600 kPa [126] which is nearly double the pressure 
amplitude needed for the PLA UCA examined in this study. While for lipid and free 
microbubbles it is believed that lower frequencies give the microbubble more time to grow 
through rectified diffusion resulting in larger cavitation bubbles and more cavitation energy. It is 
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possible that this is also true for polymer microbubbles, or that this only occurs after the gas is 
allowed to escape from the polymer shell. An alternative explanation could be that the larger 
microbubbles in the polymer microbubble distribution have the lowest resonance frequency and 
that these larger microbubbles can cavitate more effectively than the smaller polymer UCA. 
The effect of pressure amplitude on cell viability was also examined and is shown in 
figure 4.42c. Increasing the pressure amplitude to the threshold for transfection (250 kPa for 1 
and 2.25 MHz and 500 kPa for 5 MHz) also resulted in a significant drop in cell viability (63.3 ± 
3.3 %, 77.7 ± 2.8% and 90.3 ± 2.4% for 1, 2,25 and 5 MHz p<0.05) with significantly more cell 
death in samples treated with 1 MHz compared to 2.25 or 5. Similar trends have also been 
observed in other studies with lipid and albumin UCA [258, 296], as increasing sonoporation also 
results in a greater proportion of cells that are unable to repair their damaged cell membranes, 
resulting in a drop in viability. 
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Figure 4.42: The effect of pressure amplitude and center frequency on (a) transfection efficiency, (b) total 
fluorescence intensity and (c) cell viability. MCF 7 cells were insonated for 15 seconds with 0.25 mg/ml 
PLA UCA and 10 µg/ml of free plasmid DNA with a PL of 20 µs and PRF of 3000 Hz (n=5). 
 
 
 
4.4.2 Duty Cycle 
 The duty cycle of an ultrasound wave describes the percentage of time a pulse is being 
transmitted which is a function of both the PRF and PL. The DC is directly related to the ISPTA 
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and was expected to have an effect on transfection efficiency with greater transfection occurring 
with higher duty cycles. The effects of pulse length and pulse repetition frequency were examined 
with a constant center frequency of 1 MHz, pressure amplitude of 500 kPa, microbubble 
concentration of 0.25 mg/ml and exposure time of 15 seconds. Increasing the PRF while 
maintaining a constant PL of 20 µs resulted in a significant increase in transfection efficiency and 
total fluorescence intensity for samples insonated with a PRF of 9 kHz (DC=0.18, ISPTA = 1.5 
W/cm
2
) compared to 1 kHz (DC=0.02, ISPTA = 0.167 W/cm
2
) with a transfection efficiency of 
21.5 ± 1.0% compared to 6.8 ± 3.7 % (p<0.05) as shown in figure 4.43a and a fluorescence 
intensity of 5.8 × 10
6
 ± 0.3 × 10
6
 RFU compared to 2.3 × 10
6
 ± 1.1 ×10
6
 RFU as shown in figure 
4.43b. The cell viability also dropped from 80.7 ± 6.8 % to 59.6 ± 2.2 % with the same change in 
PRF as shown in figure 4.43c. A similar trend was observed as the PL was increased while 
maintaining a constant PRF of 3 kHz. Increasing the pulse length from 7 µs (DC=0.02, ISPTA = 
0.167 W/cm
2
) to 20 µs (DC=0.06, ISPTA = 0.5 W/cm
2
) and from 20 µs to 60 µs (DC=0.18, ISPTA = 
1.5 W/cm
2
) both resulted in a significant increase in transfection efficiency (3.6 ± 0.4%, 14.1 ± 
1.4 % and 24.8 ± 0.9% for 7, 20 and 60 µs) and total fluorescence intensity (1.4  10
6
 ±  0.1  10
6
 
RFU, 3.6  10
6
 ±  0.4× 106 RFU and 6.2  106 ±  0.3  106 RFU, for 7, 20 and 60 µs, p<0.05) 
and a drop in cell viability (84.5 ± 2.8 %, 68.7 ± 4.8 % and 59.9 ± 2.8 % 7, 20 and 60 µs) as 
shown in figure 4.43d, 4.43e and 4.43f. There was no significant difference in transfection 
efficiency or total fluorescence intensity when comparing samples insonated with the same DC 
and ISPTA within this small range. Insonating with a PRF of 9 kHz and PL of 20 µs was not 
significantly different from insonating with a PRF of 3 kHz and a PL of 60 µs (p>0.05). Other 
studies have also seen increased sonoporation with increasing duty cycles in vitro with lipid and 
albumin UCA triggered with duty cycles up to 0.15 [258, 297]. Some studies with lipid UCA 
only observed a dependence on PRF and not pulse lengths in a range from 10 – 40 µs [231] and 
other studies with lipid or Optison UCA observed no significant dependence on pulse lengths 
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from 20 µs to 60 ms [235, 246, 296]. One possible explanation for this may be that at higher 
pressures these soft shelled UCA are not stable and are destroyed within 100 µs [298]. Other 
studies using albumin UCA observed an increase in hemolysis with increasing pulse lengths up to 
200 µs and increasing PRFs up to 200 Hz. In both cases the higher DC was shown to generate a 
greater inertial cavitation dose as well as a cascade effect where a higher percentage of bubbles 
survived the time between pulses [299]. With polymer UCA it may be possible that free air 
bubbles are released from the polymer shell and by extending the pulse length or increasing the 
duty cycle it is possible to force these free air bubbles to cavitate before they dissolve into the 
solution. 
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Figure 4.43: The effect of pulse repetition frequency on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) viability of cells insonated with a constant pulse length of 20 µs and the effect of pulse 
length on (d) transfection efficiency, (e) total fluorescence intensity and (f) viability of cells insonated with 
a constant pulse repetition frequency of 3000 Hz. All cells were insonated for 15 seconds at 1 MHz with a 
pressure amplitude of 500 kPa and a PLA microbubble concentration of 0.25 mg/ml (n=4).   
 
 
 
4.4.3 Pulse Repetition Frequency and Pulse Length 
 Pulse lengths and pulse repetition frequencies were also varied simultaneously to 
maintain a constant DC of 0.06, a constant ISPPA of 33.3 W/cm
2
 and a constant ISPTA of 2.0 W/cm
2
 
in order to determine the importance of pulse length over a wider range from 3 µs to 12 ms. 
Increasing the PL from 20 µs to 12 ms while reducing the PRF from 3000 Hz to 5 Hz resulted in 
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a significant (p<0.01) increase in transfection and total fluorescence intensity for all three center 
frequencies tested as shown in figure 4.44a and 4.44b, with transfection efficiencies increasing 
from 17.3 ± 1.2%, 11.8 ± 1.0% and 10.1 ± 0.6% to 24.2 ± 2.0%, 24.8 ± 1.1% and 16.6 ± 0.8% for 
1, 2.25 and 5 MHz respectively. This increase in pulse length also caused a significant decrease 
(p<0.01) in cell viability as shown in figure 4.44c with cell viability dropping from 58.9 ± 1.9%, 
79.7 ± 2.4 % and 90.9 ± 1.6% to 43.5 ± 2.9%, 48.3 ± 3.0% and 80.2 ± 2.5% as the PRF and PL 
changed from 3000 Hz and 20 µs to 5 Hz and 12 ms for center frequencies of 1, 2.25 and 5 MHz 
respectively. It is also important to note that this increase in transfection efficiency is completely 
dependent on the presence of the microbubbles, when cells were insonated for 15 seconds with a 
pressure of 1 MPa, a PRF of 5 Hz, PL of 12 ms but with no UCA the transfection efficiency 
dropped to 0.01 ± 0.01%, 0.02 ± 0.01% and 0.04 ± 0.01% for center frequencies of 1, 2.25 and 
5 MHz. While many studies focus on pressure amplitude, mechanical index, acoustic energy 
density, ISPPA or ISPTA [132, 258, 295, 300] as the key parameters effecting gene deliver efficiency, 
the results in this experiment show that while these parameters were all held constant and the PL 
and PRF are simultaneously varied, to maintain the constant DC, the transfection efficiency could 
change by over 100%. While increasing the DC by increasing either the PRF or PL it was shown 
that both were equally able to improve the transfection efficiency when compared over a small 
range (figure 4.43). As this range of pulse lengths was increased, the importance of longer PL 
becomes more evident as shown in figure 4.44 and figure 4.45. The importance of PL may be an  
influential parameter to use with these PLA UCA, a parameter that may allow greater control 
over the degree of sonoporation in vivo. By increasing PL, it is possible to improve sonoporation, 
or the PL can be lowered to reduce cell death in more sensitive organs.  
 
138 
 
 
Figure 4.44: The effect of pulse repetition frequency and pulse length on (a) transfection efficiency, (b) 
total fluorescence intensity and (c) cell viability. Cells were insonated for 15 seconds with 0.25 mg/ml PLA 
UCA and 10 µg/ml free plasmid DNA with a pressure amplitude of 1 MPa and a constant duty cycle of 
0.06 (n=5). 
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Figure 4.45:Fluorescent images of MCF 7 breast cancer cells expressing GFP 24 hours after exposure to 
ultrasound with a constant acoustic pressure amplitude of 1 MPa while the PRF and PL were 
simultaneously adjusted to maintain a constant DC of 0.06 and an ISPTA of 2.0 W/cm
2
 (size bar = 100 µm). 
Pulse length (µs) along y axis and center frequency along x axis. 
 
 
 
4.4.4 Pressure and Pulse Length 
 To determine if longer pulse lengths could reduce the pressure threshold required for 
transfection, the effect of pressure and pulse length were examined together while maintaining a 
constant ISPTA of 2.0 W/cm
2
 as shown in figure 4.46, or 0.33 W/cm
2
 and shown in figure 4.47. 
Doubling the pressure amplitude from 1MPa to 2 MPa while decreasing the PL and DC by 75% 
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from 20 µs to 5 µs resulted in a significant drop in transfection and fluorescence intensity as 
shown in figure 4.46a and 4.46b (p<0.01) Transfection efficiency dropped from 17.3 ± 1.2%, 
11.8 ± 1.0 and 10.1 ± 0.6% to 3.0 ± 0.3%, 2.7 ± 0.6% and 1.6 ± 0.2% for 1, 2.25 and 5 MHz 
respectively and the cell viability increased from 58.9 ± 1.9 %, 79.7 ± 2.4 % and 90.9 ± 1.6 % to 
91.5 ± 1.8 %, 97.4 ± 1.2 % and 96.8 ± 1.7 % as shown in figure 4.46c. Decreasing the pressure 
amplitude by 50% from 1 MPa to 500 kPa and increasing the PL by 400% from 20 µs to 80 µs 
resulted in an increase in transfection efficiency to 20.7 ± 1.1%, 19.9 ± 0.4% and 16.5 ± 0.3% for 
1, 2.25 and 5 MHz respectively and was statistically significant for 2.25 and 5 MHz (p<0.01). 
However, at a lower ISPTA of 0.33 W/cm
2
 and pressure amplitudes of 400 kPa and less, the 
opposite trend was observed. Increasing the PL from 62.5 ms to 1000 ms (continuous wave) 
while decreasing the pressure amplitude from 400 kPa to 100 kPa resulted in a significant drop in 
transfection efficiency (p<0.01) from 19.6 ± 1.3%, 18.5 ± 1.1% and 15.0 ± 0.4% to 4.3 ± 0.4%, 
2.6 ± 0.5% and 0.4 ± 0.1% for 1, 2.25 and 5 MHz respectively (figure 4.47a) and a drop in 
fluorescence intensity from 4.5 × 10
6
 ± 0.7 × 10
6
 RFU, 3.8 × 10
6
 ± 0.2 × 10
6
 RFU and 3.8 × 10
6
 ± 
0.3 × 10
6
 RFU to 1.7 × 10
6
 ± 0.2 × 10
6
 RFU, 1.4 × 10
6
 ± 0.2 × 10
6
 RFU and 0.6 × 10
6
 ± 0.01 × 
10
6
 RFU (figure 4.47 b). While the results from figures 4.44 and 4.46 support the hypothesis that 
PL is the most important parameter for triggering PLA UCA to cause transfection, figures 4.42 
and 4.47 both show the importance of using a pressure amplitude of 200 kPa or greater to trigger 
these PLA UCA. 
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Figure 4.46: Effect of PL and pressure amplitude on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) viability of cells insonated with a constant PRF of 3000 Hz and a pressure and PL that 
were simultaneously changed to maintain a constant ISPTA of 2.0 W/cm
2
 (n=5).  A constant UCA 
concentration of 0.25 mg/ml and free plasmid DNA concentration of 10 µg/ml were used.   
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Figure 4.47: Effect of PL and pressure amplitude on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) viability of cells insonated for 15 seconds with a constant PRF of 1 Hz and a pressure and 
PL that were simultaneously changed to maintain a constant ISPTA of 0.33 W/cm
2
 (n=5). A constant UCA 
concentration of 0.25 mg/ml and free plasmid DNA concentration of 10 µg/ml were used.   
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4.4.5 Microbubble Concentration 
 The effect of microbubble concentration on transfection and cell viability were also 
examined with ultrasound at all three center frequencies (1, 2.25 and 5 MHz) and a constant 
pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz and are shown in figure 4.48. 
Insonation with all three frequencies resulted in less than 0.04% transfection when no PLA 
microbubbles were added to the cells. Addition of microbubbles at a concentration of 0.025 
mg/ml resulted in a significant increase in transfection at all three frequencies (20.8 ± 1.0%, 17.3 
± 1.7% and 4.3 ± 0.7% for 1, 1.25 and 5 MHz) with significantly greater transfection at 1 and 
2.25 MHz compared to 5 MHz (p<0.05)as shown in figure 4.48a. Increasing the microbubble 
concentration ten-fold from 0.025 mg/ml to 0.25 mg/ml (24.2 ± 2.0%, 24.8 ± 1.1% and 16.6 ± 
0.8%) resulted in no significant change in transfection of cells insonated at 1 MHz, however, 
there was a significant increase in transfection for cells insonated with 2.25 MHz and an even 
greater dose related increase in transfection for cells insonated with 5 MHz (p<0.05). As the 
concentration of UCA is increased to 1 mg/ml, the transfection efficiency continued to increase 
for cells insonated with 5 MHz (20.0 ± 0.4%, p<0.05), however there was a drop in transfection 
efficiency for cells insonated at 1MHz (16.1 ± 1.4%) and 2.25 MHz (21.5 ± 2.0%). A 
microbubble concentration of 1 mg/ml also caused a significant drop in the total fluorescence 
intensity with all three frequencies, from 7.5 × 10
6
  ± 1.3 × 10
6
 RFU, 8.2 × 10
6
 ± 0.5 × 10
6
 RFU 
and 5.2 × 10
6
 ± 0.2 × 10
6
 RFU at a concentration of 0.25 mg/ml to 2.6 × 10
6
 ± 0.2 × 10
6
 RFU, 3.6 
× 10
6
 ± 0.3 × 10
6
 RFU and 3.6 × 10
6
 ± 0.2 × 10
6
 RFU at a concentration of 1 mg/ml for 1, 2.25 
and 5 MHz respectively as shown in figure 4.48b, this drop in fluorescence may have been caused 
by the lower viability of cells treated with higher concentrations of microbubbles. The 
relationships between UCA concentration, center frequency and extent of transfection suggest 
that within the contrast agent, a smaller percentage of the population responds to higher 
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frequencies (5 MHz compared to 1 MHz) requiring more agent to be added to the sample to 
produce the same level of transfection. In the case of 1 and 2.5 MHz insonation, it is probable that 
at higher concentrations the microbubbles begin to shadow each other leading to a drop in 
transfection which has also been observed in other systems [242]. These results do show that 
ultrasound triggered transfection is dependent on the presence of PLA microbubbles in this 
system, and that the transfection efficiency is affected by microbubble concentration. However, 
this system is static, with cells growing in a 200 µm thick chamber and may not accurately 
represent all physiological conditions, making it difficult to determine what concentrations would 
be required for in vivo applications. 
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Figure 4.48:The effect of PLA microbubble concentration on (a) transfection efficiency, (b) total 
fluorescence intensity and (c) viability of cells insonated for 15 seconds with a constant pressure amplitude 
of 1 MPa, PL of 12 ms and PRF of 5 Hz with 10 µg/ml free plasmid DNA (n=5). 
 
 
 
4.4.6 Exposure Time 
 To determine if longer exposure times could enhance transfection the effect of insonation 
time was examined and is shown if figure 4.49. Cells were insonated with 0.05 mg/ml UCA and a 
center frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz. With 
only 2 seconds of ultrasound exposure there was a significant increase in transfection efficiency 
and total fluorescence intensity along with a significant drop in cell viability (p<0.001). 
Increasing the insonation time from 2 to 30 seconds resulted in no significant change in either 
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transfection efficiency (20.9 ± 0.8% vs 22.3 ± 0.7%, p>0.05) (figure 4.49a) or fluorescence 
intensity (10.5  10
6
 ± 0.8  10
6
 RFU vs 10.3  10
6
 ± 0.5  10
6
 RFU, p>0.05) (figure 4.49b) but 
did result in a small but statistically significant drop in cell viability (p<0.05) from 75.2 ± 2.5% to 
68.0 ± 2.0% (figure 4.49c). The limited effect of increasing exposure time beyond two seconds 
suggests that the majority of the UCA within the ultrasound beam are destroyed within the first 
two seconds. This rapid sonoporation may be useful for in vivo applications where the 
microbubbles quickly pass through the ultrasound beam. While unruptured UCA may promote 
transfection upon recirculation if they are able to avoid uptake by the RES.  
 
 
 
Figure 4.49: The effect of insonation time on the (a) transfection efficiency, (b) total fluorescence intensity 
and (c) cell viability of cells insonated with 0.05 mg/ml UCA, 10 µg/ml free plasmid DNA and a center 
frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz (n=6). 
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 To test if ultrasound exposure at 1 MHz was destroying polymer UCA, the acoustic 
enhancement of polymer UCA exposed to ultrasound was measured. The acoustic enhancement 
of native UCA measured at  5 MHz in a 50 ml sample chamber was compared with UCA (0.25 
mg/ml)  that were suspended in PBS and loaded into an Opticell placed in a 37 °C water bath for 
2 minutes but not exposed to ultrasound (uninsonated) or UCA exposed to ultrasound with a 
center frequency of 1 MHz, pressure amplitude of 1 MPa, PRF of 5 Hz and PL of 12 ms for a 
total of 2 minutes spread across 8 regions of the Opticell for 15 seconds each (insonated) by 
moving the transducer to insonate different sections of the Opticell and gently mixing the 
contents of the Opticell. After insonation the UCA were removed from the Opticell and the 
acoustic enhancement was measured in the 50 ml chamber at 5 MHz. Ultrasound exposure 
resulted in a significant drop in acoustic enhancement compared to uninsonated samples (figure 
4.50), with the peak acoustic enhancement dropping from 15.9 ± 0.7 dB to 9.5 ± 0.7 dB (p<0.01). 
This 6 dB drop represents a 50% drop in backscatter suggesting a large percentage of the PLA 
UCA are destroyed when exposed to these acoustic parameters. While the transducer was moved 
across 8 sections of the Opticell, only a small volume was exposed to ultrasound in each section 
which may have limited the percentage of microbubbles that were exposed to ultrasound.  
 
 
 
 
Figure 4.50: Effect of ultrasound on acoustic enhancement of PLA UCA. Native UCA were compared 
with uninsonated UCA incubated in a water bath for 2 minutes but not exposed to ultrasound (uninsonated) 
or microbubbles exposed to ultrasound with a center frequency of 1 MHz, a pressure amplitude of 1 MPa, 
PL of 12 ms and PRF of 5 Hz for 2 minutes (insonated). 
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4.4.7 Radiation Force 
 The design of many in vitro sonoporation experiments utilizes a rotating tube system 
where UCA and cells are both in suspension as they are exposed to ultrasound. One disadvantage 
of the rotating tube system is that most target cells in vivo are not in suspension. Growing cells in 
an Opticell cassette allows the possibility of insonating cells from the apical or basolateral side, 
either using radiation forces to push the UCA towards the cells or away from the cells. By 
reversing the direction of ultrasound exposure to push the microbubbles away from the cells, the 
transfection efficiency dropped from 21.1 ± 1.9% to 0.6 ± 0.6% (figure 4.51a) and the 
fluorescence intensity dropped from 9.3 × 10
6
 ± 0.3 × 10
6
 RFU to 0.6 × 10
6
 ± 0.07 × 10
6
 RFU 
(figure 4.51b) and was not significantly different from cells that were not exposed to ultrasound. 
Other in vitro experiments by Rahim et al. showed that lipid UCA insonated in an orientation to 
push the UCA away from the cells resulted in a significantly greater transfection rate of 
approximately 3% compared to uninsonated cells (approximately 0%) [231]. While it is not 
unexpected that radiation forces will increase the distance between cells and UCA resulting in 
reduced sonoporation, the absence of any transfection with PLA UCA may suggest these UCA 
require more time to generate enough force to transfect cells. This agrees with previous 
experiments in this study that have shown a strong dependence on longer pulse lengths with these 
UCA. It is possible that within the time required for these UCA to have an effect, the radiation 
forces push the UCA too far away. This may be relevant in large vessels or chambers larger than 
200 µm in diameter such as salivary glands or large arteries. In situations such as these it may be 
useful to rotate the orientation of ultrasound exposure to expose all surfaces of the target.  
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Figure 4.51: The effect of radiation forces on (a) transfection efficiency, (b) total fluorescence intensity 
and (c) cell viability of cells insonated for 15 seconds with a center frequency of 1 MHz, a pressure 
amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml along with 10 µg/ml 
free plasmid DNA. The direction of ultrasound exposure was changed from pushing UCA towards cells to 
away from cells (n=6). 
 
 
 
4.4.8 Calcium and Magnesium Ion Concentrations 
 Through previous experiments testing sonoporation of multiple cell lines it was observed 
that cells insonated in RPMI 1640 had consistently greater uptake of fluorescently labeled 
markers than cells insonated in DMEM. To test if the growth medium used during insonation had 
an effect on transfection efficiency cells that were grown in RPMI 1640 were insonated in either 
RPMI 1640 with 10% FBS or DMEM with 10% FBS. Both groups were insonated for 15 seconds 
with a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz, UCA 
concentration of 0.05 mg/ml and plasmid DNA concentration of 10 µg/ml. Four hours after being 
treated with ultrasound, the media in both groups was replaced with RPMI 1640 with 10% FBS 
and 1% antibiotic. Cells insonated in RPMI had significantly higher transfection and fluorescence 
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intensity compared to cells insonated in DMEM (p<0.001), with nearly 50% fewer transfected 
cells when DMEM was used (21.2 ± 0.8% vs. 10.4 ± 0.6%, figure 4.52a) and significantly lower 
fluorescence intensity (9.3 × 10
6
 ± 0.3 × 10
6
 RFU vs. 4.7 × 10
6
 ± 0.2 × 10
6
 RFU, p<0.05, figure 
4.52b) but no significant difference in cell viability (68.1 ± 0.8% vs. 70.5 ± 2.2%, p>0.3, figure 
4.52c). It is possible that this drop in transfection efficiency was caused by the sudden change in 
growth media from RPMI to DMEM then back to RPMI stressing the cells and disrupting 
growth, however this practice is common in other transfection methods including lipofection that 
requires the growth medium to be replaced with serum free OptiMEM. It is also possible that the 
change in transfection efficiency is the result of the different composition of nutrients and salts in 
each medium. 
 
 
 
 
Figure 4.52: The effect of cell culture medium on transfection efficiency (a) fluorescence intensity (b) and 
cell viability (c) of cells insonated for 15 seconds with a center frequency of 1 MHz, a pressure amplitude 
of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml along with 10 µg/ml free 
plasmid DNA. Cells were insonated in either RPMI or DMEM, both containing 10% FBS (n=6). 
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 One of many differences in the formulations of these two media is the calcium ion 
concentration (0.42 vs 1.8 mM) for RPMI 1640 and DMEM respectively (with the addition of 
10% FBS containing approximately 2 mM Ca
2+
 the final calcium ion concentrations are 
approximately 0.58 and 1.82 mM). This difference in calcium ion concentration was of interest 
due to the possible role of calcium in sonoporation [145, 157]. To test the role of calcium ions in 
transfection, cells were transfected in DMEM with 0 – 2 mM EDTA added in order to chelate 
calcium ions. Adding 1.0 mM EDTA resulted in a significant increase in transfection (20.8 ± 
0.5% vs. 10.4 ± 0.6%, figure 4.53a) and fluorescence intensity (6.9 × 10
6
 ± 0.3 ×10
6
 RFU vs. 4.7 
× 10
6
 ± 0.2 × 10
6
 RFU, figure 4.53b) and a significant drop in cell viability (56.1 ± 2.8% vs. 70.5 
± 2.2%, p<0.05, figure 4.53c) compared to DMEM alone. There was no significant difference in 
transfection between 1.0 and 1.75 mM EDTA but the addition of 2 mM EDTA resulted in a 
significant drop in transfection (15.2 ± 1.5% vs. 20.8 ± 0.5%) and fluorescence intensity (2.6 × 
10
6
 ± 0.2 × 10
6
 RFU vs. 6.9 × 10
6
 ± 0.3 ×10
6
 RFU, p<0.5) compared to 1 mM EDTA. These 
results support the hypotheses that extracellular calcium ion concentration plays a role in 
transfection, however, EDTA also has a high affinity for the magnesium ions present in DMEM 
(0.81 mM), making it difficult to conclude the contribution of each ion. EGTA, a similar chelator 
which binds to calcium with a much higher affinity than magnesium would have been more 
effective. The addition of higher concentrations of the EDTA salt also appeared to cause a slight 
drop in the pH of the medium which may have also contributed to the observed effects. To focus 
on the effects of calcium, growth medium was replaced with PBS containing known amounts of 
calcium. 
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Figure 4.53: The effect of cell EDTA concentration on transfection efficiency (a) fluorescence intensity (b) 
and cell viability (c) of cells insonated for 15 seconds with a center frequency of 1 MHz, a pressure 
amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml. Cells were 
insonated in DMEM with 10% FBS and 0-2 mM EDTA (n=6). 
 
 
 
 To determine if the lower transfection observed in DMEM and the increased transfection 
observed with the addition of EDTA were caused by changes in calcium ion concentration, cells 
were insonated in PBS with controlled calcium ion concentrations. cells were insonated with 0.05 
mg/ml UCA for 15 seconds at a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 
12 ms and PRF of 5 Hz. Culture media was replaced by PBS containing 137 mM NaCl, 8.1 mM 
Na2HPO4, 1.47 mM KCl, 2.68 mM KH2PO4, 0.49 mM MgCl2 and CaCl2 at concentrations of 0, 
0.25, 0.5, 1.0, 1.5 or 2.0 mM. Increasing the calcium ion concentration from 0 mM to 0.25 mM 
resulted in a significant (p<0.001) increase in transfection efficiency (7.3 ± 0.8% vs. 22.7 ± 0.5%) 
(figure 4.54a), fluorescence intensity (1.4 × 10
6
 ± 0.1 × 10
6
 RFU vs. 7.7 × 10
6
 ± 0.5 × 10
6
 RFU) 
(figure 4.54b) as well as a significant increase in cell viability (36.0 ± 3.4% vs. 67.2 ± 1.7%) 
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(figure 4.54c). However, upon increasing the calcium ion concentration further no additional 
increase in transfection was achieved and between 1 and 1.5 mM there was a significant 
(p<0.001) drop in transfection (21.0 ± 0 .7%  vs. 14.0 ± 0.4%) which dropped to 11.9 ± 0.6 % at 
2 mM. Cell viability, on the other hand, remained constant at around 67%. Zhou et al. have 
shown that the time for complete membrane resealing of sonoporated Xenopus oocytes is 
dependent on Ca
2+
 concentration. Complete resealing took 58-170 seconds with 0.54 mM Ca
2+
 
but only 6-26 seconds at 1.8 mM Ca
2+ 
[157]. The increase in transfection observed in figure 4.54 
as the Ca
2+
 concentration decreased from 2.0 to 0.25 mM may have been caused by the cell 
membranes of damaged cells sealing less rapidly when exposed to lower calcium ion 
concentrations allowing more time for plasmid DNA to enter the cell. However, the drop in 
transfection efficiency and viability observed when the Ca
2+
 concentration was reduced to 0 mM 
confirms the observation that calcium is required for sonoporation that has been reported by 
others [153]. The calcium ion concentration in the blood is usually greater than 2.1 mM and is not 
easily changed which may limit the transfection efficiency in some in vivo applications. In other 
applications such as transfection of the salivary gland, where the microbubble and plasmid 
suspension can be delivered into the lumen in a controlled buffer, it may be useful to optimize the 
calcium ion concentration. 
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Figure 4.54: The effect of calcium ion concentration on (a) transfection efficiency, (b) total fluorescence 
intensity and (c) cell viability of cells insonated for 15 seconds with a center frequency of 1 MHz, a 
pressure amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml. 
Microbubbles and plasmid were suspended in PBS containing 0.49 mM magnesium chloride and 0-2 mM 
calcium chloride (n=6). 
 
 
 
 In addition to requiring calcium, Steinhardt et al. have shown that resealing of disrupted 
cell membranes can be antagonized by magnesium ions [301]. This would suggest that higher 
concentrations of Mg
2+
 could slow the process of membrane resealing and allow more plasmid to 
enter the cell. However, as shown in figure 4.55, when Mg
2+
 was added together with 1 mM 
CaCl2 under the same insonation conditions as above, no significant difference in transfection was 
observed for any of the Mg
2+
 concentrations tested (19.9 ± 1.1%, 21.0 ± 0.7% and 21.2 ± 0.8% 
for Mg
2+
 concentrations of 0, 0.5 and 1 mM, p>0.05) (figure 4.55a). There was also no significant 
change in fluorescence intensity (6.7 × 10
6
 ± 0.3 × 10
6
 RFU, 7.0 × 10
6
 ± 0.4 × 10
6
 RFU and 9.0 × 
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10
6
 ± 0.5 × 10
6
 RFU) (figure 4.55b) or cell viability (71.4 ± 1.4 %, 66.5 ± 2.3 % and 65.6 ± 2.7 % 
for 0, 0.5 and 1 mM, p>0.05) (figure 4.55c). 
 
 
 
 
Figure 4.55: The effect of magnesium ion concentration on (a) transfection efficiency, (b) total 
fluorescence intensity and (c) cell viability of cells insonated for 15 seconds with a center frequency of 
1 MHz, a pressure amplitude of 1 MPa, PL of 12 ms, PRF of 5 Hz and UCA concentration of 0.05 mg/ml. 
Microbubbles and plasmid were suspended in PBS containing 1.0 mM calcium chloride and 0-1 mM 
magnesium chloride (n=6). 
 
 
 
4.4.9 Multiple Staggered Exposures 
 As shown in figure 4.49, after 2 seconds of exposure no additional transfection was 
achieved. This could be due to a lack of sufficient intact microbubbles after ultrasound exposure 
preventing addition sonoporation, or due to heterogeneity in the cell population making some 
cells less susceptible to transfection than others. Cells grown in tissue culture are particularly 
vulnerable to stressful conditions, and efforts to perform repeated transfection within a short time 
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frame (minutes) resulted in unacceptable loss of cells due to detachment from the substrate. To 
test if insonating the same cells a second time with fresh UCA and plasmid after a period of 
recovery would result in greater transfection efficiency, and if that recovery period was 
significant, cells were insonated either a single time (1x) or twice, with the second insonation 
either 4 hours after the first insonation (0 h 4 h) or 12 hours after the first insonation (0 h 12 h). 
Insonating cells with two separate exposures 4 hours apart resulted in a significantly higher 
transfection percentage compared to a single exposure (21.24 ± 0.8% vs. 28.3 ± 1.0%, p<0.001, 
figure 4.56a) as well as a higher fluorescence intensity (9.3 × 10
6
 ± 0.3 × 10
6
 RFU vs. 13.0 × 10
6
 
± 0.8 × 10
6
 RFU, figure 4.56b). However, when the second ultrasound exposure was performed 
12 hours after the initial treatment there was a significantly greater transfection efficiency 
compared to treating after 4 hours (37.01 ± 0.9% vs. 28.3 ±1.0%, p<0.001) as well as a significant 
increase in fluorescence intensity (15.8 × 10
6
 ± 0.9 × 10
6
 RFU vs. 13.0 × 10
6
 ± 0.8 × 10
6
 RFU). A 
second ultrasound treatment also resulted in a significant drop in viability from 68.0 ± 0.8% to 
51.2 ±1.6% or 51.3 ± 1.0% (figure 4.56c) when the second treatment was 4 or 12 hours after the 
first, however there was no significant difference in viability when comparing cells that were 
transfected after 4 hours compared to 12 hours. The differences in transfection efficiency 
achieved with different timings of the second exposure observed in figures 4.56 and 4.57 may be 
partly a result of the cells being in different stages of the growth cycle. Karshafian et al. have 
shown that sonoporation of KHT-C cells in suspension was dependent on cell cycle with more 
cells being permeabilized in S (where DNA is synthesized) and G2 (where other organelles are 
synthesized as cells prepare for mitosis) phase compared to G1 (a resting phase)  [302]. The cell 
cycle may have an effect on the mechanical properties of cell membranes [302-303] making the 
membrane more susceptible to sonoporation during S phase. Other non viral gene delivery 
methods have also shown a dependence on cell cycle with more cells being transfected in late S 
or G2 phase, possibly due to the breakdown of the nuclear membrane during cell division [304]. 
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This may be useful for transfecting some in vivo targets. The cell cycles of the cells in many 
healthy tissues such as the salivary gland are controlled by a circadian rhythm with the peak of 
DNA synthesis occurring during the peak of activity [305] suggesting there may be an optimal 
time of day to transfect these cells. In comparison, the cell cycles of most cancer cells are 
asynchronous; it may be more effective to transfect cancerous cells multiple times over a period 
to ensure more cells are treated while they are in S phase or G2 phase. 
 
 
 
Figure 4.56: The effect of multiple exposures on (a) transfection efficiency, (b) total fluorescence intensity 
and (c) cell viability of cells insonated for 15 seconds with 0.05 mg/ml UCA at a center frequency of 1 
MHz, a pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz. Cells were treated either once (1x) or 
twice, with the second exposure 4 hours after the first (0 h 4 h) or 12 hours after the first (0 h 12 h) (n=5). 
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Figure 4.57: Merged image of phase contrast, EGFP (green) and propidium iodide (red) in cells treated 
with 0.05 mg/ml microbubbles, 10 µg/ml plasmid DNA in RPMI with 10% FBS. (A) no ultrasound, (B) 
(1x treatment) 15 seconds of ultrasound at 1 MHz, 1 MPa, with a PL of 12 ms and PRF of 5 Hz, (C), 2x 
treatment (0 h 4 h) with the same ultrasound exposure 4 hours after the first and (D) 2x treatment (0 h 12 h) 
with the same exposure 12 hours after the first (size bar = 50 µm). 
 
 
 
4.4.10 Cell Cycle Manipulation 
 The increase in transfection observed when ultrasound exposures were separated by 12 
hours suggested the possibility that the transfection efficiency was dependent on the cell cycle. It 
was hypothesized that microbubble induced sonoporation provides plasmid DNA with an 
opportunity to enter the cytoplasm but requires the nuclear envelope to unfold during mitosis 
before in order for DNA to enter for successful transfection. To test the effect of cell cycle on 
transfection, MCF 7 cells were synchronized at the G1/S boundary by a double hydroxyurea 
block. The distribution of cells in each phase of the cell cycle is shown in the histograms in 
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figure 4.58 for control cells that were not synchronized and synchronized cells 0, 4, 8, 12 and 16 
hours after the release from the final hydroxyl urea block. In untreated cells, the percentage of 
cells in G1, S and G2-M phase was 44, 28 and 28% respectively. Synchronization with a double 
hydroxyurea block resulted in a 40% increase in the percentage of cells in G1 phase (62%) and a 
drop in the percentage of cells in S phase (26%) and G2-M phase (12%). Four hours after release 
from the hydroxyurea block the distribution shifted to 46 – 31 – 24% (G1 – S – G2-M), 25 -31- 
44% after 8 hours, 36 – 25 -38% after 12 hours and 39 -28 -33% 16 hours after hydroxyurea was 
removed. The degree of synchronization achieved with these cells was much less than what was 
reported by Lin et al. (90 – 5 -5%) [259]. 
 To determine if stage in the cell cycle had an influence on the transfection efficiency in 
cells, synchronized cells were treated with ultrasound 0, 4, 8 or 12 hours after hydroxurea was 
removed. Cells were insonated for 15 seconds, with a center frequency of 1 MHz, pressure 
amplitude of 1 MPa, PRF of 5 Hz and PL of 12 ms in RPMI 1640 with 10% FBS, 10 µg/ml 
plasmid DNA and 0.05 mg/ml UCA. Cells treated immediately after synchronization (0 h) had 
significantly less transfection 18.7 ± 0.5 % than 4, 8 and 12 hours after (24.9  ± 2.2%, 29.4 ± 
0.9% and 26.6 ± 0.5%, p<0.01, figure 4.59a). Maximum transfection was achieved at 8 hours 
after synchronization, with 29.4 ± 0.9% of cells transfected. The lowest transfection (0 h) and the 
highest transfection (8 h) corresponded with the lowest (12 %) and highest (44%) percentage of 
cells in G2-M phase which supports the hypothesis that transfection is cell cycle dependent and 
more efficient when cells are insonated prior to cell division.  
 It was also observed that the total fluorescence intensity of synchronized cells (8.6 × 106 
± 0.8 × 106 after 8 hours, figure 4.59b) was lower than unsynchronized cells (9.3× 106 ± 0.3× 
10
6
, p>0.3), despite higher transfection levels in synchronized cells. It is possible that 
synchronized cells were not as healthy as untreated cells causing them to produce less GFP. There 
was no significant difference in the cell viability of synchronized cells treated with ultrasound at 
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0, 4, 8 or 12 hours (figure 4.59c). However, viability of synchronized cell insonated after 8 hours 
was significantly lower than the viability of unsynchronized cells insonated with the same 
conditions (56.5 ± 2.4% vs. 68.1 ± 0.8%, p<0.05). 
 
 
Figure 4.58: Distribution of DNA content per cell in untreated cells and cells synchronized with a double 
hydroxyurea block and assayed 0, 4, 8, 12 and 16 hours after hydroxyurea was removed.  
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Figure 4.59: The effect of cell cycle on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) of cells synchronized by a double hydroxyurea block then insonated for 15 seconds with 0.05 
mg/ml UCA and a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz. 
Cells were insonated at 0, 4, 8 or 12 hours after the end of the second hydroxyurea block (n=6).  
 
 
 
4.4.11 Poloxamer 
 Poloxamer 188 (P188) is a non ionic surfactant that has been listed as an inactive 
excipient, however, it has been shown to prevent the death of cells affected by electrical [306] 
thermal [307] or mechanical injury [308] by restoring cell membrane integrity. It has also been 
used to improve gene delivery of naked DNA [309]. The effect of P188 on the transfection 
efficiency and viability of cells treated with polymer UCA and ultrasound was tested by 
insonating cells in the presence of P188. Cells were insonated for 15 seconds with a center 
frequency of 1 MHz, pressure amplitude of 1 MPa, PL of 12 ms and PRF of 5 Hz, in RPMI media 
with 10% FBS, 10 µg/ml plasmid DNA, 0.05 mg/ml UCA and 100 µM P188.  
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 While a slight increase in viability was observed for cells insonated in the presence of 
P188 (73.2 ± 2.3% vs. 68.0 ±0.8%, figure 4.60c) there was so significant difference in the 
transfection, fluorescence intensity or cell viability for cells treated with P188 compared to 
controls (p>0.05).  It is possible that there was no significant change in cell viability because the 
degree of damage caused by the polymer UCA was too great to be repaired by P188. One study 
examining the effect of different polymer adjuvants on sonoporation efficiency of cells in 
suspension did observe an increase in transfection of some cells treated with P188, but they also 
did not observe a large change in viability [310].  
 
 
Figure 4.60: The effect of poloxamer 188 on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) of cells insonated for 15 seconds in RPMI with 10% FBS, 0.05 mg/ml UCA, 10 µg/ml plasmid 
DNA and 0 or 100 µM poloxamer 188 and a center frequency of 1 MHz, pressure amplitude of 1 MPa, PL 
of 12 ms and PRF of 5 Hz (n=6).  
 
 
 
4.4.12 Influence of Cell Line on Transfection Efficiency 
 In addition to MCF 7 breast cancer cells the triple negative breast cancer cell line MDA-
163 
 
MB-231 and bovine aortic endothelial cells (BAEC) were also insonated under the same 
conditions and the effect on transfection efficiency was examined. MCF 7 cells had significantly 
greater transfection efficiency (21.2 ± 0.8%) compared to BAEC (12.4 ± 2.9%) and MDA-MB-
231 cells (7.7 ± 0.5%) as shown in figure 4.61a (p<0.001). The fluorescence intensity from MCF 
7 cells was also significantly higher than both other cell lines (9.33 × 10
6
 ± 0.3 × 10
6
 RFU for 
MCF7, 2.2 × 10
6
 ± 0.2 × 10
6
 RFU for MDA-MB-231 and 2.1 × 10
6
 ± 0.2 × 10
6
 RFU for BAEC,   
p<0.001). It is possible that the differences in transfection efficiency may be the result of a 
difference in the ability to survive the ultrasound/microbubble exposure in vitro. This is reflected 
in the post treatment viability which is shown in figure 4.61c, with significantly lower cell 
viability for MDA-MB-231 and BAEC cell lines after ultrasound exposure compared to MCF 7 
cells (68.0 ± 0.8 % for MCF 7, 41.4 ± 2.3 % for MDA-MB-231 and 43.1 ± 3.4% for BAEC, 
p<0.01). The effect may be related to cell attachment to the substrate.  While MDA-MB-231 cells 
and BAEC both share a similar spindle like cell morphology, MCF 7 cells have a more triangular 
morphology and from clusters which may improve their attachment to the Opticell surface and to 
each other. The effect does not appear to be related to the fact that two of the lines are cancer 
lines. Others looking at uptake of nanoparticles have shown that cell physiology can affect the 
pathway of internalization leading to difference in transfection efficiency [311]. 
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Figure 4.61: The effect of cell type on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) of cells insonated for 15 seconds in media with 10% FBS, 0.05 mg/ml UCA, 10 µg/ml plasmid 
DNA. 
 
 
 
4.4.13 DNA Loaded Microbubbles 
 To determine how well DNA loaded polymer UCA were able to transfect cells in vitro, 
0.25 mg/ml PLA UCA made with 1% PEI and loaded with 22.8 ± 0.13 µg DNA/mg (a total of  
5.7 µg/ml) were added to cells in RPMI with 10% FBS and insonated for 15 seconds with a 
center frequency of 1 MHz, pressure amplitude of 1 MPa, PRF of 5 Hz and PL of 12 ms. The 
loaded UCA were compared with normal PLA UCA added to cells at 0.25 mg/ml along with 5.5 
µg/ml free plasmid DNA. DNA loaded UCA were able to achieve a transfection efficiency of 
18.0 ± 1.2% (figure 4.62a), which was significantly lower than normal PLA UCA with free DNA 
(27.36 ± 1.4%, p<0.01). Gene delivery from DNA loaded UCA may be occurring by direct 
transfer of DNA from the bubble shell to the cell during treatment with ultrasound, or the DNA 
may have been released prior to ultrasound exposure, and allowed to act as free DNA. To test if 
165 
 
DNA was being rapidly released, DNA loaded UCA were suspended in RPMI 1640 with 10% 
FBS, then immediately centrifuged, the supernatant was discarded and the DNA loaded PEI-UCA 
that were washed with media were then suspended in fresh media and insonated with cells. DNA 
loaded UCA that were first washed with medium achieved significantly lower transfection 
efficiencies than unwashed UCA (7.4 ± 0.4% vs. 18.0 ± 1.2%, p<0.01, figure 4.62). This agrees 
with the results observed in figure 4.61 that showed plasmid DNA was released from DNA 
loaded UCA once they were incubated in medium containing 10% FBS. The rapid release of 
DNA from loaded UCA suggests these DNA loaded UCA will not have any advantage in vivo 
over normal UCA injected with naked DNA. While many studies have successfully used DNA 
loaded cationic UCA to transfect cells in vivo, there are very few comparisons of DNA loaded vs. 
naked DNA. Nomikou et al. observed a slight increase in transfection when using DNA loaded 
cationic UCA compared to neutral UCA with free DNA, however, in this study they injected the 
microbubbles directly into muscle tissue prior to insonation and did not expose the UCA to serum 
or the MPS [312]. Wang et al. reported that transfection achieved in a solid tumor with cationic 
lipid UCA was approximately 5-7 times greater than neutral lipid UCA of the same size [313]. 
However it was later shown that the delivery efficiency observed with cationic UCA was limited 
to the lowest plasmid DNA doses (10 µg) but the advantage of cationic UCA was greatly reduced 
at higher DNA doses (50 µg). Other studies by Burke et al. showed that when animals were 
transfected with negatively charged UCA delivered with neutral PEI-PEG-DNA nanoparticles 
they achieved over 60 fold greater luciferase activity compared to the same UCA delivered with 
naked DNA [314]. This demonstrates the benefits of complexing DNA to reduce particle size and 
prevent degradation in serum, and also shows that the DNA does not need to be directly 
conjugated to the UCA to be effective. Delivering nucleic acids in the form of naked DNA or 
PEG-PEI-DNA particles offers the potential to deliver a much higher dose compared to DNA 
loaded onto UCA which is limited by the surface area of the microbubbles and the rapid clearance 
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of microbubbles due to their large size. Plasmid DNA is also inexpensive, not toxic and does not 
efficiently transfect cells on its own which may allow higher doses to be delivered.  
 
 
 
 
Figure 4.62: Effect of DNA loaded UCA on transfection efficiency (a) fluorescence intensity (b) and cell 
viability (c) (all measured 24 hours after transfection) of cells insonated for 15 seconds in RPMI with 10% 
FBS, 0.25 mg/ml UCA, 5.5 µg/ml plasmid DNA and a center frequency of 1 MHz, pressure amplitude of 1 
MPa, PL of 12 ms and PRF of 5 Hz (n=3). 
 
 
 
4.4.14 Ultrasound Triggered Gene Delivery Conclusions: 
 Gene delivery to MCF 7 breast cancer cells was achieved by insonating a monolayer of 
cells incubated with a suspension of PLA UCA and free plasmid DNA with a range of ultrasound 
exposures. A threshold pressure amplitude of 250 kPa or greater was required for gene delivery 
167 
 
with PLA UCA and a strong dependence on frequency and pulse length was also observed, with 
more efficient transfection at lower frequencies (1 MHz) and longer pulse lengths (12 ms). The 
exposure times tested also had no effect on transfection indicating sonoporation occurs in two 
seconds or less. In vitro ultrasound triggered gene delivery with PLA UCA did show a strong 
dependence on extracellular calcium ion concentration and a possible relationship between 
transfection and cell cycle. The conditions tested in these experiments were limited by the 
equipment used and it is possible that insonating with frequencies lower than 1 MHz or longer 
pulse lengths may be more efficient. The detection and quantification of transfected and dead 
cells could have also been improved by using flow cytometry to not only measure the transfection 
efficiency but also the level of gene expression in each cell.  
  While these experiments have shown that PLA UCA and ultrasound can be used to 
transfect cells with naked plasmid DNA in vitro, further work is necessary to evaluate the ability 
of these results to translate in vivo. In the future, it may be possible to take advantage of the 
enhanced drug loading properties of these polymer UCA [3, 277] in order to simultaneously 
deliver chemotherapeutics along with tumor suppressor genes to achieve a synergistic antitumor 
effect [315]. 
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5. CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
5.1 Conclusions 
 The overall objectives of this thesis were to characterize the efficacy of a PLA 
microbubble drug delivery platform and to develop methods for delivering other therapeutic 
bioactive compounds.  
 Dox loaded PLA microbubbles were used to treat a rat liver cancer model and compared 
with Dox loaded NP, a combination of UCA and NP or Free Dox. Ultrasound triggered UCA 
were able to deliver significantly more drug to the tumor compared to free Dox and were also 
able to significantly reduce the amount of drug found in the heart compared to free Dox. 
Unfortunately, a majority of the Dox loaded UCA were taken up by the spleen and liver. 
 As an alternative to Dox, both Ptx and Dtx were also loaded into PLA microbubbles. 
Both taxanes were incorporated into polymer microbubbles at significantly higher levels than the 
more hydrophilic Dox without a significant drop in peak acoustic enhancement measured in vitro. 
The Ptx and Dtx loaded agents were able to provide a sustained release of drug over 40 days in 
vitro and were also capable of inhibiting the growth of human breast cancer cells in vitro. 
 As an alternative to delivering chemotherapeutics which may have toxic effects on the 
macrophages of the mononuclear phagocyte system, nucleic acids were loaded onto polymer 
microbubbles. Two methods of loading plasmid DNA into polymer UCA were developed. 
PEI/DNA complexes were included in the aqueous phase of the primary emulsion or plasmid 
DNA was adsorbed to the surface of polymer microbubbles coated with PEI. DNA was loaded 
without causing a significant drop in acoustic enhancement, however DNA loading did result in a 
significant increase in microbubble size and a drop in the percentage of supercoiled plasmid 
compared to unloaded plasmid DNA. Plasmid DNA loaded onto polymer UCA was observed to 
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quickly release from microbubbles within 15 minutes of incubation with medium containing 10% 
serum. 
 The effect of the acoustic parameters and cell culture conditions on the ability of PLA 
UCA triggered by ultrasound to enhance gene delivery in vitro was also examined. A pressure 
amplitude of 250 kPa or greater was required for gene delivery with PLA UCA and a strong 
dependence on frequency and pulse length was also observed. Gene delivery efficiency was also 
dependent on the concentration of calcium ions in the medium as well as the cell cycle. While 
multiple cell lines were able to be transfected with these PLA UCA in vitro, the transfection 
efficiency achieved with less robust cell lines was significantly lower. 
 
5.2 Future Recommendations 
 Within this thesis there are several areas for future improvement. Results from specific 
aim one showed a significant uptake of Dox by the liver and spleen but it was not possible to 
determine if this was due to uptake of micron sized Dox loaded UCA or nanoshards that were not 
taken up by the tumor or a combination of both. It is also not clear if there were any toxic effects 
caused by this uptake or if multiple doses would lead to any significant toxicity. Additionally, it 
may be useful to explore methods of reducing uptake in the spleen and liver in order to improve 
the payload delivered to the desired target. While coating the surface of particles with polymers 
such as PEG has been shown to reduce opsonization and slow the uptake of nanoparticles it is not 
clear if similar methods can be used to slow the uptake of larger micron sized UCA or to what 
degree mechanical filtration in the spleen is responsible for removing larger particles. It may be 
useful to test the rate of uptake of drug loaded UCA in the spleen and liver when the UCA have 
not been triggered with ultrasound and compare this with the rate of uptake of drug loaded UCA 
that had been triggered with ultrasound in vitro to create nanoshards. It is also important to know 
if the drug delivered to the tumor remained in an active form after 2 weeks. While measuring 
14
C 
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activity is useful for quantifying drug levels it would be advantageous to use HPLC to not only 
quantify drug levels but also to discriminate between Dox and its metabolites such as 
doxorubicinol [316-317]. 
 In specific aim 2 we showed that the loading efficiency of hydrophobic drugs was much 
greater than hydrophilic drugs, helping confirm the hypothesis that the drug is loaded within the 
polymer shell. In future work where Dox loaded UCA are needed, it may be useful to use an 
uncharged form of Doxorubicin in place of Dox HCl. Specific aim 2 also examined the release of 
drug over 40 days in vitro and found only 60% of the total payload had been released over 40 
days. While drug release in vivo may be accelerated due to the enzymes and/or the lower pH 
found in some tumors, it is still possible that only a small percentage of the drug delivered to the 
tumor is available at any point of time. In the future it may be useful to increase the dose 
delivered to animals or increase the release rate of drug and examine drug release over an 
extended time period.  
 While specific aim 3 showed that DNA was able to be loaded onto polymer UCA, the use 
of the cationic polymer PEI makes this approach less appealing due to its toxicity. In the future it 
may be useful to conjugate PEG to PEI which has been shown to significantly reduce the toxicity 
of PEI. It may also be useful to include PEI in the polymer solution or to form covalent bonds 
between the PEI and the polymer shell of the microbubble in order to reduce the rapid burst 
release observed, or to adopt a layer by layer strategy to coat the DNA containing UCA with a 
protective layer of negatively charged polymer. As an alternative to loading DNA onto the UCA 
it may also be interesting to examine the co-delivery of UCA with uncharged nanoparticles 
composed of PEG/PEI/DNA or uncharged DNA loaded liposomes. This co-delivery may take 
advantage of both the beneficial biological effects achieved by insonating microbubbles, and the 
ability of nanoparticles to protect DNA and provide an extended circulation through the blood. 
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 Finally, within aim 4, multiple trends were shown to enhance gene transfection efficiency 
in vitro, however, it is not clear how well these trends can be translated in vivo. It may be possible 
to use the salivary gland as a simple model to confirm the effects of the insonation conditions on 
both the transfection efficiency and viability of cells in tissue. The most successful ultrasound 
parameters may then be combined with carefully constructed plasmids for transfecting other 
targets. In the future it may also be useful to examine the mechanisms involved in sonoporation 
with polymer microbubbles and examine the differences in cell uptake when the microbubbles are 
triggered with short pulses (<1 µs) and longer pulses. 
 
 
 
 
 
 
 
  
172 
 
List of References 
 
 
 
1. Cancer Facts & Figures. American Cancer Society 2012. 
2. Chomas, J.E., P.A. Dayton, D. May, J.G. Allen, A.L. Klibanov and K. Ferrara, Optical 
observation of contrast agent destruction. Appl. Phys. Lett. 2000; 7:1056-1058. 
3. Eisenbrey, J.R., O.M. Burstein, R. Kambhampati, F. Forsberg, J.B. Liu and M.A. 
Wheatley, Development and optimization of a doxorubicin loaded poly(lactic acid) 
contrast agent for ultrasound directed drug delivery. J. Control. Release 2010; 1:38-44. 
4. Eisenbrey, J.R., M.C. Soulen and M.A. Wheatley, Delivery of encapsulated Doxorubicin 
by ultrasound-mediated size reduction of drug-loaded polymer contrast agents. IEEE 
Trans. Biomed. Eng. 2010; 1:24-8. 
5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 
15-year survival: an overview of the randomised trials. Lancet 2005; 9472:1687-717. 
6. von Minckwitz, G., Docetaxel/anthracycline combinations for breast cancer treatment. 
Expert Opin. Pharmacother. 2007; 4:485-95. 
7. Henderson, I.C., D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, S. Martino, 
J.N. Ingle, M.R. Cooper, D.F. Hayes, K.H. Tkaczuk, G. Fleming, J.F. Holland, D.B. 
Duggan, J.T. Carpenter, E. Frei, R.L. Schilsky, W.C. Wood, H.B. Muss, and L. Norton, 
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating 
Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-
Positive Primary Breast Cancer. J. Clin. Oncol. 2003; 6:976-983. 
8. El-Serag, H.B. and K.L. Rudolph, Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology 2007; 7:2557-76. 
9. Tzeng, C.-W. and T. Aloia, Colorectal Liver Metastases. J. Gastrointest. Surg.:1-8. 
10. Farazi, P.A. and R.A. DePinho, Hepatocellular carcinoma pathogenesis: from genes to 
environment. Nat. Rev. Cancer 2006; 9:674-87. 
11. World Health Statistics 2012. World Health Organization 2012. 
12. Llovet, J.M. and J. Bruix, Novel advancements in the management of hepatocellular 
carcinoma in 2008. J. Hepatol. 2008:S20-37. 
13. Llovet, J.M., M.I. Real, X. Montana, R. Planas, S. Coll, J. Aponte, C. Ayuso, M. Sala, J. 
Muchart, R. Sola, J. Rodes, J. Bruix, and G. Barcelona Liver Cancer, Arterial 
embolisation or chemoembolisation versus symptomatic treatment in patients with 
unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 
9319:1734-9. 
14. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell 1990; 
5:759-67. 
173 
 
15. Bergers, G. and L.E. Benjamin, Tumorigenesis and the angiogenic switch. Nat. Rev. 
Cancer 2003; 6:401-10. 
16. Papetti, M. and I.M. Herman, Mechanisms of normal and tumor-derived angiogenesis. 
Am. J. Physiol. Cell Physiol. 2002; 5:C947-70. 
17. Moeller, B.J., Y. Cao, Z. Vujaskovic, C.Y. Li, Z.A. Haroon and M.W. Dewhirst, The 
relationship between hypoxia and angiogenesis. Semin. Radiat. Oncol. 2004; 3:215-21. 
18. Volpert, O.V., J. Lawler and N.P. Bouck, A human fibrosarcoma inhibits systemic 
angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. 
Natl. Acad. Sci. 1998; 11:6343-6348. 
19. Gohongi, T., D. Fukumura, Y. Boucher, C.O. Yun, G.A. Soff, C. Compton, T. Todoroki 
and R.K. Jain, Tumor-host interactions in the gallbladder suppress distal angiogenesis 
and tumor growth: involvement of transforming growth factor beta1. Nat. Med. 1999; 
10:1203-8. 
20. Carmeliet, P. and R.K. Jain, Angiogenesis in cancer and other diseases. Nature 2000; 
6801:249-57. 
21. Hobbs, S.K., W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin and R.K. 
Jain, Regulation of transport pathways in tumor vessels: role of tumor type and 
microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998; 8:4607-12. 
22. Yuan, F., M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin and R.K. Jain, 
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff 
size. Cancer Res. 1995; 17:3752-6. 
23. Hashizume, H., P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. 
Jain and D.M. McDonald, Openings between defective endothelial cells explain tumor 
vessel leakiness. Am. J. Pathol. 2000; 4:1363-80. 
24. Jang, S.H., M.G. Wientjes, D. Lu and J.L. Au, Drug delivery and transport to solid 
tumors. Pharm. Res. 2003; 9:1337-50. 
25. Lum, H. and A.B. Malik, Regulation of vascular endothelial barrier function. Am. J. 
Physiol. 1994; 3 Pt 1:L223-41. 
26. Heldin, C.H., K. Rubin, K. Pietras and A. Ostman, High interstitial fluid pressure - an 
obstacle in cancer therapy. Nat. Rev. Cancer 2004; 10:806-13. 
27. Alitalo, K. and P. Carmeliet, Molecular mechanisms of lymphangiogenesis in health and 
disease. Cancer Cell 2002; 3:219-27. 
28. Jain, R.K. and B.T. Fenton, Intratumoral lymphatic vessels: a case of mistaken identity or 
malfunction? J. Natl. Cancer Inst. 2002; 6:417-21. 
29. Jain, R.K., Vascular and interstitial barriers to delivery of therapeutic agents in tumors. 
Cancer Metastasis Rev. 1990; 3:253-66. 
174 
 
30. Jain, R.K., Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv 
Rev 1997; 2-3:71-90. 
31. Watson, K.D., C.Y. Lai, S. Qin, D.E. Kruse, Y.C. Lin, J.W. Seo, R.D. Cardiff, L.M. 
Mahakian, J. Beegle, E.S. Ingham, F.R. Curry, R.K. Reed, and K.W. Ferrara, Ultrasound 
increases nanoparticle delivery by reducing intratumoral pressure and increasing 
transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res. 2012; 
6:1485-93. 
32. Fisher, B., S. Anderson, J. Bryant, R.G. Margolese, M. Deutsch, E.R. Fisher, J.H. Jeong 
and N. Wolmark, Twenty-year follow-up of a randomized trial comparing total 
mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive 
breast cancer. The New England journal of medicine 2002; 16:1233-41. 
33. Kinsella, T.J., J. Sohn and B. Wessels, Principles of Radiation Oncology, in Oncology, 
A.E. Chang, et al., Editors. 2006, Springer New York. p. 41-57. 
34. Llovet, J.M., A. Burroughs and J. Bruix, Hepatocellular carcinoma. Lancet 2003; 
9399:1907-17. 
35. Bismuth, H. and P.E. Majno, Hepatobiliary surgery. J. Hepatol. 2000; 1 Suppl:208-24. 
36. Llovet, J.M., J. Fuster and J. Bruix, Intention-to-treat analysis of surgical treatment for 
early hepatocellular carcinoma: resection versus transplantation. Hepatology (Baltimore, 
Md ) 1999; 6:1434-40. 
37. Freeman, R.B., Jr., R.H. Wiesner, A. Harper, S.V. McDiarmid, J. Lake, E. Edwards, R. 
Merion, R. Wolfe, J. Turcotte and L. Teperman, The new liver allocation system: moving 
toward evidence-based transplantation policy. Liver Transpl. 2002; 9:851-8. 
38. Lencioni, R., F. Pinto, N. Armillotta, A.M. Bassi, M. Moretti, M. Di Giulio, S. Marchi, 
M. Uliana, S. Della Capanna, M. Lencioni, and C. Bartolozzi, Long-term results of 
percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a 
European experience. Eur. Radiol. 1997; 4:514-9. 
39. Silva, M.A., B. Hegab, C. Hyde, B. Guo, J.A.C. Buckels and D.F. Mirza, Needle track 
seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a 
systematic review and meta-analysis. Gut 2008; 11:1592-6. 
40. Hortobagyi, G.N., Anthracyclines in the treatment of cancer. An overview. Drugs 
1997:1-7. 
41. Minotti, G., P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, Anthracyclines: molecular 
advances and pharmacologic developments in antitumor activity and cardiotoxicity. 
Pharmacol. Rev. 2004; 2:185-229. 
42. Aubel-Sadron, G. and D. Londos-Gagliardi, Daunorubicin and doxorubicin, 
anthracycline antibiotics, a physicochemical and biological review. Biochimie 1984; 
5:333-52. 
175 
 
43. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. 
Pharmacol. 1999; 7:727-41. 
44. Singal, P.K. and N. Iliskovic, Doxorubicin-induced cardiomyopathy. The New England 
journal of medicine 1998; 13:900-5. 
45. Behnia, K. and M. Boroujerdi, Inhibition of aldo-keto reductases by phenobarbital alters 
metabolism, pharmacokinetics and toxicity of doxorubicin in rats. J. Pharm. Pharmacol. 
1999; 11:1275-82. 
46. Yoo, H.S., K.H. Lee, J.E. Oh and T.G. Park, In vitro and in vivo anti-tumor activities of 
nanoparticles based on doxorubicin–PLGA conjugates. J. Control. Release 2000; 3:419-
431. 
47. McGrogan, B.T., B. Gilmartin, D.N. Carney and A. McCann, Taxanes, microtubules and 
chemoresistant breast cancer. Biochim. Biophys. Acta 2008; 2:96-132. 
48. Amos, L.A. and J. Lowe, How Taxol stabilises microtubule structure. Chem. Biol. 1999; 
3:R65-9. 
49. Hernandez-Vargas, H., J. Palacios and G. Moreno-Bueno, Molecular profiling of 
docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and 
apoptosis. Oncogene 2007; 20:2902-13. 
50. Yeung, T.K., C. Germond, X. Chen and Z. Wang, The mode of action of taxol: apoptosis 
at low concentration and necrosis at high concentration. Biochem. Biophys. Res. 
Commun. 1999; 2:398-404. 
51. Immordino, M.L., P. Brusa, S. Arpicco, B. Stella, F. Dosio and L. Cattel, Preparation, 
characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. 
Control. Release 2003; 3:417-29. 
52. Bissery, M.C., Preclinical pharmacology of docetaxel. Eur J Cancer 1995:S1-6. 
53. Verweij, J., Docetaxel (Taxotere): a new anti-cancer drug with promising potential? Br. J. 
Cancer 1994; 2:183-4. 
54. Andersen, A., D.J. Warren, P.F. Brunsvig, S. Aamdal, G.B. Kristensen and H. Olsen, 
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase 
extraction and high-performance liquid chromatography with UV detection. BMC Clin. 
Pharmacol. 2006:2. 
55. Ishitobi, M., E. Shin and N. Kikkawa, Metastatic breast cancer with resistance to both 
anthracycline and docetaxel successfully treated with weekly paclitaxel. International 
journal of clinical oncology / Japan Society of Clinical Oncology 2001; 1:55-8. 
56. Conlin, A.K. and A.D. Seidman, Taxanes in breast cancer: an update. Curr. Oncol. Rep. 
2007; 1:22-30. 
176 
 
57. Thigpen, J.T., J.A. Blessing, H. Ball, S.J. Hummel and R.J. Barrett, Phase II trial of 
paclitaxel in patients with progressive ovarian carcinoma after platinum-based 
chemotherapy: a Gynecologic Oncology Group study. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 1994; 9:1748-53. 
58. Liggins, R.T., W.L. Hunter and H.M. Burt, Solid-state characterization of paclitaxel. J. 
Pharm. Sci. 1997; 12:1458-63. 
59. Weiss, R.B., R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. 
Baker, Jr., D.A. Van Echo, D.D. Von Hoff and B. Leyland-Jones, Hypersensitivity 
reactions from taxol. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 1990; 7:1263-8. 
60. Rowinsky, E.K. and R.C. Donehower, Paclitaxel (taxol). The New England journal of 
medicine 1995; 15:1004-14. 
61. Wolinsky, J.B., Y.L. Colson and M.W. Grinstaff, Local drug delivery strategies for 
cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J. Control. 
Release 2012; 1:14-26. 
62. Mishra, B., B.B. Patel and S. Tiwari, Colloidal nanocarriers: a review on formulation 
technology, types and applications toward targeted drug delivery. Nanomedicine: 
Nanotechnology, Biology and Medicine 2010; 1:9-24. 
63. Maeda, H., J. Wu, T. Sawa, Y. Matsumura and K. Hori, Tumor vascular permeability and 
the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000; 1-
2:271-84. 
64. Fang, J., H. Nakamura and H. Maeda, The EPR effect: Unique features of tumor blood 
vessels for drug delivery, factors involved, and limitations and augmentation of the 
effect. Adv Drug Deliv Rev 2011; 3:136-51. 
65. Soundararajan, A., A. Bao, W.T. Phillips, R. Perez, 3rd and B.A. Goins, 
[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging 
and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl. 
Med. Biol. 2009; 5:515-24. 
66. O'Brien, M.E., N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. 
Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler, 
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated 
liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-
line treatment of metastatic breast cancer. Ann. Oncol. 2004; 3:440-9. 
67. Symon, Z., A. Peyser, D. Tzemach, O. Lyass, E. Sucher, E. Shezen and A. Gabizon, 
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth 
liposomes. Cancer 1999; 1:72-8. 
68. Uster, P.S., P.K. Working and J. Vaage, Pegylated liposomal doxorubicin (DOXIL®, 
CAELYX®) distribution in tumour models observed with confocal laser scanning 
microscopy. Int. J. Pharm. 1998; 1–2:77-86. 
177 
 
69. Chanan-Khan, A., J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving and F.M. 
Muggia, Complement activation following first exposure to pegylated liposomal 
doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003; 
9:1430-7. 
70. Pastorino, F., D. Di Paolo, F. Piccardi, B. Nico, D. Ribatti, A. Daga, G. Baio, C.E. 
Neumaier, C. Brignole, M. Loi, D. Marimpietri, G. Pagnan, M. Cilli, E.A. Lepekhin, S.V. 
Garde, R. Longhi, A. Corti, T.M. Allen, J.J. Wu, and M. Ponzoni, Enhanced antitumor 
efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin. Cancer Res. 
2008; 22:7320-9. 
71. Tuscano, J.M., S.M. Martin, Y. Ma, W. Zamboni and R.T. O'Donnell, Efficacy, 
biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin 
in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin. Cancer. Res. 2010; 
10:2760-8. 
72. Green, M.R., G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, P. Bhar and M.J. 
Hawkins, Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel 
for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006; 8:1263-8. 
73. Miele, E., G.P. Spinelli, F. Tomao and S. Tomao, Albumin-bound formulation of 
paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomedicine 
2009:99-105. 
74. Henderson, I.C. and V. Bhatia, Nab-paclitaxel for breast cancer: a new formulation with 
an improved safety profile and greater efficacy. Expert Rev. Anticancer Ther. 2007; 
7:919-943. 
75. Sparreboom, A., C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. 
Figg, M. Hawkins and N. Desai, Comparative preclinical and clinical pharmacokinetics 
of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel 
formulated in Cremophor (Taxol). Clin. Cancer. Res. 2005; 11:4136-43. 
76. Hawkins, M.J., P. Soon-Shiong and N. Desai, Protein nanoparticles as drug carriers in 
clinical medicine. Adv. Drug Delivery. Rev. 2008; 8:876-85. 
77. Singla, A.K., A. Garg and D. Aggarwal, Paclitaxel and its formulations. Int. J. Pharm. 
2002; 1-2:179-92. 
78. Mu, L. and S.S. Feng, A novel controlled release formulation for the anticancer drug 
paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 
2003; 1:33-48. 
79. Xie, J. and C.H. Wang, Self-assembled biodegradable nanoparticles developed by direct 
dialysis for the delivery of paclitaxel. Pharm. Res. 2005; 12:2079-90. 
80. Hamaguchi, T., Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, I. Nakamura, I. 
Nakatomi, M. Yokoyama, K. Kataoka and T. Kakizoe, NK105, a paclitaxel-incorporating 
micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the 
neurotoxicity of paclitaxel. Br. J. Cancer 2005; 7:1240-6. 
178 
 
81. Yan, F., C. Zhang, Y. Zheng, L. Mei, L. Tang, C. Song, H. Sun and L. Huang, The effect 
of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. 
Nanomed. 2010; 1:170-8. 
82. Yang, M., Y. Ding, L. Zhang, X. Qian, X. Jiang and B. Liu, Novel thermosensitive 
polymeric micelles for docetaxel delivery. J. Biomed. Mater. Res. A 2007; 4:847-57. 
83. Esmaeili, F., M.H. Ghahremani, S.N. Ostad, F. Atyabi, M. Seyedabadi, M.R. Malekshahi, 
M. Amini and R. Dinarvand, Folate-receptor-targeted delivery of docetaxel nanoparticles 
prepared by PLGA-PEG-folate conjugate. J. Drug Target. 2008; 5:415-23. 
84. Farokhzad, O.C., J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie and 
R. Langer, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in 
vivo. Proc. Natl. Acad. Sci. U. S. A. 2006; 16:6315-20. 
85. Susa, M., A.K. Iyer, K. Ryu, F.J. Hornicek, H. Mankin, M.M. Amiji and Z. Duan, 
Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug 
resistance in osteosarcoma. BMC Cancer 2009:399. 
86. Cho, K., X. Wang, S. Nie, Z.G. Chen and D.M. Shin, Therapeutic nanoparticles for drug 
delivery in cancer. Clin. Cancer. Res. 2008; 5:1310-6. 
87. Ganta, S., H. Devalapally, A. Shahiwala and M. Amiji, A review of stimuli-responsive 
nanocarriers for drug and gene delivery. J. Control. Release 2008; 3:187-204. 
88. Rapoport, N., Physical stimuli-responsive polymeric micelles for anti-cancer drug 
delivery. Progress in Polymer Science 2007; 8-9:962-990. 
89. Alexiou, C., W. Arnold, R.J. Klein, F.G. Parak, P. Hulin, C. Bergemann, W. Erhardt, S. 
Wagenpfeil and A.S. Lubbe, Locoregional cancer treatment with magnetic drug targeting. 
Cancer Res. 2000; 23:6641-8. 
90. Unger, E.C., T. Porter, W. Culp, R. Labell, T. Matsunaga and R. Zutshi, Therapeutic 
applications of lipid-coated microbubbles. Adv. Drug Delivery. Rev. 2004; 9:1291-314. 
91. van Furth, R., Z.A. Cohn, J.G. Hirsch, J.H. Humphrey, W.G. Spector and H.L. 
Langevoort, The mononuclear phagocyte system: a new classification of macrophages, 
monocytes, and their precursor cells. Bull. W.H.O 1972; 6:845-52. 
92. Papahadjopoulos, D., T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, 
K.D. Lee, M.C. Woodle, D.D. Lasic and C. Redemann, Sterically stabilized liposomes: 
improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. 
Sci. U. S. A. 1991; 24:11460-4. 
93. Peracchia, M.T., E. Fattal, D. Desmaele, M. Besnard, J.P. Noel, J.M. Gomis, M. Appel, J. 
d'Angelo and P. Couvreur, Stealth PEGylated polycyanoacrylate nanoparticles for 
intravenous administration and splenic targeting. J. Control. Release 1999; 1:121-8. 
94. Vonarbourg, A., C. Passirani, P. Saulnier and J.-P. Benoit, Parameters influencing the 
stealthiness of colloidal drug delivery systems. Biomaterials 2006; 24:4356-73. 
179 
 
95. Moghimi, S.M., A.C. Hunter and J.C. Murray, Long-circulating and target-specific 
nanoparticles: theory to practice. Pharmacol. Rev. 2001; 2:283-318. 
96. Ilium, L., I.M. Hunneyball and S.S. Davis, The effect of hydrophilic coatings on the 
uptake of colloidal particles by the liver and by peritoneal macrophages. Int. J. Pharm. 
1986; 1:53-65. 
97. Kao, Y.J. and R.L. Juliano, Interactions of liposomes with the reticuloendothelial system 
effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. 
Biochimica et Biophysica Acta (BBA) - General Subjects 1981; 3–4:453-461. 
98. Gref, R., A. Domb, P. Quellec, T. Blunk, R.H. Müller, J.M. Verbavatz and R. Langer, 
The controlled intravenous delivery of drugs using PEG-coated sterically stabilized 
nanospheres. Adv. Drug Delivery. Rev. 1995; 2–3:215-233. 
99. Ishida, T., X. Wang, T. Shimizu, K. Nawata and H. Kiwada, PEGylated liposomes elicit 
an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 2007; 
3:349-355. 
100. Gref, R., M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk and 
R.H. Muller, 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol 
(PEG): influences of the corona (PEG chain length and surface density) and of the core 
composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 
Biointerfaces 2000; 3-4:301-313. 
101. Lee, C.M., Y. Choi, E.J. Huh, K.Y. Lee, H.C. Song, M.J. Sun, H.J. Jeong, C.S. Cho and 
H.S. Bom, Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving 
blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer 
Biother. Radiopharm. 2005; 6:620-8. 
102. Moghimi, S.M. and J. Szebeni, Stealth liposomes and long circulating nanoparticles: 
critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. 
Lipid Res. 2003; 6:463-78. 
103. Awasthi, V.D., D. Garcia, B.A. Goins and W.T. Phillips, Circulation and biodistribution 
profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm. 
2003; 1-2:121-32. 
104. Owens, D.E., 3rd and N.A. Peppas, Opsonization, biodistribution, and pharmacokinetics 
of polymeric nanoparticles. Int. J. Pharm. 2006; 1:93-102. 
105. Chen, L.T. and L. Weiss, The role of the sinus wall in the passage of erythrocytes 
through the spleen. Blood 1973; 4:529-37. 
106. Moghimi, S.M., C.J. Porter, I.S. Muir, L. Illum and S.S. Davis, Non-phagocytic uptake of 
intravenously injected microspheres in rat spleen: influence of particle size and 
hydrophilic coating. Biochem. Biophys. Res. Commun. 1991; 2:861-6. 
107. Moghimi, S.M., H. Hedeman, I.S. Muir, L. Illum and S.S. Davis, An investigation of the 
filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat 
spleen. Biochim. Biophys. Acta 1993; 3:233-40. 
180 
 
108. Harashima, H., S. Komatsu, S. Kojima, C. Yanagi, Y. Morioka, M. Naito and H. Kiwada, 
Species difference in the disposition of liposomes among mice, rats, and rabbits: 
allometric relationship and species dependent hepatic uptake mechanism. Pharm. Res. 
1996; 7:1049-54. 
109. Walbrun, P., C. Hellerbrand, T.S. Weiss, S. Netter, D. Neumaier, E. Gaebele, R. Wiest, J. 
Schoelmerich and M. Froh, Characterization of rat and human Kupffer cells after 
cryopreservation. Cryobiology 2007; 2:164-172. 
110. Helmy, K.Y., K.J. Katschke Jr, N.N. Gorgani, N.M. Kljavin, J.M. Elliott, L. Diehl, S.J. 
Scales, N. Ghilardi and M. van Lookeren Campagne, CRIg: A Macrophage Complement 
Receptor Required for Phagocytosis of Circulating Pathogens. Cell 2006; 5:915-927. 
111. Hauff, P., M. Reinhardt and S. Foster, Ultrasound basics. Handb. Exp. Pharmacol. 2008; 
185 Pt 1:91-107. 
112. Nelson, T.R., J.B. Fowlkes, J.S. Abramowicz and C.C. Church, Ultrasound biosafety 
considerations for the practicing sonographer and sonologist. J. Ultrasound Med. 2009; 
2:139-50. 
113. Ying, C.F. and R. Truell, Scattering of a Plane Longitudinal Wave by a Spherical 
Obstacle in an Isotropically Elastic Solid. J Appl. Phys. 1956; 9:1086-1098. 
114. Calliada, F., R. Campani, O. Bottinelli, A. Bozzini and M.G. Sommaruga, Ultrasound 
contrast agents: basic principles. Eur. J. Radiol. 1998:S157-60. 
115. Ophir, J. and K.J. Parker, Contrast agents in diagnostic ultrasound. Ultrasound Med. Biol. 
1989; 4:319-33. 
116. Ferrara, K., R. Pollard and M. Borden, Ultrasound microbubble contrast agents: 
fundamentals and application to gene and drug delivery. Annu. Rev. Biomed. Eng. 
2007:415-47. 
117. Sontum, P.C., Physicochemical characteristics of Sonazoid, a new contrast agent for 
ultrasound imaging. Ultrasound Med. Biol. 2008; 5:824-33. 
118. Harvey, C.J., J.M. Pilcher, R.J. Eckersley, M.J. Blomley and D.O. Cosgrove, Advances 
in ultrasound. Clin. Radiol. 2002; 3:157-77. 
119. Ophir, J., A. Gobuty, R.E. McWhirt and N.F. Maklad, Ultrasonic backscatter from 
contrast producing collagen microspheres. Ultrason. Imaging 1980; 1:67-77. 
120. Wheatley, M.A., B. Schrope and P. Shen, Contrast agents for diagnostic ultrasound: 
development and evaluation of polymer-coated microbubbles. Biomaterials 1990; 9:713-
7. 
121. Harris, J.R., F. Depoix and K. Urich, The structure of gas-filled n-butyl-2-cyanoacrylate 
(BCA) polymer particles. Micron 1995; 2:103-111. 
181 
 
122. Straub, J.A., E. Mathiowitz, H. Bernstein, H. Brush and R.E. Wing, Method for Making 
Porous Microparticles by Spray Drying, U.S. Patent, Editor. 1998, Acusphere, Inc.,: 
United States. 
123. Bernstein, H., J.A. Straub, H. Brush and C. Church, Polymer-Lipid Microencapsulated 
Gases for Use as Imaging Agents, U.S. Patent, Editor. 1998, Acusphere: United States. 
124. Straub, J.A., D.E. Chickering, C.C. Church, B. Shah, T. Hanlon and H. Bernstein, Porous 
PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent 
for use in echocardiography. J. Control. Release 2005; 1:21-32. 
125. Ottoboni, T.B., R.E. Short and R.K. Yamamoto, Microparticles Useful as Ultrasonic 
Contrast Agents, U.S. Patent, Editor. 2001, Point Biomedical Corporation: United States. 
126. Mehier-Humbert, S., F. Yan, P. Frinking, M. Schneider, R.H. Guy and T. Bettinger, 
Ultrasound-mediated gene delivery: influence of contrast agent on transfection. 
Bioconjug. Chem. 2007; 3:652-62. 
127. Cavalieri, F., A. El Hamassi, E. Chiessi and G. Paradossi, Stable Polymeric 
Microballoons as Multifunctional Device for Biomedical Uses:  Synthesis and 
Characterization. Langmuir 2005; 19:8758-8764. 
128. El-Sherif, D.M. and M.A. Wheatley, Development of a novel method for synthesis of a 
polymeric ultrasound contrast agent. J. Biomed. Mater. Res. A 2003; 2:347-55. 
129. Wheatley, M.A., F. Forsberg, K. Oum, R. Ro and D. El-Sherif, Comparison of in vitro 
and in vivo acoustic response of a novel 50:50 PLGA contrast agent. Ultrasonics 2006; 
4:360-7. 
130. Postema, M., A. van Wamel, C.T. Lancee and N. de Jong, Ultrasound-induced 
encapsulated microbubble phenomena. Ultrasound Med. Biol. 2004; 6:827-40. 
131. Newman, C.M.H. and T. Bettinger, Gene therapy progress and prospects: ultrasound for 
gene transfer. Gene Ther. 2007; 6:465-75. 
132. Forbes, M.M., R.L. Steinberg and W.D. O'Brien, Jr., Examination of inertial cavitation of 
Optison in producing sonoporation of chinese hamster ovary cells. Ultrasound Med. Biol. 
2008; 12:2009-18. 
133. Postema, M., A. van Wamel, F.J. ten Cate and N. de Jong, High-speed photography 
during ultrasound illustrates potential therapeutic applications of microbubbles. Med. 
Phys. 2005; 12:3707-11. 
134. Prentice, P., A. Cuschieri, K. Dholakia, M. Prausnitz and P. Campbell, Membrane 
disruption by optically controlled microbubble cavitation. Nat Phys 2005; 2:107-110. 
135. Postema, M. and O.H. Gilja, Ultrasound-directed drug delivery. Curr. Pharm. Biotechnol. 
2007; 6:355-61. 
136. Marmottant, P. and S. Hilgenfeldt, Controlled vesicle deformation and lysis by single 
oscillating bubbles. Nature 2003; 6936:153-6. 
182 
 
137. Wu, J., Theoretical study on shear stress generated by microstreaming surrounding 
contrast agents attached to living cells. Ultrasound Med. Biol. 2002; 1:125-9. 
138. van Wamel, A., K. Kooiman, M. Harteveld, M. Emmer, F.J. ten Cate, M. Versluis and N. 
de Jong, Vibrating microbubbles poking individual cells: drug transfer into cells via 
sonoporation. J. Control. Release 2006; 2:149-155. 
139. Mehier-Humbert, S., T. Bettinger, F. Yan and R.H. Guy, Plasma membrane poration 
induced by ultrasound exposure: implication for drug delivery. J. Control. Release 2005; 
1:213-222. 
140. Yudina, A., M. Lepetit-Coiffe and C.T.W. Moonen, Evaluation of the temporal window 
for drug delivery following ultrasound-mediated membrane permeability enhancement. 
Mol. Imaging Biol. 2011; 2:239-49. 
141. Tran, T.A., S. Roger, J.Y. Le Guennec, F. Tranquart and A. Bouakaz, Effect of 
ultrasound-activated microbubbles on the cell electrophysiological properties. Ultrasound 
Med. Biol. 2007; 1:158-63. 
142. Juffermans, L.J.M., O. Kamp, P.A. Dijkmans, C.A. Visser and R.J.P. Musters, Low-
intensity ultrasound-exposed microbubbles provoke local hyperpolarization of the cell 
membrane via activation of BK(Ca) channels. Ultrasound Med. Biol. 2008; 3:502-8. 
143. Juffermans, L.J.M., P.A. Dijkmans, R.J.P. Musters, C.A. Visser and O. Kamp, Transient 
permeabilization of cell membranes by ultrasound-exposed microbubbles is related to 
formation of hydrogen peroxide. American journal of physiology Heart and circulatory 
physiology 2006; 4:H1595-601. 
144. Lawrie, A., A.F. Brisken, S.E. Francis, D. Wyllie, E. Kiss-Toth, E.E. Qwarnstrom, S.K. 
Dower, D.C. Crossman and C.M. Newman, Ultrasound-enhanced transgene expression in 
vascular cells is not dependent upon cavitation-induced free radicals. Ultrasound Med. 
Biol. 2003; 10:1453-1461. 
145. Kumon, R.E., M. Aehle, D. Sabens, P. Parikh, D. Kourennyi and C.X. Deng, Ultrasound-
induced calcium oscillations and waves in Chinese hamster ovary cells in the presence of 
microbubbles. Biophys. J. 2007; 6:L29-31. 
146. Yellowley, C.E., C.R. Jacobs, Z. Li, Z. Zhou and H.J. Donahue, Effects of fluid flow on 
intracellular calcium in bovine articular chondrocytes. The American journal of 
physiology 1997; 1 Pt 1:C30-6. 
147. Zupancic, G., D. Ogden, C.J. Magnus, C. Wheeler-Jones and T.D. Carter, Differential 
exocytosis from human endothelial cells evoked by high intracellular Ca(2+) 
concentration. The Journal of physiology 2002; Pt 3:741-55. 
148. Henkel, A.W. and W. Almers, Fast steps in exocytosis and endocytosis studied by 
capacitance measurements in endocrine cells. Curr. Opin. Neurobiol. 1996; 3:350-7. 
149. Meijering, B.D.M., L.J.M. Juffermans, A. van Wamel, R.H. Henning, I.S. Zuhorn, M. 
Emmer, A.M.G. Versteilen, W.J. Paulus, W.H. van Gilst, K. Kooiman, N. de Jong, R.J.P. 
Musters, L.E. Deelman, and O. Kamp, Ultrasound and microbubble-targeted delivery of 
183 
 
macromolecules is regulated by induction of endocytosis and pore formation. Circ. Res. 
2009; 5:679-87. 
150. Mehier-Humbert, S., T. Bettinger, F. Yan and R.H. Guy, Ultrasound-mediated gene 
delivery: kinetics of plasmid internalization and gene expression. J. Control. Release 
2005; 1:203-211. 
151. Lentacker, I., N. Wang, R.E. Vandenbroucke, J. Demeester, S.C. De Smedt and N.N. 
Sanders, Ultrasound exposure of lipoplex loaded microbubbles facilitates direct 
cytoplasmic entry of the lipoplexes. Mol. Pharm. 2009; 2:457-67. 
152. Geers, B., I. Lentacker, A. Alonso, N.N. Sanders, J. Demeester, S. Meairs and S.C. De 
Smedt, Elucidating the mechanisms behind sonoporation with adeno-associated virus-
loaded microbubbles. Mol. Pharm. 2011; 6:2244-51. 
153. Schlicher, R.K., H. Radhakrishna, T.P. Tolentino, R.P. Apkarian, V. Zarnitsyn and M.R. 
Prausnitz, Mechanism of intracellular delivery by acoustic cavitation. Ultrasound Med. 
Biol. 2006; 6:915-24. 
154. Lee, N.G., J.L. Berry, T.C. Lee, A.T. Wang, S. Honowitz, A.L. Murphree, N. Varshney, 
D.R. Hinton and A.A. Fawzi, Sonoporation enhances chemotherapeutic efficacy in 
retinoblastoma cells in vitro. Invest. Ophthalmol. Vis. Sci. 2011; 6:3868-73. 
155. Zhou, Y., R.E. Kumon, J. Cui and C.X. Deng, The size of sonoporation pores on the cell 
membrane. Ultrasound Med. Biol. 2009; 10:1756-60. 
156. Reddy, A., E.V. Caler and N.W. Andrews, Plasma membrane repair is mediated by 
Ca(2+)-regulated exocytosis of lysosomes. Cell 2001; 2:157-69. 
157. Zhou, Y., J. Shi, J. Cui and C.X. Deng, Effects of extracellular calcium on cell membrane 
resealing in sonoporation. J. Control. Release 2008; 1:34-43. 
158. Mehier-Humbert, S. and R.H. Guy, Physical methods for gene transfer: improving the 
kinetics of gene delivery into cells. Advanced Drug Delivery Reviews 2005; 5:733-53. 
159. Brayman, A.A., L.M. Lizotte and M.W. Miller, Erosion of artificial endothelia in vitro by 
pulsed ultrasound: acoustic pressure, frequency, membrane orientation and microbubble 
contrast agent dependence. Ultrasound Med. Biol. 1999; 8:1305-20. 
160. Song, J., J.C. Chappell, M. Qi, E.J. VanGieson, S. Kaul and R.J. Price, Influence of 
injection site, microvascular pressure and ultrasound variables on microbubble-mediated 
delivery of microspheres to muscle. J. Am. Coll. Cardiol. 2002; 4:726-31. 
161. Skyba, D.M., R.J. Price, A.Z. Linka, T.C. Skalak and S. Kaul, Direct in vivo visualization 
of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. 
Circulation 1998; 4:290-3. 
162. Price, R.J., D.M. Skyba, S. Kaul and T.C. Skalak, Delivery of colloidal particles and red 
blood cells to tissue through microvessel ruptures created by targeted microbubble 
destruction with ultrasound. Circulation 1998; 13:1264-7. 
184 
 
163. Song, J., M. Qi, S. Kaul and R.J. Price, Stimulation of arteriogenesis in skeletal muscle 
by microbubble destruction with ultrasound. Circulation 2002; 12:1550-5. 
164. Chappell, J.C., J. Song, C.W. Burke, A.L. Klibanov and R.J. Price, Targeted delivery of 
nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction 
for therapeutic arteriogenesis. Small 2008; 10:1769-77. 
165. Geis, N.A., C.R. Mayer, R.D. Kroll, S.E. Hardt, H.A. Katus and R. Bekeredjian, Spatial 
Distribution of Ultrasound Targeted Microbubble Destruction Increases Cardiac 
Transgene Expression But Not Capillary Permeability. Ultrasound Med. Biol. 2009; 
7:1119-1126. 
166. Bekeredjian, R., R.D. Kroll, E. Fein, S. Tinkov, C. Coester, G. Winter, H.A. Katus and H. 
Kulaksiz, Ultrasound targeted microbubble destruction increases capillary permeability in 
hepatomas. Ultrasound Med. Biol. 2007; 10:1592-8. 
167. Bohmer, M.R., C.H.T. Chlon, B.I. Raju, C.T. Chin, T. Shevchenko and A.L. Klibanov, 
Focused ultrasound and microbubbles for enhanced extravasation. J. Control. Release 
2010; 1:18-24. 
168. Hynynen, K., Ultrasound for drug and gene delivery to the brain. Adv. Drug Delivery. 
Rev. 2008; 10:1209-17. 
169. Caskey, C.F., S. Qin, P.A. Dayton and K.W. Ferrara, Microbubble tunneling in gel 
phantoms. The Journal of the Acoustical Society of America 2009; 5:EL183-9. 
170. Dayton, P.A., J.S. Allen and K.W. Ferrara, The magnitude of radiation force on 
ultrasound contrast agents. The Journal of the Acoustical Society of America 2002; 5 Pt 
1:2183-92. 
171. Dayton, P.A., K.E. Morgan, A.L. Klibanov, G. Brandenburger, K.R. Nightingale and 
K.W. Ferrara, A preliminary evaluation of the effects of primary and secondary radiation 
forces on acoustic contrast agents. Ultrasonics, Ferroelectrics and Frequency Control, 
IEEE Transactions on 1997; 6:1264-1277. 
172. Zhao, S., M. Borden, S.H. Bloch, D. Kruse, K.W. Ferrara and P.A. Dayton, Radiation-
force assisted targeting facilitates ultrasonic molecular imaging. Mol. Imaging 2004; 
3:135-48. 
173. Borden, M.A., M.R. Sarantos, S.M. Stieger, S.I. Simon, K.W. Ferrara and P.A. Dayton, 
Ultrasound radiation force modulates ligand availability on targeted contrast agents. Mol. 
Imaging 2006; 3:139-47. 
174. Lum, A.F., M.A. Borden, P.A. Dayton, D.E. Kruse, S.I. Simon and K.W. Ferrara, 
Ultrasound radiation force enables targeted deposition of model drug carriers loaded on 
microbubbles. J. Control. Release 2006; 1-2:128-34. 
175. Saad, A.H. and G.M. Hahn, Ultrasound enhanced drug toxicity on Chinese hamster ovary 
cells in vitro. Cancer Res. 1989; 21:5931-4. 
185 
 
176. Escoffre, J.M., J. Piron, A. Novell and A. Bouakaz, Doxorubicin delivery into tumor cells 
with ultrasound and microbubbles. Mol. Pharm. 2011; 3:799-806. 
177. Sonoda, S., K. Tachibana, E. Uchino, T. Yamashita, K. Sakoda, K.-H. Sonoda, T. 
Hisatomi, Y. Izumi and T. Sakamoto, Inhibition of melanoma by ultrasound-
microbubble-aided drug delivery suggests membrane permeabilization. Cancer Biol. 
Ther. 2007; 8:1276-83. 
178. Kheirolomoom, A., L.M. Mahakian, C.-Y. Lai, H.A. Lindfors, J.W. Seo, E.E. Paoli, K.D. 
Watson, E.M. Haynam, E.S. Ingham, L. Xing, R.H. Cheng, A.D. Borowsky, R.D. 
Cardiff, and K.W. Ferrara, Copper-doxorubicin as a nanoparticle cargo retains efficacy 
with minimal toxicity. Mol. Pharm. 2010; 6:1948-58. 
179. Tinkov, S., C. Coester, S. Serba, N.A. Geis, H.A. Katus, G. Winter and R. Bekeredjian, 
New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo 
characterization. J. Control. Release 2010; 3:368-372. 
180. Yan, F., X. Li, Q. Jin, C. Jiang, Z. Zhang, T. Ling, B. Qiu and H. Zheng, Therapeutic 
ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, 
characterization and application to ultrasound-assisted chemotherapy in breast cancer 
cells. Ultrasound Med. Biol. 2011; 5:768-79. 
181. Kang, J., X. Wu, Z. Wang, H. Ran, C. Xu, J. Wu, Z. Wang and Y. Zhang, Antitumor 
effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted 
microbubble activation on VX2 rabbit liver tumors. J. Ultrasound Med. 2010; 1:61-70. 
182. Phillips, L.C., A.L. Klibanov, B.R. Wamhoff and J.A. Hossack, Localized ultrasound 
enhances delivery of rapamycin from microbubbles to prevent smooth muscle 
proliferation. J. Control. Release 2011; 1:42-49. 
183. Bekeredjian, R., S. Chen, P.A. Grayburn and R.V. Shohet, Augmentation of cardiac 
protein delivery using ultrasound targeted microbubble destruction. Ultrasound Med. 
Biol. 2005; 5:687-91. 
184. Bekeredjian, R., H.F. Kuecherer, R.D. Kroll, H.A. Katus and S.E. Hardt, Ultrasound-
targeted microbubble destruction augments protein delivery into testes. Urology 2007; 
2:386-9. 
185. Crowder, K.C., M.S. Hughes, J.N. Marsh, A.M. Barbieri, R.W. Fuhrhop, G.M. Lanza and 
S.A. Wickline, Sonic activation of molecularly-targeted nanoparticles accelerates 
transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: 
implications for enhanced local drug delivery. Ultrasound Med. Biol. 2005; 12:1693-700. 
186. Kheirolomoom, A., P.A. Dayton, A.F.H. Lum, E. Little, E.E. Paoli, H. Zheng and K.W. 
Ferrara, Acoustically-active microbubbles conjugated to liposomes: characterization of a 
proposed drug delivery vehicle. J. Control. Release 2007; 3:275-284. 
187. Lentacker, I., B. Geers, J. Demeester, S.C. De Smedt and N.N. Sanders, Design and 
evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin 
delivery: cytotoxicity and mechanisms involved. Mol. Ther. 2010; 1:101-8. 
186 
 
188. Klibanov, A.L., T.I. Shevchenko, B.I. Raju, R. Seip and C.T. Chin, Ultrasound-triggered 
release of materials entrapped in microbubble-liposome constructs: A tool for targeted 
drug delivery. J. Control. Release 2010; 1:13-17. 
189. Ibsen, S., M. Benchimol, D. Simberg, C. Schutt, J. Steiner and S. Esener, A novel nested 
liposome drug delivery vehicle capable of ultrasound triggered release of its payload. J. 
Control. Release 2011; 3:358-366. 
190. Kopechek, J.A., T.M. Abruzzo, B. Wang, S.M. Chrzanowski, D.A.B. Smith, P.H. Kee, S. 
Huang, J.H. Collier, D.D. McPherson and C.K. Holland, Ultrasound-mediated release of 
hydrophilic and lipophilic agents from echogenic liposomes. J. Ultrasound Med. 2008; 
11:1597-606. 
191. Unger, E.C., T.P. McCreery, R.H. Sweitzer, V.E. Caldwell and Y. Wu, Acoustically 
active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent. 
Invest. Radiol. 1998; 12:886-92. 
192. Gao, Z., A.M. Kennedy, D.A. Christensen and N.Y. Rapoport, Drug-loaded 
nano/microbubbles for combining ultrasonography and targeted chemotherapy. 
Ultrasonics 2008; 4:260-70. 
193. Rapoport, N., A.M. Kennedy, J.E. Shea, C.L. Scaife and K.-H. Nam, Ultrasonic 
nanotherapy of pancreatic cancer: lessons from ultrasound imaging. Mol. Pharm. 2010; 
1:22-31. 
194. Fabiilli, M.L., J.A. Lee, O.D. Kripfgans, P.L. Carson and J.B. Fowlkes, Delivery of 
water-soluble drugs using acoustically triggered perfluorocarbon double emulsions. 
Pharm. Res. 2010; 12:2753-65. 
195. Fabiilli, M.L., K.J. Haworth, I.E. Sebastian, O.D. Kripfgans, P.L. Carson and J.B. 
Fowlkes, Delivery of chlorambucil using an acoustically-triggered perfluoropentane 
emulsion. Ultrasound Med. Biol. 2010; 8:1364-75. 
196. Kooiman, K., M.R. Bohmer, M. Emmer, H.J. Vos, C. Chlon, W.T. Shi, C.S. Hall, 
S.H.P.M. de Winter, K. Schroen, M. Versluis, N. de Jong, and A. van Wamel, Oil-filled 
polymer microcapsules for ultrasound-mediated delivery of lipophilic drugs. J. Control. 
Release 2009; 2:109-18. 
197. Lensen, D., E.C. Gelderblom, D.M. Vriezema, P. Marmottant, N. Verdonschot, M. 
Versluis, N. de Jong and J.C.M. van Hest, Biodegradable polymeric microcapsules for 
selective ultrasound-triggered drug release. Soft Matter 2011; 11:5417-5422. 
198. Eisenbrey, J.R., P. Huang, J. Hsu and M.A. Wheatley, Ultrasound triggered cell death in 
vitro with doxorubicin loaded poly lactic-acid contrast agents. Ultrasonics 2009; 8:628-
33. 
199. Edelstein, M.L., M.R. Abedi and J. Wixon, Gene therapy clinical trials worldwide to 
2007--an update. J. Gene Med. 2007; 10:833-42. 
200. Barajas, M., G. Mazzolini, G. Genove, R. Bilbao, I. Narvaiza, V. Schmitz, B. Sangro, I. 
Melero, C. Qian and J. Prieto, Gene therapy of orthotopic hepatocellular carcinoma in 
187 
 
rats using adenovirus coding for interleukin 12. Hepatology (Baltimore, Md ) 2001; 1:52-
61. 
201. Morgan, R.A., M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, 
R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, Z. Zheng, A. Nahvi, C.R. de 
Vries, L.J. Rogers-Freezer, S.A. Mavroukakis, and S.A. Rosenberg, Cancer regression in 
patients after transfer of genetically engineered lymphocytes. Science (New York, N Y ) 
2006; 5796:126-9. 
202. Donahue, R.E., S.W. Kessler, D. Bodine, K. McDonagh, C. Dunbar, S. Goodman, B. 
Agricola, E. Byrne, M. Raffeld, R. Moen, and et al., Helper virus induced T cell 
lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 
1992; 4:1125-35. 
203. Patil, S.D., D.G. Rhodes and D.J. Burgess, DNA-based therapeutics and DNA delivery 
systems: a comprehensive review. AAPS J. 2005; 1:E61-77. 
204. Liu, Q. and D.A. Muruve, Molecular basis of the inflammatory response to adenovirus 
vectors. Gene Ther. 2003; 11:935-40. 
205. Thomas, C.E., A. Ehrhardt and M.A. Kay, Progress and problems with the use of viral 
vectors for gene therapy. Nat. Rev. Genet. 2003; 5:346-58. 
206. Kay, M.A., J.C. Glorioso and L. Naldini, Viral vectors for gene therapy: the art of turning 
infectious agents into vehicles of therapeutics. Nat. Med. 2001; 1:33-40. 
207. Kawabata, K., Y. Takakura and M. Hashida, The fate of plasmid DNA after intravenous 
injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 
1995; 6:825-30. 
208. Coonrod, A., F.Q. Li and M. Horwitz, On the mechanism of DNA transfection: efficient 
gene transfer without viruses. Gene Ther. 1997; 12:1313-21. 
209. Lechardeur, D., K.J. Sohn, M. Haardt, P.B. Joshi, M. Monck, R.W. Graham, B. Beatty, J. 
Squire, H. O'Brodovich and G.L. Lukacs, Metabolic instability of plasmid DNA in the 
cytosol: a potential barrier to gene transfer. Gene Ther. 1999; 4:482-97. 
210. Capecchi, M.R., High efficiency transformation by direct microinjection of DNA into 
cultured mammalian cells. Cell 1980; 2 Pt 2:479-88. 
211. Zanta, M.A., P. Belguise-Valladier and J.P. Behr, Gene delivery: a single nuclear 
localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl. 
Acad. Sci. U. S. A. 1999; 1:91-6. 
212. Finn, J., A.C.H. Lee, I. MacLachlan and P. Cullis, An enhanced autogene-based dual-
promoter cytoplasmic expression system yields increased gene expression. Gene Ther. 
2004; 3:276-83. 
213. Gersbach, C.A., T. Gaj, R.M. Gordley, A.C. Mercer and C.F. Barbas, 3rd, Targeted 
plasmid integration into the human genome by an engineered zinc-finger recombinase. 
Nucleic Acids Res. 2011; 17:7868-78. 
188 
 
214. Zabner, J., Cationic lipids used in gene transfer. Adv. Drug Delivery. Rev. 1997; 1:17-28. 
215. Nishikawa, M. and L. Huang, Nonviral vectors in the new millennium: delivery barriers 
in gene transfer. Hum. Gene. Ther. 2001; 8:861-70. 
216. Chen, X., K. Kandasamy and R.K. Srivastava, Differential Roles of RelA (p65) and c-Rel 
Subunits of Nuclear Factor κB in Tumor Necrosis Factor-related Apoptosis-inducing 
Ligand Signaling. Cancer Res. 2003; 5:1059-1066. 
217. Filion, M.C. and N.C. Phillips, Major limitations in the use of cationic liposomes for 
DNA delivery. Int J Pharm 1998; 1–2:159-170. 
218. Neu, M., D. Fischer and T. Kissel, Recent advances in rational gene transfer vector 
design based on poly(ethylene imine) and its derivatives. The journal of gene medicine 
2005; 8:992-1009. 
219. Godbey, W.T., K.K. Wu and A.G. Mikos, Tracking the intracellular path of 
poly(ethylenimine)/DNA complexes for gene delivery. Proc. Natl. Acad. Sci. U. S. A. 
1999; 9:5177-81. 
220. Bieber, T., W. Meissner, S. Kostin, A. Niemann and H.-P. Elsasser, Intracellular route 
and transcriptional competence of polyethylenimine-DNA complexes. J. Control. Release 
2002; 2-3:441-54. 
221. Moghimi, S.M., P. Symonds, J.C. Murray, A.C. Hunter, G. Debska and A. Szewczyk, A 
two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene 
transfer/therapy. Molecular therapy : the journal of the American Society of Gene 
Therapy 2005; 6:990-5. 
222. Pack, D.W., A.S. Hoffman, S. Pun and P.S. Stayton, Design and development of 
polymers for gene delivery. Nature reviews Drug discovery 2005; 7:581-93. 
223. Zhang, X.-Q., J. Intra and A.K. Salem, Comparative study of poly (lactic-co-glycolic 
acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion 
methods. J. Microencapsul. 2008; 1:1-12. 
224. Liu, C., W. Yu, Z. Chen, J. Zhang and N. Zhang, Enhanced gene transfection efficiency 
in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene 
glycol) nanoparticles through caveolae-mediated endocytosis. J. Control. Release 2011; 
2:162-175. 
225. Ravi Kumar, M.N.V., U. Bakowsky and C.M. Lehr, Preparation and characterization of 
cationic PLGA nanospheres as DNA carriers. Biomaterials 2004; 10:1771-7. 
226. Lawrie, A., A.F. Brisken, S.E. Francis, D.I. Tayler, J. Chamberlain, D.C. Crossman, D.C. 
Cumberland and C.M. Newman, Ultrasound enhances reporter gene expression after 
transfection of vascular cells in vitro. Circulation 1999; 20:2617-20. 
227. Duvshani-Eshet, M. and M. Machluf, Efficient transfection of tumors facilitated by long-
term therapeutic ultrasound in combination with contrast agent: from in vitro to in vivo 
setting. Cancer Gene Ther. 2007; 3:306-15. 
189 
 
228. Manome, Y., N. Nakayama, K. Nakayama and H. Furuhata, Insonation facilitates 
plasmid DNA transfection into the central nervous system and microbubbles enhance the 
effect. Ultrasound Med. Biol. 2005; 5:693-702. 
229. Huber, P.E., M.J. Mann, L.G. Melo, A. Ehsan, D. Kong, L. Zhang, M. Rezvani, P. 
Peschke, F. Jolesz, V.J. Dzau, and K. Hynynen, Focused ultrasound (HIFU) induces 
localized enhancement of reporter gene expression in rabbit carotid artery. Gene Ther. 
2003; 18:1600-7. 
230. Lawrie, A., A.F. Brisken, S.E. Francis, D.C. Cumberland, D.C. Crossman and C.M. 
Newman, Microbubble-enhanced ultrasound for vascular gene delivery. Gene Ther. 
2000; 23:2023-7. 
231. Rahim, A., S.L. Taylor, N.L. Bush, G.R. ter Haar, J.C. Bamber and C.D. Porter, Physical 
parameters affecting ultrasound/microbubble-mediated gene delivery efficiency in vitro. 
Ultrasound Med. Biol. 2006; 8:1269-79. 
232. Wang, G.-z., J.-h. Liu, S.-z. Lu, Y. Lu, C.-j. Guo, D.-h. Zhao, D.-p. Fang, D.-f. He, Y. 
Zhou and C.-j. Ge, Ultrasonic destruction of albumin microbubbles enhances gene 
transfection and expression in cardiac myocytes. Chin. Med. J. (Engl.) 2011; 9:1395-400. 
233. Guo, D.-P., X.-Y. Li, P. Sun, Y.-B. Tang, X.-Y. Chen, Q. Chen, L.-M. Fan, B. Zang, L.-
Z. Shao and X.-R. Li, Ultrasound-targeted microbubble destruction improves the low 
density lipoprotein receptor gene expression in HepG2 cells. Biochem. Biophys. Res. 
Commun. 2006; 2:470-4. 
234. Negishi, Y., K. Matsuo, Y. Endo-Takahashi, K. Suzuki, Y. Matsuki, N. Takagi, R. 
Suzuki, K. Maruyama and Y. Aramaki, Delivery of an angiogenic gene into ischemic 
muscle by novel bubble liposomes followed by ultrasound exposure. Pharm. Res. 2011; 
4:712-9. 
235. Miao, C.H., A.A. Brayman, K.R. Loeb, P. Ye, L. Zhou, P. Mourad and L.A. Crum, 
Ultrasound enhances gene delivery of human factor IX plasmid. Hum. Gene. Ther. 2005; 
7:893-905. 
236. Mou, Y., Y. Ye, X.-Y. Zhao, L. Yao, L.-P. Yan, J. Sun, Z.-H. Zhu and S.-J. Hu, Partial 
restoration of left ventricular systolic function by asPLB gene transfer using ultrasound-
mediated microbubble destruction. Ultrasound Med. Biol. 2009; 10:1638-46. 
237. Shen, Z.P., A.A. Brayman, L. Chen and C.H. Miao, Ultrasound with microbubbles 
enhances gene expression of plasmid DNA in the liver via intraportal delivery. Gene 
Ther. 2008; 16:1147-55. 
238. Wang, X.-H., Role of constituents of Optison in Optison-mediated gene transfection 
enhancement in skeletal muscle in vivo. J. Ultrasound Med. 2011; 3:325-32. 
239. Samuni, Y. and B.J. Baum, Gene delivery in salivary glands: From the bench to the 
clinic. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2011; 
11:1515-1521. 
190 
 
240. Voutetakis, A., M.R. Kok, C. Zheng, I. Bossis, J. Wang, A.P. Cotrim, N. Marracino, 
C.M. Goldsmith, J.A. Chiorini, Y.P. Loh, L.K. Nieman, and B.J. Baum, Reengineered 
salivary glands are stable endogenous bioreactors for systemic gene therapeutics. Proc. 
Natl. Acad. Sci. U. S. A. 2004; 9:3053-3058. 
241. Baum, B.J., C. Zheng, I. Alevizos, A.P. Cotrim, S. Liu, L. McCullagh, C.M. Goldsmith, 
N. McDermott, J.A. Chiorini, N.P. Nikolov, and G.G. Illei, Development of a gene 
transfer-based treatment for radiation-induced salivary hypofunction. Oral Oncol. 2010; 
1:4-8. 
242. Passineau, M.J., L. Zourelias, L. Machen, P.C. Edwards and R.L. Benza, Ultrasound-
assisted non-viral gene transfer to the salivary glands. Gene Ther. 2010. 
243. Lentacker, I., B.G. De Geest, R.E. Vandenbroucke, L. Peeters, J. Demeester, S.C. De 
Smedt and N.N. Sanders, Ultrasound-responsive polymer-coated microbubbles that bind 
and protect DNA. Langmuir 2006; 17:7273-8. 
244. Fujii, H., Z. Sun, S.-H. Li, J. Wu, S. Fazel, R.D. Weisel, H. Rakowski, J. Lindner and R.-
K. Li, Ultrasound-targeted gene delivery induces angiogenesis after a myocardial 
infarction in mice. JACC Cardiovascular imaging 2009; 7:869-79. 
245. Shohet, R.V., S. Chen, Y.T. Zhou, Z. Wang, R.S. Meidell, R.H. Unger and P.A. 
Grayburn, Echocardiographic destruction of albumin microbubbles directs gene delivery 
to the myocardium. Circulation 2000; 22:2554-6. 
246. Chen, S., R.V. Shohet, R. Bekeredjian, P. Frenkel and P.A. Grayburn, Optimization of 
ultrasound parameters for cardiac gene delivery of adenoviral or plasmid 
deoxyribonucleic acid by ultrasound-targeted microbubble destruction. J. Am. Coll. 
Cardiol. 2003; 2:301-8. 
247. Phillips, L.C., A.L. Klibanov, B.R. Wamhoff and J.A. Hossack, Targeted gene 
transfection from microbubbles into vascular smooth muscle cells using focused, 
ultrasound-mediated delivery. Ultrasound Med. Biol. 2010; 9:1470-80. 
248. Christiansen, J.P., B.A. French, A.L. Klibanov, S. Kaul and J.R. Lindner, Targeted tissue 
transfection with ultrasound destruction of plasmid-bearing cationic microbubbles. 
Ultrasound Med. Biol. 2003; 12:1759-67. 
249. Chen, S., J.-h. Ding, R. Bekeredjian, B.-z. Yang, R.V. Shohet, S.A. Johnston, H.E. 
Hohmeier, C.B. Newgard and P.A. Grayburn, Efficient gene delivery to pancreatic islets 
with ultrasonic microbubble destruction technology. Proc. Natl. Acad. Sci. U. S. A. 2006; 
22:8469-74. 
250. Sirsi, S.R., S.L. Hernandez, L. Zielinski, H. Blomback, A. Koubaa, M. Synder, S. 
Homma, J.J. Kandel, D.J. Yamashiro and M.A. Borden, Polyplex-microbubble hybrids 
for ultrasound-guided plasmid DNA delivery to solid tumors. J. Control. Release 2012; 
2:224-34. 
251. Chumakova, O.V., A.V. Liopo, V.G. Andreev, I. Cicenaite, B.M. Evers, S. Chakrabarty, 
T.C. Pappas and R.O. Esenaliev, Composition of PLGA and PEI/DNA nanoparticles 
191 
 
improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 2008; 
2:215-25. 
252. Seemann, S., P. Hauff, M. Schultze-Mosgau, C. Lehmann and R. Reszka, Pharmaceutical 
evaluation of gas-filled microparticles as gene delivery system. Pharm. Res. 2002; 3:250-
7. 
253. Hauff, P., S. Seemann, R. Reszka, M. Schultze-Mosgau, M. Reinhardt, T. Buzasi, T. 
Plath, S. Rosewicz and M. Schirner, Evaluation of gas-filled microparticles and 
sonoporation as gene delivery system: feasibility study in rodent tumor models. 
Radiology 2005; 2:572-8. 
254. Fonseca, C., S. Simoes and R. Gaspar, Paclitaxel-loaded PLGA nanoparticles: 
preparation, physicochemical characterization and in vitro anti-tumoral activity. J. 
Control. Release 2002; 2:273-286. 
255. Maataoui, A., J. Qian, D. Vossoughi, M.F. Khan, E. Oppermann, W.O. Bechstein and 
T.J. Vogl, Transarterial chemoembolization alone and in combination with other 
therapies: a comparative study in an animal HCC model. Eur. Radiol. 2005; 1:127-33. 
256. Yang, R., F.J. Rescorla, C.R. Reilly, P.R. Faught, N.T. Sanghvi, L. Lumeng, T.D. 
Franklin and J.L. Grosfeld, A reproducible rat liver cancer model for experimental 
therapy: introducing a technique of intrahepatic tumor implantation. The Journal of 
surgical research 1992; 3:193-8. 
257. Tseng, W.-C., F.R. Haselton and T.D. Giorgio, Transfection by Cationic Liposomes 
Using Simultaneous Single Cell Measurements of Plasmid Delivery and Transgene 
Expression. J. Biol. Chem. 1997; 41:25641-25647. 
258. Karshafian, R., P.D. Bevan, R. Williams, S. Samac and P.N. Burns, Sonoporation by 
ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters 
on cell membrane permeability and cell viability. Ultrasound Med. Biol. 2009; 5:847-60. 
259. Lin, W. and G. Arthur, Phosphatidylcholine catabolism in the MCF-7 cell cycle. 
Biochem. Cell Biol. 2006; 5:737-44. 
260. Wilding, G., M.E. Lippman and E.P. Gelmann, Effects of steroid hormones and peptide 
growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer 
Res. 1988; 4:802-5. 
261. Cosgrove, D., Angiogenesis imaging – ultrasound. Br. J. Radiol. 2003; suppl 1:S43-S49. 
262. Storm, G., S.O. Belliot, T. Daemen and D. Lasic, Surface modification of nanoparticles 
to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 
17:31-48. 
263. Brannon-Peppas, L. and J.O. Blanchette, Nanoparticle and targeted systems for cancer 
therapy. Adv Drug Deliv Rev 2004; 11:1649-59. 
264. Brigger, I., C. Dubernet and P. Couvreur, Nanoparticles in cancer therapy and diagnosis. 
Adv Drug Deliv Rev 2002; 5:631-51. 
192 
 
265. Rahman, A., A. Ganjei and J.R. Neefe, Comparative immunotoxicity of free doxorubicin 
and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemother. Pharmacol. 
1986; 1:28-34. 
266. Drummond, D.C., O. Meyer, K. Hong, D.B. Kirpotin and D. Papahadjopoulos, 
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. 
Pharmacol. Rev. 1999; 4:691-743. 
267. Goldberg, B.B., J.B. Liu and F. Forsberg, Ultrasound contrast agents: a review. 
Ultrasound Med. Biol. 1994; 4:319-33. 
268. Staples, B.J., W.G. Pitt, B.L. Roeder, G.A. Husseini, D. Rajeev and G.B. Schaalje, 
Distribution of doxorubicin in rats undergoing ultrasonic drug delivery. J Pharm Sci 
2010; 7:3122-31. 
269. Beijnen, J.H., O.A.G.J. van der Houwen and W.J.M. Underberg, Aspects of the 
degradation kinetics of doxorubicin in aqueous solution. Int J Pharm 1986; 2–3:123-131. 
270. Schlosser, T., C. Pohl, C. Veltmann, S. Lohmaier, J. Goenechea, A. Ehlgen, J. Koster, D. 
Bimmel, S. Kuntz-Hehner, H. Becher, and K. Tiemann, Feasibility of the flash-
replenishment concept in renal tissue: which parameters affect the assessment of the 
contrast replenishment? Ultrasound Med. Biol. 2001; 7:937-44. 
271. Gorce, J.M., M. Arditi and M. Schneider, Influence of bubble size distribution on the 
echogenicity of ultrasound contrast agents: a study of SonoVue. Invest. Radiol. 2000; 
11:661-71. 
272. Xing, W., W.Z. Gang, Z. Yong, Z.Y. Yi, X.C. Shan and R.H. Tao, Treatment of 
Xenografted Ovarian Carcinoma Using Paclitaxel-loaded Ultrasound Microbubbles. 
Acad. Radiol. 2008; 12:1574-1579. 
273. Shah, S.S., Cha, Y., Pitt, C.G., Poly(glycolic acid-co-DL-lactic acid): diffusion or 
degradation controlled drug delivery? J. Control. Release 1992:261-270. 
274. Kost, J., K. Leong and R. Langer, Ultrasound-enhanced polymer degradation and release 
of incorporated substances. Proc. Natl. Acad. Sci. U. S. A. 1989; 20:7663-6. 
275. Kuijpers, W.M., Iedema, P.D., Kemmere, M.F., Keurentjes, T.J., The mechanism of 
cavitation-induced polymer scission; experimental and computational verification. 
Polymer 2004:6461-6467. 
276. El-Sherif, D.M., J.D. Lathia, N.T. Le and M.A. Wheatley, Ultrasound degradation of 
novel polymer contrast agents. J. Biomed. Mater. Res. A 2004; 1:71-8. 
277. Cochran, M.C., J. Eisenbrey, R.O. Ouma, M. Soulen and M.A. Wheatley, Doxorubicin 
and paclitaxel loaded microbubbles for ultrasound triggered drug delivery. Int. J. Pharm. 
2011; 1-2:161-70. 
278. Diaz, J.F. and J.M. Andreu, Assembly of purified GDP-tubulin into microtubules induced 
by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 
1993; 11:2747-55. 
193 
 
279. Borden, M.A., C.F. Caskey, E. Little, R.J. Gillies and K.W. Ferrara, DNA and polylysine 
adsorption and multilayer construction onto cationic lipid-coated microbubbles. 
Langmuir 2007; 18:9401-8. 
280. Hou, S., N. Ziebacz, S.A. Wieczorek, E. Kalwarczyk, V. Sashuk, T. Kalwarczyk, T.S. 
Kaminski and R. Holyst, Formation and structure of PEI/DNA complexes: quantitative 
analysis. Soft Matter 2011; 15:6967-6972. 
281. Kircheis, R., S. Schüller, S. Brunner, M. Ogris, K.-H. Heider, W. Zauner and E. Wagner, 
Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. The Journal 
of Gene Medicine 1999; 2:111-120. 
282. Kuo, J.-h.S., M.-s. Jan and K.C. Sung, Evaluation of the stability of polymer-based 
plasmid DNA delivery systems after ultrasound exposure. Int. J. Pharm. 2003; 1–2:75-84. 
283. Ren, K., Y. Wang, J. Ji, Q. Lin and J. Shen, Construction and deconstruction of 
PLL/DNA multilayered films for DNA delivery: Effect of ionic strength. Colloids and 
Surfaces B: Biointerfaces 2005; 2:63-69. 
284. Bekeredjian, R., S. Chen, P.A. Frenkel, P.A. Grayburn and R.V. Shohet, Ultrasound-
targeted microbubble destruction can repeatedly direct highly specific plasmid expression 
to the heart. Circulation 2003; 8:1022-6. 
285. Brunot, C., L. Ponsonnet, C. Lagneau, P. Farge, C. Picart and B. Grosgogeat, 
Cytotoxicity of polyethyleneimine (PEI), precursor base layer of polyelectrolyte 
multilayer films. Biomaterials 2007; 4:632-640. 
286. Liang, B., M.-L. He, Z.-P. Xiao, Y. Li, C.-y. Chan, H.-F. Kung, X.-T. Shuai and Y. Peng, 
Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-
targeted gene delivery. Biochem. Biophys. Res. Commun. 2008; 4:874-880. 
287. Cherng, J.Y., N.M.E. Schuurmans-Nieuwenbroek, W. Jiskoot, H. Talsma, N.J. Zuidam, 
W.E. Hennink and D.J.A. Crommelin, Effect of DNA topology on the transfection 
efficiency of poly((2-dimethylamino)ethyl methacrylate)–plasmid complexes. J. Control. 
Release 1999; 2–3:343-353. 
288. Remaut, K., N.N. Sanders, F. Fayazpour, J. Demeester and S.C. De Smedt, Influence of 
plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes. J. 
Control. Release 2006; 3:335-343. 
289. Singh, M., M. Ugozzoli, E. Soenawan, A. Pannu, E. Pushnova, J. Allen and D.T. 
O'Hagan, Extent of Supercoiling in Plasmid DNA Vaccines: Should Restrictions be 
Relaxed? American Journal of Drug Delivery 2006; 4:195-199. 
290. Miller, D.L., S. Bao and J.E. Morris, Sonoporation of cultured cells in the rotating tube 
exposure system. Ultrasound Med. Biol. 1999; 1:143-149. 
291. Apfel, R.E. and C.K. Holland, Gauging the likelihood of cavitation from short-pulse, 
low-duty cycle diagnostic ultrasound. Ultrasound Med. Biol. 1991; 2:179-185. 
194 
 
292. Meijering, B.D.M., R.H. Henning, W.H. Van Gilst, I. Gavrilović, A. Van Wamel and 
L.E. Deelman, Optimization of ultrasound and microbubbles targeted gene delivery to 
cultured primary endothelial cells. J. Drug Target. 2007; 10:664-671. 
293. Bao, S., B.D. Thrall and D.L. Miller, Transfection of a reporter plasmid into cultured 
cells by sonoporation in vitro. Ultrasound Med. Biol. 1997; 6:953-959. 
294. Greenleaf, W.J., M.E. Bolander, G. Sarkar, M.B. Goldring and J.F. Greenleaf, Artificial 
Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. 
Ultrasound Med. Biol. 1998; 4:587-595. 
295. Larina, I.V., B.M. Evers and R.O. Esenaliev, Optimal drug and gene delivery in cancer 
cells by ultrasound-induced cavitation. Anticancer Res. 2005; 1A:149-56. 
296. Guzman, H.R., D.X. Nguyen, S. Khan and M.R. Prausnitz, Ultrasound-mediated 
disruption of cell membranes. I. Quantification of molecular uptake and cell viability. J. 
Acoust. Soc. Am. 2001; 1:588-96. 
297. Pan, H., Y. Zhou, O. Izadnegahdar, J. Cui and C.X. Deng, Study of sonoporation 
dynamics affected by ultrasound duty cycle. Ultrasound Med. Biol. 2005; 6:849-856. 
298. Mannaris, C. and M.A. Averkiou, Investigation of Microbubble Response to Long Pulses 
Used in Ultrasound-Enhanced Drug Delivery. Ultrasound Med. Biol. 2012; 4:681-691. 
299. Chen, W.-S., A.A. Brayman, T.J. Matula, L.A. Crum and M.W. Miller, The pulse length-
dependence of inertial cavitation dose and hemolysis. Ultrasound Med. Biol. 2003; 
5:739-748. 
300. Pislaru, S.V., C. Pislaru, R.R. Kinnick, R. Singh, R. Gulati, J.F. Greenleaf and R.D. 
Simari, Optimization of ultrasound-mediated gene transfer: comparison of contrast agents 
and ultrasound modalities. Eur. Heart J. 2003; 18:1690-1698. 
301. Steinhardt, R.A., G. Bi and J.M. Alderton, Cell membrane resealing by a vesicular 
mechanism similar to neurotransmitter release. Science 1994; 5145:390-3. 
302. Karshafian, R., P. Bevan, G. Czarnota and P. Bums. P4E-1 The Dependence of 
Sonoporation on Cell Cycle Phase: Enhanced Effect During G2 and S-Phase. in 
Ultrasonics Symposium, 2007. IEEE. 2007. 
303. Zhang, G., M. Long, Z.Z. Wu and W.Q. Yu, Mechanical properties of hepatocellular 
carcinoma cells. World J. Gastroenterol. 2002; 2:243-6. 
304. Brunner, S., E. Furtbauer, T. Sauer, M. Kursa and E. Wagner, Overcoming the nuclear 
barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or 
electroporation. Mol. Ther. 2002; 1:80-6. 
305. Klein, R.M., Acinar cell proliferation in the parotid and submandibular salivary glands of 
the neonatal rat. Cell Tissue Kinet. 1982; 2:187-95. 
195 
 
306. Lee, R.C., L.P. River, F.S. Pan, L. Ji and R.L. Wollmann, Surfactant-induced sealing of 
electropermeabilized skeletal muscle membranes in vivo. Proc. Natl. Acad. Sci. U. S. A. 
1992; 10:4524-8. 
307. Merchant, F.A., W.H. Holmes, M. Capelli-Schellpfeffer, R.C. Lee and M. Toner, 
Poloxamer 188 Enhances Functional Recovery of Lethally Heat-Shocked Fibroblasts. J. 
Surg. Res. 1998; 2:131-140. 
308. Serbest, G., J. Horwitz and K. Barbee, The effect of poloxamer-188 on neuronal cell 
recovery from mechanical injury. J. Neurotrauma 2005; 1:119-32. 
309. Hartikka, J., L. Sukhu, C. Buchner, D. Hazard, V. Bozoukova, M. Margalith, W.K. 
Nishioka, C.J. Wheeler, M. Manthorp and M. Sawdey, Electroporation-facilitated 
delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and 
effect of poloxamer 188. Mol. Ther. 2001; 5:407-15. 
310. Mehier-Humbert, S., T. Bettinger, F. Yan and R. Guy, Influence of polymer adjuvants on 
the ultrasound-mediated transfection of cells in culture. Eur. J. Pharm. Biopharm. 2009; 
3:567-73. 
311. Douglas, K.L., C.A. Piccirillo and M. Tabrizian, Cell line-dependent internalization 
pathways and intracellular trafficking determine transfection efficiency of nanoparticle 
vectors. Eur. J. Pharm. Biopharm. 2008; 3:676-687. 
312. Nomikou, N., P. Tiwari, T. Trehan, K. Gulati and A.P. McHale, Studies on neutral, 
cationic and biotinylated cationic microbubbles in enhancing ultrasound-mediated gene 
delivery in vitro and in vivo. Acta Biomater. 2012; 3:1273-80. 
313. Wang, D.S., C. Panje, M.A. Pysz, R. Paulmurugan, J. Rosenberg, S.S. Gambhir, M. 
Schneider and J.K. Willmann, Cationic versus Neutral Microbubbles for Ultrasound-
mediated Gene Delivery in Cancer. Radiology 2012; 3:721-732. 
314. Burke, C.W., J.S. Suk, A.J. Kim, Y.H. Hsiang, A.L. Klibanov, J. Hanes and R.J. Price, 
Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted 
delivery of non-viral gene nanocarriers with microbubbles. J. Control. Release 2012; 
2:414-421. 
315. Nielsen, L.L., P. Lipari, J. Dell, M. Gurnani and G. Hajian, Adenovirus-mediated p53 
gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, 
ovarian, prostate, and breast cancer. Clin. Cancer Res. 1998; 4:835-846. 
316. Ahmed, S., N. Kishikawa, K. Ohyama, M. Wada, K. Nakashima and N. Kuroda, 
Selective determination of doxorubicin and doxorubicinol in rat plasma by HPLC with 
photosensitization reaction followed by chemiluminescence detection. Talanta 2009; 
1:94-100. 
317. Álvarez-Cedrón, L., M.L. Sayalero and J.M. Lanao, High-performance liquid 
chromatographic validated assay of doxorubicin in rat plasma and tissues. Journal of 
Chromatography B: Biomedical Sciences and Applications 1999; 2:271-278. 
196 
 
318. Liu, Z., A.C. Fan, K. Rakhra, S. Sherlock, A. Goodwin, X. Chen, Q. Yang, D.W. Felsher 
and H. Dai, Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo 
cancer therapy. Angew. Chem. Int. Ed. Engl. 2009; 41:7668-72. 
 
 
 
 
 
 
 
 
 
 
 
  
197 
 
Appendix A: Sonoporation with Short Pulse Lengths 
 
 
 The use of ultrasound to increase the permeability of cell membranes is known as 
sonoporation and can be useful to enhance the delivery of therapeutic molecules that will not 
normally pass through the cell membrane. Our initial attempts at sonoporation used polymer 
microbubbles exposed to short pulses from a 5 MHz single element 0.5 inch diameter transducer 
(Panametrics-NDT Waltham, MA) with a focal length of 45 mm and a -6dB bandwidth of 89.3%. 
The transducer was triggered by a Panametrics 5072pulser/receiver resulting in short asymmetric 
pulses less than 1 µs long as shown in figure AA.1. The effects of the acoustic parameters 
including pulse repetition frequency (PRF) and peak positive pressure on the sonoporation 
efficiency using polymer (polylactic acid) ultrasound contrast agents (UCA) was examined with 
this setup. 
 
 
 
 
Figure AA.1: Acoustic pulse of a focused 5 MHz transducer triggered by a pulser/receiver measured using 
a 0.5 mm PVDF needle hydrophone by Piyush Arora in Dr. Lewin‟s lab in the department of Biomedical 
Engineering at Drexel. 
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 MDA-MB-231 breast cancer cells were grown in RPMI 1640 with 10% FBS in an 
Opticell until 70-80% confluent then exposed to ultrasound for 15 seconds (peak positive 
pressure (PPP) = 1.68 MPa, PNP = 0.94 MPa) with polymer contrast agent (0.6 mg/ml) and 0.15 
mg/ml FITC labeled dextran (4.4 kDa) which does not pass through intact cell membranes. After 
insonation, cells were washed twice with PBS, then phase and fluorescent images were taken. 
The diameter of the region of cells with enhanced FITC labeled dextran uptake was measured for 
each sample and used to calculate the total area of enhanced uptake as shown in figure AA.2. The 
sonoporation efficiency was determined by counting the number of cells with enhanced FITC-
dextran uptake divided by the total number of cells at the center of the transducer‟s focus. Cell 
death was determined with a propidium iodide assay.  
 
 
 
 
Figure AA.2: Florescent image of cells insonated with a PRF of 5 kHz and a PPP of 1.68 MPa. Only cells 
within the focus of the transducer had enhanced uptake. The diameter of the area with enhanced uptake was 
measured and shown in red. 
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Effect of PRF  
 Insonating cells with a PRF up to 5 kHz (frequency 5 MHz, time 15 seconds, PPP 1.68 
MPa) did not appear to have a significant effect the viability of the cells as shown in figure AA.3a 
(p>0.6).  However, sonoporation efficacy as measured by FITC-dextran uptake increased 
dramatically (over control for the same settings ranging from 4.37 ± 1.94 % at 100 Hz up to 34.52 
± 5.53 % at 5KHz (p<0.01, figure AA.3b). Pulse repetition frequency also has an influence on the 
observed area with enhanced uptake, increasing over tenfold passing from 100 Hz (0.22 ± 0.12 
mm
2
) up to 5 KHz (3.03 ± 0.23 mm
2
) (p<0.01 figure AA.3c). This increase in the area may have 
been caused by a drop in the pressure threshold required when using a higher PRF. 
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Figure AA.3: Effect of pulse repetition frequency (PRF) on cell viability (a), sonoporation efficiency (b) 
and sonoporation area (c) (*p<0.05, **p<0.01, ***p<0.001). 
 
 
 
Effect of Insonation Pressure 
Insonating cells with increasing PPP from 0.918 to 1.68 MPa (frequency 5 MHz, PRF = 2000 Hz, 
time = 15 seconds) had a significant effect on sonoporation area (p<0.01) as shown in figure 
AA.4a. The total area with enhanced uptake increased from 0.17 ± 0.04 mm
2
 at 0.917 MPa up to 
1.99 ± 0.12 mm
2
 at 1.68 MPa. Sonoporation efficiency also increased with increasing PPP as 
shown in figure AA.4b (6.54 ± 1.26 % at 0.918 MPa up to 19.30 ± 1.12 at 1.68 MPa. 
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Figure AA.4: Effect of peak positive pressure amplitude on area of FITC-dextran uptake (a) and 
sonoporation efficiency (b) (*p<0.01). 
 
 
Effect of Insonation Time 
 The effect of insonation time was also measured from 0 to 30 seconds. Cells were 
insonated with a PPP of 1.68 MPa and PRF of 5 kHz.  Increasing the insonation time from 5 
seconds to 60 seconds resulted in a significant increase in sonoporation efficiency (p<0.01) from 
18.51 ±2.1 % after 5 seconds to 44.19 ± 1.5 % after 60 seconds. This trend of increasing 
sonoporation with longer exposure times is the opposite of the trend observed when gene delivery 
was examined with different exposures using ultrasound with longer pulse lengths. This suggests 
that in this experiment microbubble destruction is not required for sonoporation with these 
conditions, or that the area of sonoporation is small enough for fresh microbubbles to flow into 
the transducer focus. However, it is difficult to make comparisons between the two experiments 
because with FITC dextran, only the fluorescent molecule needs to enter the cell to achieve 
sonoporation, but with plasmid DNA not only does the gene need to enter the cell intact but also 
needs to enter the nucleus and be transcribed and translated into fluorescent protein before the 
cell is considered transfected. 
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Figure AA.5: Effect of insonation time on sonoporation efficiency (*p>0.01). 
 
 
 
 As shown in figure AA.2, only cells within the focus of the ultrasound transducer had 
enhanced uptake of FITC-dextran. The diameter of this area was measured for different 
treatments and was shown to increase with increasing PRF as shown in figure AA.6. This 
increasing diameter with increasing PRF suggests that higher PRFs can reduce the pressure 
required to sonoporate cells. 
 
 
Figure AA.6: Effect of PRF on diameter of the region of cells with enhanced uptake of FITC-dextran. 
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To determine the extent of the relationship between PRF and pressure, a beam plot and pressure 
profile of the 5 MHz transducer were measured (by Piyush Arora in Dr. Lewin‟s lab in the 
department of Biomedical Engineering at Drexel using a PVDF needle hydrophone and a 
computer controlled xyz stage) and are shown in figure AA.7 and figure AA.8. As shown in 
figure AA.6, with a PRF of 500 Hz the diameter of enhanced dextran uptake is close to 800µm. 
The peak positive pressure at the center of the focus is 1.68 MPa and the pressure at the edge of 
region with enhanced dextran uptake is 82% of the max or about 1.37MPa as shown in figure 
AA.8.  By increasing the PRF to 5000 Hz the diameter is increased to approximately 1700µm and 
the pressure at the edge of this region is 45% of the maximum, or 0.76MPa. So by increasing the 
PRF the pressure required to sonoporate cells can be significantly reduced.    
 
 
 
 
Figure AA.7: Beam plot of focused 5 MHz transducer used in sonoporation experiments measured using a 
0.5 mm PVDF needle hydrophone by Piyush Arora in Dr. Lewin‟s lab in the department of Biomedical 
Engineering at Drexel. 
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Figure AA.8: Pressure profile along the x axis of the focused 5 MHz transducer used in these sonoporation 
experiments. Measured using a 0.5 mm PVDF needle hydrophone by Piyush Arora in Dr. Lewin‟s lab in 
the department of Biomedical Engineering at Drexel. 
 
Radiation Force 
 To test the importance of acoustic radiation forces on sonoporation efficiency, an 
experiment was performed within an Opticell
™ 
loaded with polymer bubbles and cells seeded on 
one surface of the cassette.  The ultrasound transducer was either placed in the “forward” position 
which allowed the acoustic radiation forces to force bubbles towards the cells, or the transducer 
was placed in the “reverse” position which pushed bubbles away from the cells as shown below 
in figure AA.9.  Significantly less sonoporation was observed when the transducer was aligned to 
push microbubbles away from cells (9.1 ± 1.7 %) when the microbubbles were pushed away from 
cells compared to 31.6 ± 1.2% in the forward direction. When longer pulse lengths were used for 
delivery of plasmids, no gene deliver was observed when the transducer was aligned to push 
microbubbles away from the cells. It is possible that that the degree of sonoporation required to 
allow enhanced uptake of FITC-dextran (4.4 kDa) is much less than the amount of sonoporation 
required for the uptake of plasmid DNA. The dextran may be able to enter the cell through small 
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pores than larger molecules, or they may be entering the cell through an entirely different 
mechanism.  
 
 
 
 
Figure AA.9: Effect of radiation force on sonoporation efficiency. Diagram of direction of applied 
ultrasound (a), effect of direction on sonoporation efficiency (b) and effect of direction on sonoporation 
area (c). 
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Gene Delivery with Short Pulses 
 The maximum output from the pulser receiver was used to excite the same 5 MHz 
focused transducer (PRF=5kHz, PPP=1.68 MPa) in order to trigger polymer microbubbles. 
Plasmid DNA (20 µg/ml) encoding GFP was incubated along with the microbubbles with either 
MDA MB 231 or MCF7 breast cancer cells, however no enhanced gene expression was observed 
in with insonation for up to 2 minutes suggesting that while these conditions can enhance the 
uptake of smaller molecules they are not sufficient for enhanced uptake of much larger plasmid 
DNA. In the future it may be interesting to determine if there are differences in the mechanisms 
of uptake or differences in the response of cells when microbubbles are triggered with short vs. 
long pulses. 
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Appendix B: Dose Escalation and Multiple Doses of Dox UCA in Rat HCC Model 
 
 The results from specific aim 1 of this thesis showed that Dox loaded PLA UCA were 
able to deliver significantly more drug to tumors in a rat HCC model compared to free Dox, 
however due to the low loading efficiency of Dox the total drug payload was small (167 µg Dox). 
To determine if it was possible to increase the dose of Doxorubicin by increase the dose of drug 
loaded UCA being injected a dose escalation of Dox loaded UCA was tested in a rat HCC model 
to evaluate the safety, tolerability and effectiveness.  
 Tumors implanted into the left lobe of the liver as described in aim 1 however tumors 
were allowed to grow for a full 3 weeks and reach a diameter of approximately 1 cm before 
the first treatment. On the day of treatment, rats were anesthetized with isofluorane and the 
abdomens were shaved and treated with a depilatory cream. The rats were then scanned with 
an ATL/Philips HDI-5000 scanner (Bothel, WA) using a linear 12-5 MHz transducer and 
measurements of the tumor were taken in all three dimensions. The transducer was then 
focused on the tumor and set to Doppler mode with the maximum mechanical index (0.4-
0.45). The animals were then injected with a 1 ml suspension of saline containing one of four 
doses of microbubbles or free Dox consisting of: A: 120 µg Dox (0.8 mg Dox/kg, ~10 mg 
UCA (total mass of UCA used per injection)), B: 240 µg Dox (1.6 mg Dox/kg, ~20 mg 
UCA), C: 600 µg Dox (4.0 mg Dox/kg, ~50 mg UCA) or D: 600 µg of free un-encapsulated 
Dox (4.0 mg Dox/kg).   
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Table AB.1: Number of Rats in Each Treatment Group 
Group Treatment Dose (mg Dox/kg)  
per injection 
# of rats receiving 
dose 1 (day 0) 
# of rats also receiving 
dose 2 (day 21) 
A UCA 0.8 8 6 
B UCA 1.6 8 4 
C UCA 4.0 6 5 
D Free Dox 4.0 3 2 
 
 The tumors were then manually scanned for 20 minutes in order to trigger 
microbubble cavitation and fragmentation of the drug loaded shell into nanoparticles capable 
of escaping the vasculature and accumulating within the tumor interstitium. After treatment 
the rats were returned to their cages to recover and monitored for signs of distress. Tumor 
sizes were measured again by ultrasound after 2 weeks, and three weeks after the initial 
treatments, the rats were treated again with the same dose they received in the first treatment. 
Tumors were again measured by ultrasound at week 5 and all animals surviving to week 6 
were sacrificed and the tumors and organs harvested for histology and quantification of drug 
levels by fluorescence.  
 At sacrifice, the heart, lungs, liver, spleen and tumor were harvested then frozen and 
stored at -80 °C. Dox levels in the organs and tumors were quantified using a method 
described by Liu et al. [318]. Frozen samples of tissue were cut and weighed (0.1-0.2 g per 
sample) then homogenized (with an Tissue Master 125 manufactured by Omni International, 
Kennesaw, GA) for 1 min in 0.5 ml of a lysis buffer (0.25 M sucrose, 40 mM tris acetate, 10 
mM EDTA). The tissue was homogenized for at least 30 seconds at the 3
rd
 speed setting until 
no whole portions of tissue were visible. Then 200 µl of lysate was removed and added to 
100 µl of 10% Triton X-100. The lysate/Triton X-100 solution was vortexed for 1 minute 
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before adding 1 ml of an extraction solution (0.75 M HCl, in isopropyl alcohol). This mixture 
was then vortexed for an additional minute before being wrapped in foil and placed in a -
20 °C freezer to incubate for 18 hours. The sample (in isopropyl alcohol) was then 
centrifuged at max speed for 15 minutes then 150 µl of the supernatant was transferred to a 
black 96 well plate and the fluorescence was quantified with an excitation wavelength of 
495 nm an emission wavelength of 585 nm and a gain of 121. The total fluorescence was 
calculated based on a linear standard curve using samples of known concentrations put 
through the same extraction procedure. While this protocol was able to provide a linear 
standard curve in the 50-5000 ng range, using HPLC with a fluorescent detector would be 
able to detect the differences between Dox and its metabolites.  
 Rats tolerated the first cycle of treatment at all dose levels with no procedure related 
deaths or signs of distress. This represents at the highest dose, a 5-fold increase not only of 
Dox dose but also of the polymeric carrier microcapsules (4.0 mg Dox/kg, ~50 mg UCA in 
the first cycle of treatment). Plasma Dox levels were 0.40, 0.83, 3.18 and 5.32 µg Dox/mL at 
5 minutes for the 120, 240, 600 µg Dox (UCA) and free Dox treatments, all drug levels 
dropped significantly after 15 minutes (0.02, 0.04, 0.77 and 0.63 µg Dox/mL). During the 
second treatment 6 rats experienced respiratory distress and died within 20 minutes, 1 in 
group A, 2 in group B and 3 in group C. Five out of six of these rats had much higher drug 
levels in the lung at autopsy compared to other rats in the respective group (one rat from 
group C died after the second injection but had average drug levels in the lung and a normal 
spleen size), the same five rats also had spleens that were nearly two times larger than the 
spleens of rats that survived the treatment with no distress (1040 ± 155 mg vs. 1756 ± 340 
mg, p<0.05). Figure AB1 shows the average mass of the spleens removed from rats treated 
with each dose. Other studies looking to improve the circulation time of particles have shown 
that by injecting large doses of placebo particles prior to injection of a radioactive liposome, 
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it is possible to reduce the uptake of the radioactive particles taken up by the liver and spleen 
from 90% to 30%, however this increased uptake in the lung from 5% to 60% [96-97]. It is 
possible that the total dose of microbubbles given in the combination of both doses in this 
study were enough to reduce the uptake efficiency by the spleen and liver leaving more 
particles to accumulate in the lung.  
 
 
 
Figure AB1: Effect of microbubble dose on the size of the rat spleen measured after death. 
 
 
 
 The distribution of Dox in the lungs, spleen, liver, heart and tumor for animals treated 
with each of the four doses is shown in table AB1 and in figure AB2.  In rats treated with the 
highest dose of UCA significantly greater drug levels were found in the lungs, spleen and 
liver compared to the heart and tumor. This is most likely the result of particle uptake by the 
mononuclear phagocyte system. In this study the drug levels found in the spleen and liver 
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were much lower than the drug levels found after 14 days when using 
14
C labeled Dox with 
only 3.46 ± 0.9 ng Dox/mg tissue found in the liver when dox loaded UCA containing 600 µg 
of drug were injected compared to 3.99 ± 0.77 ng Dox/mg tissue when dox loaded UCA 
containing 167 µg 
14
C Dox were injected. It is possible that these lower drug levels found in 
the liver are due to inefficiencies in the extraction method used in this study or that a large 
portion of the drug was metabolized in the organ causing a drop in fluorescence that was not 
measured when using 
14
C to quantify drug delivery. Drug levels in all organs and tumors 
were greater in rats treated with drug loaded UCA (containing 600 µg Dox) compared to free 
Dox (600 µg) suggesting that the drug loaded UCA were still able to deliver drug to the 
tumor when triggered by ultrasound.  
 It is important to note that because animals were sacrificed 6 weeks after the first 
treatment or when signs of distress were observed, the time between treatment and animal 
death varied greatly making comparison of drug levels difficult.  
 
Table AB2: Dox Concentration in Organs and Tumor at 6 Weeks (ng Dox/mg Tissue) 
Drug dose 
(per injection) 
Lung Spleen Liver Heart Tumor 
(Center) 
Tumor 
(Periphery) 
0.8 mg/kg 0.47 ± 0.29 0.93 ± 0.27 0.66 ± 0.20 0.24 ± 0.09 0.35 ± 0.05 0.14 ± 0.06 
1.6 mg/kg 1.15 ± 0.60 0.85 ± 0.37 1.25 ± 0.55 0.40 ± 0.16 0.43 ± 0.08 0.46 ± 0.16 
4.0 mg/kg 3.13 ± 1.21 3.85 ± 1.06 3.46 ± 0.90 0.84 ± 0.35 0.85 ± 0.29 0.88 ± 0.35 
Free Drug 
(4.0mg/kg) 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.06 ± 0.03 0.17 ± 0.10 0.00 ± 0.00 
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Figure AB2: Dox levels in the tumor and organs 6 weeks after the first treatment or after animal 
sacrifice due to distress. Animal death occurred at different times after treatment making comparison 
difficult.  
 
 
 While drug levels found in the peripheral tumor were significantly higher in all 
groups treated with microbubbles (A, B and C) compared to rats treated with free Dox, 
however no inhibition of tumor growth was observed in any of the treatment groups with 
tumor volumes increasing from less than 0.35 cm
3
 to 1.46, 2.33, 1.38 and 1.87 cm
3
 (120, 240, 
600 µg Dox (MB) and freeDox) 2 weeks after treatment (Table AB2). No significant 
difference in tumor growth was observed between any of the tested groups. 
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Table AB2:  Diameter of Tumors Measured by Ultrasound (cm) 
Dose Level Day 0 Day 14 Day 21 Day 35 
0.8mg/kg  0.9 ± 0.3 1.4 ± 0.8 1.8 ± 1.2 2.1 ± 1.5 
1.6 mg/kg  1.0 ± 0.3 1.7 ± 0.7 2.2 ± 1.1 3.3 ± 0.8 
4.0 mg/kg  1.1 ±0.3 1.5 ± 0.7 2.1± 1.1 3.4 ± 0.8 
4.0mg/kg  
(free Dox) 
1.0 ± 0.3 1.6 ± 0.9 1.6 ± 1.3 1.5 ± 2.1 
 
 
 
 Animals were sacrificed when they were observed to be  in distress. The dose escalation 
showed no effect on animal survival, similar to the lack of effect on tumor growth despite 
significantly higher drug levels in the tumors treated with UCA compared to free dox.  
 
 
 
 
Figure AB3: Effect of treatment and dose on animal survival. 
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 The results shown in specific aim 1 showed that drug loaded UCA may be capable of 
reducing tumor growth however in this study the total drug levels found in the tumor were lower 
and there was no reduction in tumor growth or improvement in survival. The method of drug 
level measurement was changed from 
14
C to fluorescence which would have influenced the 
findings and also it was later learned that the homogenizer used to make the microbubbles used in 
this study may not have been operating normally due to problems with the bearings in the 
homogenizer probe. An SEM image of Dox loaded UCA made with the damaged homogenizer 
shows microcapsules with a very irregular morphology which may have reduced drug deliver 
efficiency (figure AB4). 
 
 
  
Figure AB4: Scanning electron microscope image of Dox loaded microbubbles made damaged 
homogenizer probe. 
 
 
 This dose escalation study showed that rats could tolerate the first cycle of treatments at 
all doses with no procedure related deaths or signs of distress (inanition, weight loss, jaundice, 
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bleeding or infection) suggesting that the microbubbles did not cause any immediate toxicity at 
any of the dose levels tested. Despite the irregular microbubbles used in this experiment there was 
still significantly more drug found in the tumor when animals were treated with Dox loaded UCA 
compared to free Dox. However significantly greater drug levels were also observed in the lung, 
spleen and liver of animals treated with UCA compared to free Dox. The increased uptake found 
in the lung may be the result of the high doses of UCA delivered in multiple treatments or due to 
the poorly made microbubbles that clumped together and became trapped in the pulmonary bed. 
All treatments had no effect on tumor growth or animal survival suggesting that the higher drug 
levels found in the tumor were not great enough or not available to help reduce tumor growth, 
however this may also be due to the poorly made microbubbles.  
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